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Abstract 
The highest concentration of zinc in human tissues is found in the retinal pigment 
epithelium (RPE)-choroid complex. Despite the association of zinc deficiency with 
age-related macular degeneration (AMD) and the widespread use of zinc 
supplementation to slow the progression ofAMD, very little is known about how 
zinc affects the RPE and the choroid. Molecular and cell biology techniques were 
used to uncover how changes in zinc levels could play a role in regulating the RPE-
choroid complex.  
First, QRT-PCR was used to assess the expressions of all 24 known zinc 
transporters in cadaveric human RPE, cultured RPE cells and cells isolated from 
other parts of the retina, ZIP12 was identified as a potentially important transporter 
to regulate zinc levels at the RPE-choroid interface. As there is very little published  
about ZIP12, bioinformatics and data mining were used to understand how this 
protein might function. Confirmation of these predictions was achieved through the 
cloning and expression of V5-tagged ZIP12 protein in different cell lines. Based on 
these experiments, we concluded that ZIP12 is a plasma membrane transporter that 
mediates zinc influx.  
In parallel, we tested the hypothesis that extracellular zinc levels in Bruch’s 
membrane might be involved in regulating both the RPE as well as the fenestrated 
choroidal capillaries using cultures of ARPE19 and bEND5 cells respectively. The 
presence of extracellular zinc in the growth media affected the characteristics of 
ARPE19 cells as well as fenestrae formation in bEND5 cells.  
In summary, the range of zinc transporter at the RPE-choroid interface was defined 
and properties of one particular transporter, ZIP12 which may have a specific role 
at this site, were elucidated. Using cellular systems some of the effects of zinc on 
the RPE-choroid complex were investigated. Future studies are required to 
elucidate the role of zinc in the AMD pathogenesis. 
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1. General Introduction
1
 
1.1. Zinc Overview 
1.1.1. Biological functions of Zinc 
Zinc is an indispensable and ubiquitous trace element present in many tissues in a 
wide range of organisms. The total amount of zinc found in human body is 
estimated to be 1.4-2.3 grams, with an average of approximately 20-30 µg/g zinc 
present in non-pathological human tissues (Karcioglu, 1982). The highest tissue 
concentrations of zinc in man are found in the retina and choroid complex, where, 
464 and 472 µg/g of zinc is found respectively (Galin et al., 1962).  
Zinc requirements for the body differ with gender and age. The National Institutes 
of Health established a recommended daily allowance (RDA) of 2-3 mg for infants, 
9 mg for adult female, and 11 mg for adult male. For pregnant and lactating 
women, the RDA is raised to 12-13 mg (http://ods.od.nih.gov/factsheets/Zinc-
HealthProfessional/). Within the body, zinc is predominantly obtained through 
dietary means. Food sources rich in zinc include oyster, red meat such as beef, as 
well as pulses and beans (http://ods.od.nih.gov/factsheets/Zinc-
HealthProfessional/). Dietary zinc absorption occurs in the gastrointestinal tract; 
however, the level of absorption can be affected by the presence of as phytate. 
Phytate, an indigestible molecule present in majority of grains and legumes is able 
to form stable complexes with various metal cations such as zinc, copper, nickel, 
cobalt, manganese, iron and calcium (Rink, L (ed) 2011, Zinc in Human Health, 
Amsterdam). This results in poor absorption of these metals, causing a possibility 
of zinc and other metal deficiency if phytate is consumed in large quantities.   
Zinc is able to bind into other proteins through interactions with other amino acids. 
It predominantly binds through the sulphur residue in cysteine, oxygen present in 
glutamate and aspartate, as well as nitrogen present in histidines (Rink, L (ed) 2011, 
Zinc in Human Health, Amsterdam). The affinity of zinc metal to the other atoms is 
                                                 
1
 Some elements of this chapter have been published in: 
Barzegar-Befroei, N., Cahyadi, S., Gango, A., Peto, T., and Lengyel, I. 2011. Zinc 
in Eye Diseases. Zinc in Human Health. Amsterdam: IOS Press.  
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determined by the presence of hydrogen bonds in the structure. This has been 
shown in the case of carbonic anhydrase, one of the strongest binders of zinc metal. 
Carbonic anhydrase has 4 ligands for zinc, all of which are connected with 
hydrogen bonds with the side chains. This greatly increases the affinity of the 
binding site for zinc (Lesburg and Christianson, 1995).  Zinc has been widely 
implicated as a structural component of metal-binding proteins such as 
metalloproteinases (Vallee and Falchuk, 1993). The zinc-binding metalloproteins 
such as protein kinase C (PKC) and superoxide dismutase (SOD) are involved in 
cellular proliferation, signalling, and structural functions. Furthermore, the binding 
of zinc to domains and motifs such as zinc finger, zinc cluster and zinc twist, 
enables specific gene regulatory processes to be activated (Vallee and Falchuk, 
1993). Most strongly bound zinc form part of the structural component of proteins. 
If zinc affinity in the metal binding site is weak, the metal may participate in 
catalytic activities by acting as nucleophiles. For instance, alcohol dehydrogenases 
possess zinc binding site within the structure of the enzyme. The presence of zinc 
allows the transfer of negatively charged hydride ion from NADH to acetaldehyde 
(CH3CHO), ultimately resulting in production of ethanol (CH3CH2OH). This is 
achieved through stabilisation of the oxygen residue in acetaldehyde, which in turn 
create a positive charge on the carbonyl residue of acetaldehyde where the hydride 
ion is transferred to (Kimura, Koike, and Shionoya, 1997).  
Phagocytosing leukocytes such as natural killer (NK) cells, neutrophils and 
macrophages require zinc in order to function properly as a part of innate immunity. 
In adaptive immunity, CD4T+ T cell maturation is induced when intracellular zinc 
level is reduced (Murakami and Hirano, 2008). Furthermore, in mammals, SOD 
activity converts O2
•- 
to H2O2, which reduces oxidative stress within the cell. 
Neuronal death following axonal injury was increased in Cu/ZnSOD-/-mice 
(Reaume et al., 1996). 
Zinc has an anti-inflammatory effect on cells through negatively regulating NFκB. 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a 
transcription factor that mediate both pro- and anti-apoptotic genes (Uzzo, et al., 
2006) in cells. Under normal condition, NF-κB protein complex is retained in the 
cytosol by IkB, a negative regulator of NF-κB. Under cellular stress, IkB 
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degradation occurs, subsequently translocating NF-κB into the nucleus, activating a 
series of transcription of transcription factor and genes (Uzzo et al., 2006). Zinc is 
able to interfere with the activation of NF-κB through reducing expression of the 
pro-inflammatory cytokine TNF-α (Prasad, 2008, Uzzo et al., 2006). Studies using 
pulmonary artery-derived endothelial cells showed that zinc deficiency aggravate 
production of IL-6, a pro-inflammatory cytokines triggered by exposure to TNF-α 
(Hennig 1999, activation zinc in porcine). Furthermore, zinc is able to interact with 
pro-apoptotic caspase 3 and reduce the activity of the enzyme (Clegg et al., 2005).  
Previous reports have demonstrated the ability of zinc to act as a neurotransmitter 
as well as a second messenger.  Synaptic vesicles have been shown to contain zinc. 
Glutamate and gamma-aminobutyric acid (GABA) receptors contain zinc binding 
sites which enable  synaptic vesicles to store zinc and they also have zinc 
transporters that facilitate the release of zinc into the cytoplasm (Ueno et al., 2002, 
Hosie et al., 2003). Redenti and Chappell reported the presence of zinc transporter 3 
(ZnT3) as specific for the brain synaptic vesicles (Redenti and Chappell, 2004b). 
Zinc binding to calcium activated potassium channels may cause oxidative stress 
and lead to brain toxicity (Sensi et al., 2000). Zinc may also have an intracellular 
signalling effect. In dendritic cells lipopolysaccharide binding to toll-like receptor 
induces dendritic cell maturation as well as activation of CD4+ T- cells through up-
regulation of zinc exporters and downregulation of zinc importers (Kitamura et al., 
2006).  
1.1.2. Zinc Homeostasis 
Intracellularly, the bioavailable zinc concentration is maintained at a nanomolar 
level through uptake, storage and secretion (Bozym et al., 2010). Studies have 
indicated that zinc transporters are likely to be the main mechanism of zinc 
movement in various mammalian cells, although diffusion of zinc ions may occur 
under physiological conditions (Reyes, 1996). In mammals, there are two zinc 
transporter families one composed of solute-linked carrier genes, ZRT or IRT-like 
proteins (also known as ZIP proteins) and the other of cation diffusion facilitators 
(CDFs, also known as ZnT proteins)(Kambe et al., 2004). So far, at least 14 ZIPs 
and 10 CDFs (Kambe et al., 2004) havebeen identified.  
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Metallothioneins are small metal-binding proteins that have the capability to bind 
zinc, and act as a buffer against oxidative stress. This allows metallothionein to 
become the first line of defense when the concentration of intracellular zinc rises. 
For instance, it has been shown that the expression of metallothionein mRNA is 
induced after cells from a human colonic epithelial cell line are exposed to zinc 
(Kindermann et al., 2005). Bobilya and colleagues constructed a blood-brain barrier 
model using porcine brain capillary endothelial cells and demonstrated that a 50 
µm/L Zn
2+
 exposure increased the expression of metallothionein and protein level 
in 12 hours, suggesting that metallothionein is crucial to limit zinc concentration in 
the brain capillary endothelial cells (Bobilya et al., 2008).  
The majority of zinc is bound with a high affinity to metalloproteins, and so is said 
to be non-bioavailable. Approximately 40% of putative zinc-binding proteins are 
transcription factors possessing zinc-binding domains such as zinc finger motifs. 
Other proteins are zinc transporters or enzymes. Many groups of enzymes require 
zinc binding to function properly. Hydrolases and phosphatases utilise zinc to 
induce a nucleophilic attack on substrate. Kinases use zinc mainly for structural 
support. Ligases, isomerases, and oxidoreductases also join the zinc-binding group. 
Furthermore, zinc is also needed for proteins involved in gene regulatory processes 
such as DNA repair, transcription, translation and signalling protein (Andreini et 
al., 2006).  
In blood serum, approximately 19 µm of Zn
2+ 
is found bound to zinc-binding 
albumin. Endothelial cells were reported to have zinc-bound albumin receptors. 
When Zn
65
 uptake was measured, endothelial cells specifically transported only 
albumin with zinc bound to it. After endocytosis, the albumin appears to be 
recycled to the cytosol (Rowe and Bobilya, 2000).  
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1.2.  Zinc Transporters 
Zinc transporters are likely to be the main method of maintaining the appropriate 
zinc concentrations within the cells. Alternatively, calcium channels (Reyes, 1996) 
and proton pumps can also transport zinc. They can also be transported by calcium 
channels or proton pumps (Sekler et al., 2007). There are two zinc transporter 
families belonging to solute-linked carrier genes, ZRT or IRT-like proteins (also 
known as ZIP proteins) and cation diffusion facilitators (CDFs, also known as ZNT 
proteins). So far, research has identified at least 14 ZIPs and 10 ZnTs (Kambe et al., 
2004). In this thesis, we will refer to the protein under the name ZIP and ZnT, with 
its genes named SLC39A, and SLC30A respectively.  
1.2.1. SLC30A Family of Transporters 
The SLC30 gene codes for a family of zinc transporters (ZnTs) which are 
ubiquitously expressed in all organisms (Liuzzi and Cousins, 2004b). There are 
three subfamilies of which the ZnTs are assigned to, and the 10 members of the 
mammalian ZnT proteins belong in subfamily 2 and 3 whereby non-mammalian 
transporters are grouped in subfamily 1. The ZnT family of transporters specifically 
promotes the transport of zinc from the cytosol to extracellular environment or 
compartmentalise zinc into organelles within the cell thereby reducing the 
concentration of zinc within the cells. Most ZnTs, with the exception of ZnT5 
possess six transmembrane domains with a variable region between domains III and 
IV, which contains many histidine residues able to bind zinc (See Figure 1.1). Loss 
of these histidine residues due to gene mutations or incorrect translation of mRNA 
has been reported to result in various pathological conditions, which may include 
embryonic lethality, incorrect absorption of zinc, reduced body fat and weight in 
mice (Huang et al., 2007)  and lethal milk syndrome caused by a mutation in the 
SLC30A4 gene encoding the ZnT4 protein. In lethal milk syndrome, the milk 
produced by the dams were devoid of zinc, causing death of pups (Murgia et al., 
2006). Mutations in ZnT8 has been associated with Type I diabetes (Wenzlau et al., 
2007). The distribution of ZnTs is widespread; although some are cell-specific 
(Redenti and Chappell, 2004b, Palmiter and Huang, 2004).  
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1.2.2. SLC39A ZIP FAMILY OF TRANSPORTERS 
The SLC39 genes encode a family of zinc transporters (ZIPs) that are ubiquitously 
expressed in all organisms. Structurally, ZIP proteins are composed of eight 
transmembrane domains with a cytoplasmic loop between domain III and IV 
composed of histidine residues. It is further divided into 4 subfamilies, with ZIP9 in 
subfamily I, ZIP1, ZIP2 and ZIP3 in subfamily II, ZIP11 in subfamily III (also 
known as gufA).  The rest of the transporters belong in LIV-1 subfamily, with ZIP7 
and ZIP13 further characterized as HKE4 family members (Taylor et al., 2004). 
Figure 1.1 shows a typical structure of the LIV-1 subfamily of ZIP transporters with 
8 transmembrane domains. The HIS labeling is predicted to be histidine-rich 
regions, the  symbol represents N-linked glycan sites. Transmembrane 4 and 5 
contains histidine rich sequences (NH and HHE in the diagram) thought to be 
involved in transporting zinc (Taylor et al., 2004). ZIP family of zinc transporters 
promote the transport of zinc from the extracellular environment into the cytoplasm 
or from the cellular organelles to the cytoplasm (Liuzzi and Cousins, 2004b). 
Mutations in protein or genetic level of SLC39/ZIP family members may lead to 
the development of various pathological conditions such as acrodermatitis 
enteropathica (AE), an autosomal recessive metabolic disorder caused by mutations 
in ZIP4 (Dufner-Beattie et al., 2003). Overexpression of SLC39A2 (encoding ZIP2 
protein) has been implicated in asthmatic infants (Xu et al., 2009). The 
overexpression of ZIP7 is upregulated in tamoxifen-resistant breast cancer cell line 
(Taylor et al., 2008) and a mutation in ZIP13 has been implicated in Ehlers-Danlos 
syndrome (Fukada et al., 2008).  
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Figure 1-1 -Structure of SLC30 family and SLC39 (LIV-1) family of zinc 
transporters. 
 
(A) The typical structure of SLC30 (ZnT protein) family member shows the 6 
transmembrane domain with a histidine rich region between transmembrane 4 and 
5. (B) The typical figure of the LIV-1 subfamily of ZIP proteins shows the 8 
transmembrane domains along with histidine rich regions (His) and  N-linked 
gylcan sites. Transmembrane 4 and 5 contains histidine rich regions which have 
been predicted as zinc binding sites. Picture taken from (Eide, 2006, Taylor et al., 
2004).  
 
 
 
24 
 
No studies have so far addressed the question as to why mammalians need 24 
mammalian zinc transporters to regulate zinc homeostasis. Cousins and Lichten 
have suggested that this could be due to the vast requirement of zinc within the 
human body compared to other metals such as copper or iron. As it has been 
explained in section 1.1.1, zinc is involved in structural, enzymatic as well as 
becoming a part of the transcription factor which requires a tight homeostasis. 
Furthermore, studies have shown that zinc can co-transport other metals. ZIP8 has 
been shown to co-transport manganese (He et al., 2006), ZIP14 is able to transport 
iron, furthermore, studies using Arabidopsis Thaliana have suggested that zinc 
transporters belonging to this species can transport other metals such as iron or 
copper (Robinson, 2007, Lin et al., 2003).   
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1.3. Overview of the Structure of the Eye 
The human eye is an organ that receives external light, converting it into signals, 
which are then transmitted along the optic nerve head towards the brain. The brain 
further processes the information and generates visual perception.  
Human eyes are spherical and approximately 24 mm diameter. They are formed of 
three layers, (1) the external layer is comprised of the cornea at the front and the 
sclera posteriorly. The cornea is 8mm in diameter and its transparent structure 
allows light to enter the eye. The white fibrous sclera provides structural support for 
the rest of the eye. (2) The highly vascular ‘uveal’ layer lies internal to the sclera 
and is comprised of iris, ciliary body and choroid. The rich vasculature of this layer 
mainly provides oxygen and nutrients to the eye and clears waste products. (3) The 
neural layer is comprised of the retina. The retina contains photoreceptor cells and 
other neurons which are crucial in detecting light stimuli and converting them into 
visual signals (see next section).  
Inside the eye globe, there are three chambers present (see Figure 1.2). The anterior 
chamber lies just behind the cornea. Directly behind the anterior chamber is the 
posterior chamber in which the lens is located. The largest chamber is the vitreous 
cavity, which contains vitreous humor, a clear gel material that is almost devoid of 
cells and composed mainly of collagen and hyaluronic acid. The vitreous functions 
to maintain ocular shape and contributes to the forces that hold the retina and 
choroid in place. 
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Figure 1-2- Schematic diagram of the eye 
Schematic diagram of the eye (Image obtained from Remington, Lee Ann. Clinical 
Anatomy of the Visual System. Newton, Massachusetts: Butterworth-Heinemann, 
1998. 
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1.4. Zinc in the Eye 
The eye contains the highest concentration of zinc, compared to other tissues 
including bone, muscle, liver, pancreas and kidney. In 1962, Galin extensively 
reviewed the concentration of zinc in ocular tissues, concluding that the highest 
concentration of zinc is present in the retina and choroid (see Table 1.1), followed 
by the ciliary body and the optic nerve. The concentration of zinc in the cornea, iris 
and sclera are significantly lower compared to the other parts of the eye (Galin et 
al., 1962). While majority of zinc found within the eye is tightly bound to zinc-
binding proteins, a substantial amount is termed exchangeable owing to its dynamic 
nature and involvement in various biological processes (Maret, 2008, Colvin et al., 
2010).  
Table 1-1- Total zinc concentration in tissues 
Total zinc concentration in the ocular tissue, bone, muscle, liver, pancreas and 
kidney (Galin et al., 1962, McBean et al., 1972). Parts per million is equivalent to 
µg/g of dry mass. 
 
 Parts Per Million (PPM) Reference 
Cornea 25-35 Galin 1962 
Iris 17-26 Galin 1962 
Ciliary Body 189-288 Galin 1962 
Retina 385-571 Galin 1962 
Choroid 419-562 Galin 1962 
Optic Nerve 67-161 Galin 1962 
Sclera 47-52 Galin 1962 
Lens 17-29 Galin 1962 
Bone 218 McBean 1972 
Muscle 197 McBean 1972 
Liver 179 McBean 1972 
Pancreas 115 McBean 1972 
Kidney 194 McBean 1972 
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1.4.1. Retina, RPE, Choroid 
This thesis is concerned with zinc at the RPE-choroid interface and in this section a 
review of the currently available literature on zinc in the retina, RPE and choroid is 
presented with some coverage of zinc metabolism in other parts of the eye. The 
human neural retina is highly structured and may be considered to be formed of 
multiple layers: the inner limiting membrane (ILM), nerve fibre layer (NFL), 
ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), 
outer plexiform layer (OPL), outer nuclear layer (ONL), external limiting 
membrane (ELM) and photoreceptor layer (See Figure 1.2). The retina rests on the 
RPE. The inner limiting membrane is at the interface between the vitreous humor 
and the retina. Here astrocytes as well as Muller cells (cells which span the length 
of the retina) can be found. Within the GCL, ganglion cells are present. These 
transmit visual information from the outer retina to the brain. The axonal 
projections of ganglion cells can be found in the NFL. In the IPL dendritic 
projections of the ganglion cells synapse with amacrine cells and bipolar cells, two 
other neuronal cells within the retina. The OPL contains synapses from 
photoreceptor cells to bipolar and horizontal cells. The ONL contains the cell 
bodies and the inner fibres of the two classes of photoreceptor cell, the rods and 
cones. The ELM is not a true membrane but is formed by junctions between the 
outer ends of the Muller cells and the photoreceptors. The photoreceptor outer 
segment contains visual pigment. The rods are much more abundant than cones and 
optimally detect light in the dark whereas cones mediate colour vision in daylight 
(Clinical Anatomy of The Visual System – Page 49-75). Cones are most abundant 
at the macula, a region within the retina, which processes the high-resolution 
central visual field. Atrophy of photoreceptor cells within the macula results in loss 
of vision in AMD.  
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The retina contains the second-highest concentration of total zinc after the choroid 
(Grahn et al., 2001, Galin et al., 1962) and Figure 1.3 annotates the localisation of 
total as well as bioavailable zinc within the retina. The effect of zinc on 
neuromodulation in the retina has been demonstrated by Rosenstein and Chappell, 
where activation of glutamate-dependent gamma-aminobutyric acid (GABA) 
receptors in bipolar cells of skate was successfully blocked by the addition of 1µM 
zinc (Rosenstein and Chappell, 2003). Furthermore, depolarisation of rat retinal 
cells was associated with increased exchangeable zinc concentration within the 
OPL and photoreceptor inner segments as measured using zinc-selective dye 
Newport Green (Redenti and Chappell, 2005). Within the OPL and IPL, 
bioavailable zinc was has been visualised using autometallography in various cells 
in the INL, Muller cells and the Golgi apparatus of the horizontal and amacrine 
cells (Akagi et al., 2001, Kaneda et al., 2005, Redenti and Chappell, 2004b). 
Bioavailable zinc labeling in the outer segment discs has been reported in several 
studies (Hirayama, 1990, Wang et al., 2006b). Here zinc is involved in stabilization 
of photoreceptor discs (Bettger, 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1-3–Organisation of the retina/RPE/choroid complex
A simplified diagram depicting the cellular organization of the retina/RPE/choroid 
complex: Cho, choroid; BM, Bruch’s membrane; RPE, retinal
OS, outer segment; IS, inner segment; ONL, outer nuclear layer; OPL, outer 
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer and GC, 
ganglion cell layer. The shaded bar on the right represent exchangeable zinc level
in the different layers based on 
2005, Wang et al., 2006b
bar on the left represents total zinc levels based on
al., 1962, Tam et al., 1976
1990, Fabe et al., 2000
2009). 
 
Picture taken from Barzegar
Lengyel, I. 2011. Zinc in Eye Diseases. 
Press.  
 
 
 
 
 pigment epithelium; 
various studies (Akagi et al., 2001
, Ugarte and Osborne, 2001, Wu et al., 1993
(Bowness et al., 1952
, Eckhert, 1983, Koumantakis et al., 1983
, Bentley and Grubb, 1991, Wills et al., 2008
-Befroei, N., Cahyadi, S., Gango, A., Peto, T., and 
Zinc in Human Health. Amsterdam: IOS 
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The RPE is a monolayer of hexagonal cells present underneath the photoreceptor 
outer segments (POS) of the retina (Figure 1.4). The main function of the RPE is to 
scavenge POS through its phagocytic capability. Much of the phagocytosed outer 
segment material is recycled but some accumulates in lysosomes to form lipofuscin 
and may ultimately be extruded into the sub-RPE space. From here, some material 
may gain access to the choroidal circulation (Strauss, 2005). Another function of 
the RPE cell is to mediate the retinal cycle (see section 1.4.3 on the retinal cycle). It 
also forms the outer blood-retina barrier. The majority of zinc within the RPE is 
tightly bound to zinc-binding proteins such as metallothionein, melanin, as well as 
enzymes responsible for the retinal cycle (Bok, 1993). Pigment granules have been 
associated with protection from oxidative stress as well as regulating 
phagolysosomal activity (Schraermeyer et al., 1999). Zinc is stored within melanin 
granules in the RPE cells, and hypopigmentation of the RPE has been linked to 
AMD. The RPE and choroid is rich in bioavailable zinc, significant amounts of 
which can be found within the Golgi apparatus (Huang et al., 2007), melanosomes 
and lysosomes (Ugarte and Osborne, 2001, Ulshafer, 1989). Zinc deficiency in the 
RPE predominantly compromises its anti-oxidative capacity, where cytotoxicity, 
reduced cellular proliferation and lowered metallothionein concentration have been 
observed (Tate et al., 1995, Tate et al., 1997). Furthermore, the failure in control of 
zinc homeostasis may contribute to aggregation of immunoproteins such as CFH 
found in sub-RPE deposits (Nan et al., 2008), ultimately leading to diseases like 
AMD.  
 
The choriocapillaris is located directly underneath the RPE and Bruch’s membrane. 
It is composed of a unique vascular network which provides nutrients and fluid for 
the RPE and the retina (Bernstein and Hollenberg, 1965). The abundance of 
fenestrations on the RPE aspect of the choriocapillaris endothelium makes this 
vascular bed much leakier than non-fenestrated vessels (Bernstein and Hollenberg, 
1965). It is thought that the fenestration is maintained through VEGF secretion 
(Saint-Geniez et al., 2009b) from the RPE. A compromised interface can result in 
various abnormalities such as choroidal neovascularisation (CNV) and age-related 
macular degeneration (Lutty et al., 2010). 
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The choroid contains 416-572µg/g total zinc concentration, the highest within the 
eye (Galin et al., 1962, Wills et al., 2009). Discrepancies are present in studies 
attempting to measure the total zinc concentration in AMD or other non-AMD 
condition. A study by Wills et al reported an increase of total zinc concentration in 
human AMD eyes compared to control eyes (Wills et al., 2009). The result has 
been disputed by Erie, whose study reported reduced concentration of total zinc 
within the RPE and choroid in human AMD eyes. Unlike the retina, very little is 
known regarding the function of zinc within the choriocapillaris. However, both the 
RPE and choroid are heavily pigmented and pigmentation has been known to act as 
a mechanism for zinc storage (Kokkinou et al., 2004). The potential effect of zinc 
on a cellular model for fenestrated endothelium will be reported within this thesis 
(see Chapter 6).  
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Figure 1-4- Transmission electron micrograph picture of a normal RPE 
A TEM picture showing normal RPEwhich is situated between the photoreceptor 
outer segments (POS) and the choriocapillaris (CH). On its apical side, the 
microvilli projection (V) aids the scavenging of POS by RPE. Within the 
intracellular region of the RPE, melanin granules (M), nucleus (N) and lysosomes 
(L) are present. On the basal side of the RPE, Bruch’s membrane (B) separates the 
RPE from the CH. (Schraermeyer et al., 1999). 
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1.4.2. RPE Barrier Function  
The retinal pigment epithelium (RPE) maintains the outer blood-retinal barrier 
function through expression of cell to cell junctions, secretion of growth factors and 
polarisation of its various receptor or proteins. An impairment of function in any of 
these functions can lead to RPE abnormalities. 
Two main types of cell to cell junctions present in the RPE are tight and adherens 
junctions, each made up of complexes of transmembrane and non-transmembrane 
proteins. The functions of these junctions in the RPE include maintaining the 
integrity and polarity of epithelial cells and prevent leaking of fluid into the cells.  
Located between the apical/ basolateral interface, tight junctions efficiently controls 
transportation of solutes, ions and immune cells between the cells (Hartsock, and 
Nelson, 2008). The two major transmembrane proteins forming tight junctions 
include claudin and occludin, as well as cytoskeletal connecting proteins such as 
zona occludens 1 (ZO-1) proteins. Tight junctions are important in maintaining 
cellular permeability which controls material diffusion in RPE cells. Occludins, a 
group of approximately 65kDa integral proteins were first reported by Furuse and 
colleagues (Furuse, et al., 1993). Occludins are indispensable in maintaining the 
characteristically high measurement of transepithelial resistance in epithelial cells. 
In MDCK cells, transfection with a mutant non-functioning occludin protein fails to 
form proper tight junctions as measured by the low transepithelial resistance. 
(Balda, et al., 1996). Occludins are known as the binding partner of various tight 
junction proteins, especially ZO-1 protein (Furuse, et al 1994). Peripheral 
membrane protein ZO-1 is important to maintain paracellular permeability as well 
as regulating cellular signalling through transcription factor ZO-1-associated 
nucleic-acid-binding protein (ZONAB) (Balda, and Matter, 2000). Claudins are a 
group of ubiquitous proteins of about 20-27 kDa in size with four transmembrane 
domains (Balkovetz, 2006). Claudins are also responsible in regulating 
permeability of the tight junction, whereby mice lacking claudin-1 failed to survive 
after birth due to dehydration caused by lack of epidermal barrier (Furuse, et al., 
2002) meanwhile overexpression of claudin-2 protein in MDCK cells was found to 
increase permeability of the cells to cations (Amasheh, 2002).  
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Adherens junction mediates cell adhesion, intracellular signalling as well as 
regulating the actin cytoskeleton in epithelial cells. They are located underneath 
tight junctions and are composed of two groups of protein complexes, namely 
cadherin-catenin complex and nectin-afadin complex. Nectins and afadins bind to 
actin cytoskeleton meanwhile cadherins bind to a group of catenins, most 
commonly α and β-catenin. Through catenins, cadherins are able to mediate the 
intracellular signalling pathway, most notably through the Wnt signalling pathway 
which controls mouse RPE morphogenesis (Niessen, 2007, Westenkow, Piccolo 
and Fuhrmann, 2009). There are various types of cadherins, although the RPE 
predominantly expresses the neural cadherin (N-cadherin) and later during 
development the epithelial cadherin (E-cadherin) (Burke, et al., 1999). Despite it 
being a late onset, the expression of E-cadherin is crucial for differentiation of 
cultured primary cultures of human RPE and formation of adherens junction 
(Burke, et al., 1999). 
Other than cellular junctions, the RPE is unique that it secretes a myriad of factors 
including vascular endothelial growth factor (VEGF), fibroblast growth factor 
(FGF), platelet derived growth factor (PDGF), epidermal growth factor (EGF) as 
well as pigment epithelium derived factor (PEDF).  The main function of these 
factors is to mediate RPE metabolism, as well as the adjacent choriocapillaris. 
Arguably the most widely studied growth factor in RPE research, VEGF is secreted 
by the RPE to affect the choriocapillaris (Saint-Geniez 2009). The paracrine 
secretion of VEGF by the RPE has been shown to induce fenestration (Saint-Geniez 
2009, Shimomura et al., 2009), and without RPE, choriocapillaris development fails 
to occur in mice (Marneros, et al., 2005). VEGF signalling is maintained through 
the polarised expression of VEGF receptors. In the RPE-choroid interface of human 
RPE primary cultures, expression of VEGF receptor can be found towards the RPE 
side (VEGFR 2 and 3), as well as within the choriocapillaris (VEGFR1) 
(Blaauwgeers, et al., 1999).  
PEDF was first described in 1991 by Tombran-Tink and colleagues as an anti-
angiogenic factor which promotes differentiation and neuroprotection in the retina 
(Tombran-Tink, Chader, and Johnson 1991, Barnstable and Tombran-Tink, 2004). 
PEDF counteracts the action of VEGF. Studies in rat shows that neovascularisation 
triggered by photocoagulation upregulates the expression of both PEDF and VEGF, 
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but expression of PEDF was maintained for three weeks in contrast to VEGF 
expression receded after a week, suggesting that PEDF protects against oxidative 
stress in the RPE (Ogata, et al., 2002). Polarisation of the RPE increased the level 
of expression and secretion of VEGF and PEDF significantly. PEDF is 
predominantly located apically in polarized cells meanwhile basolateral localization 
is preferred in non-polarised cells (Sonoda, et al., 2010). The research for PEDF 
receptor has not been as extensive as VEGFR research. However, the receptor for 
PEDF has been reported in neural retina (Aymerich et al., 2001).  
Other than VEGF receptor, the expression of Na,K-ATPase is strictly confined to 
the apical RPE membrane. This receptor is responsible in providing energy for the 
purpose of transepithelial transport (Gundersen, 1991). Na,K-ATPase functions 
through transporting 3 sodium ions out and 2 potassium ions influx gradient which 
is mediated by ATP.  This process ensures that the RPE has the energy to able to 
perform transport of solutes and molecules in and out of RPE cells (Preben-Morth 
et al., 2011). It has been suggested that Na,K-ATPase can interact with tight 
junction. Localisation of of Na, K-ATPase in the apical and basolateral membrane 
can be affected by Na, K-ATPase. Inhibition of Na, K-ATPase activity using 
ouabain was found to reduce transepithelial resistance value in cultured human RPE 
cells and associated with reduced permeability as there is no formation of tight 
junctions and another cellular junction desmosome (Rajasekaran, et al., 2001) 
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1.4.3. Zinc in Retinal Cellular Function 
The retinal cycle is required for vision (Figure 1.5) and zinc is needed for the retinal 
cycle to function properly, as many of the retinal cycle enzymes are zinc-binding 
proteins. In the outer segment of the rod photoreceptor cells in the retina, 11-cis-
retinal is tightly bound to opsin, producing a molecule called rhodopsin. The 
absorption of a photon of light induces the 11-cis retinal to undergo 
transisomerisation, which allows it to be transported into the RPE cell as all-trans-
retinal. This occurs as the photoreceptors do not possess the cis-trans isomerase 
needed for the isomerisation of 11-cis-retinal to all-trans-retinol. The activated 
rhodopsin in turn activates transducin and the phototransduction cascade is 
initiated. Through phosphorylation of rhodopsin by rhodopsin receptor kinase and 
arrestin, all-trans-retinal is released, and transported through the disc membrane by 
the ATP binding cassette protein (ABCR). Using chaperones RPE65, CRBP, and 
LRAT the all-trans-retinal is converted to all-trans-retinyl ester. Isomerohydrolase 
converts the molecule to 11-cis-retinol and using NAD/NADP as substrate, through 
the action of retinol dehydrogenase 5 (RDH5), this gets converted to 11-cis-retinal 
to be transported back to photoreceptor outer segments (Strauss, 2005).  
 
As majority of enzymes and other proteins involved in the retinal cycle require zinc 
to function properly, sub-RPE deposits found between the RPE cell and Bruch’s 
membrane may indicate impaired activity of several zinc-related proteins. In 
summary, zinc is required for the proper functioning of proteins involved in the 
retinal cycle, and if proteins of the retinal cycle become disrupted, vision is 
disrupted.  
Enzymes that aid phagocytosis of photoreceptor outer segments require zinc to be 
activated: Α-mannosidase is a lytic enzyme found in RPE cell lysosomes which 
degrade photoreceptor outer segment. Wyszynski and colleagues reported that 
increasing the level of zinc induces the activity of α-mannosidase. The enzymatic 
activity of α-mannosidase, as determined by a decreased Vmax was also shown to 
decrease with older age. The Km value of the enzyme does not decrease. This 
suggested impairment in the degradation of photoreceptor outer segments in the 
retina with older age, which may lead to constant accumulation of debris in the 
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cells (Wyszynski et al., 1989, Tate et al., 1995). In addition, another report 
demonstrated that 0.25 µM of zinc was sufficient to induce a reduction in enzymes 
catalase and alkaline phosphatase and antioxidant metallothionein.  
Neovascularisation is one of the hallmarks of late stage AMD. In order for blood 
vessels to breach Bruch’s membrane, its remodelling must be disturbed with net, 
albeit focal, breakdown. The process of remodelling requires several protein-
degrading enzymes namely matrix metalloproteinases (MMPs), suggesting that 
MMPs may have significant function in morphological changes of Bruch’s 
membrane. MMPs are zinc-binding proteins. It has been reported that MMP3 
inhibits angiogenesis in endothelial cell chemotaxis (Anand-Apte et al., 1997).  
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Figure 1-5- The retinal cycle 
The retinal cycle (Diagram adapted from Olaf Strauss 2005). 
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1.4.4. Bruch’s Membrane 
Bruch’s membrane is a connective matrix structure linking the RPE and the 
choriocapillaris as a part of the blood-ocular barriers. Bruch’s membrane has  5 
layers, formed of RPE basement membrane, inner collagen fibre layer, elastic fibre 
sheet, outer collagen fibre layer and basement membrane of the choriocapillaris 
(Sumita, 1961). It is heavily involved in controlling solutes and micronutrients 
passing between the two interfaces but restricts diffusion of large molecules 
(Cunha-Vaz, 1979). The thickening of Bruch’s membrane, which can be followed 
by formation of protein aggregates (sub-RPE deposits) in aged-related diseases, 
could obstruct this material exchange. Very little is known about the presence of 
zinc in Bruch’s membrane although the macula of normal BM contains 137ppm 
zinc, increasing to 254ppm in macula of AMD subjects (Lengyel et al., 2007). 
Information about zinc concentration in each respective layer is not available.  
1.4.5. Cornea and Sclera 
The cornea and sclera are interconnected and form the outer coat of the eye. The 
cornea is a clear and curved structure, which is involved in light transmission and 
light refraction. The cornea absorbs oxygen from the environment. Despite 
containing five layers within its structure, the cornea remains transparent; any 
opacity would compromise its function. The transparency of the cornea is 
maintained in part through the lack of blood vessels present within its structure. As 
a result of this, the cornea obtains its nutrition from the aqueous humor located in 
the anterior chamber as well as from vessels at the limbus (Clinical Anatomy of 
The Visual System – Page 19-25). As the concentration of zinc within the cornea is 
low (Karcioglu, 1982), studies have suggested that zinc delivery to the cornea is 
achieved through tears and systemically but not through the aqueous humor 
(Anderson et al., 1987). Zinc is required within the cornea to promote the process 
of wound healing. Neovascularisation has been observed in cornea of rats subjected 
to zinc deficiency (Leure-Dupree, 1986). Enzymes such as matrix-
metalloproteinases are highly zinc-dependent (Takahashi et al., 2000) suggesting 
the involvement of zinc in corneal wound healing. Indeed, zinc deficiency in Wistar 
rats was found to lead to reduced microvilli on the corneal epithelium, an 
abnormality which was able to be reversed with zinc supplementation. Reduced 
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microvilli can promote tear film breakage which can compromise corneal immunity 
(Gong et al., 2004). 
The sclera makes up the rest of the outermost layer of the eye. Formed of a layer of 
vascularised tissue and a robust fibrous layer of connective tissue, the sclera 
provides internal and structural support for the eye. The scleral fibers are composed 
of collagen fibrils arranged in an irregular way which contributes to its white colour 
and opacification (Clinical Anatomy of The Visual System – Page 24). Zinc may 
have a function in the connective tissue turnover in the sclera as zinc has been 
shown to affect collagen (Berman and Manabe, 1973) and matrix 
metalloproteinases in the anterior segment of the eye (Gaton et al., 1999). 
1.4.6. Lens and Iris 
Similar to the cornea, the lens is an avascular, transparent structure which functions 
to project light onto the retina. Approximately a third of the lens structure is 
protein, with water making up the rest. The cells within the lens continue to divide 
in one’s lifetime; meanwhile the cells present are not removed but are instead 
compressed into thin layers. This results in increased lens weight and size 
throughout life, which can result in formation of cataract and impaired ocular optics 
(Clinical Anatomy of The Visual System – Page 79). The zinc content in the lens is 
lower than in the retina-choroid. However, studies have shown a possible 
correlation between zinc deficiency and formation of cataract in both animal 
models and man (Ketola, 1979, Richardson et al., 1985, Racz et al., 1979, Barash et 
al., 1982). Loss of zinc-copper superoxide dismutase activity has been associated 
with cataract (Behndig et al., 1998), suggestive of the loss of zinc mediated 
protection in cataract cases. However, zinc supplementation was not found to 
prevent progression of cataract (Seddon, 2007). 
The iris is a pigmented structure which controls the amount of light that passes 
through the eye by altering the diameter of the pupil. Iris colour is determined by 
the amount of pigmentation present. Darker-coloured irides contain more 
melanocytes and melanosomes than those that are blue or lighter-coloured 
(Kokkinou et al., 2004). As melanin binds zinc, Newsome and colleagues have 
reported that the amount of melanin in the RPE can affect the uptake and 
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accumulation of zinc (Newsome et al., 1992). Melanin and zinc concentrations in 
the tissue are both reduced with age (Kokkinou et al., 2004). 
1.4.7. Vitreous and Optic Nerve 
The vitreous humor fills the large space in the posterior segment of the eye between 
the lens and retina. The gel-like substance contains 98.5-99.7% water, salt, soluble 
proteins and a network of fibers made up of type II collagen fibers and hyaluronic 
acid. The viscosity of the vitreous humor enables it to function as an effective 
shock absorber to prevent retinal damage. While few cells are found within the 
vitreous, hyalocytes and fibroblasts are thought to aid in the synthesis of 
glycoproteins and collagen (Clinical Anatomy of the Visual System page 95-99). 
The amount of zinc found within the vitreous humor can be affected by disease 
states such as cataract and diabetes (Nourmohammadi et al., 2006, Konerirajapuram 
et al., 2004). It has been suggested that zinc forms a part of the immune-defence 
mechanism through its anti-oxidative property (Bhooma et al., 1997). 
Axons from the ganglion cells concentrate at the optic nerve head and signals are 
transmitted to the nervous system (Clinical Anatomy of the Visual System page 
230-233). Rat models of zinc deficiency showed reduced myelinated axons and 
thinner myelin sheaths (Gong and Amemiya, 2001). The same observation was 
seen in monkeys treated with ethambutol, a tuberculosis drug which chelates zinc 
(Graham et al., 1998). The reduction in myelination was unable to be recovered 
with zinc supplementation, suggesting that zinc deficiency can lead to permanent 
loss of vision (Gong and Amemiya, 2001). 
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1.5. Consequences of Zinc Deficiency and Overload in the Body and Eye 
1.5.1. Zinc Deficiency 
Under normal conditions, cellular zinc concentration is very tightly controlled 
within a range of tolerable concentrations. Zinc homeostasis is achieved by 
regulating zinc-sequestering proteins such as metallothioneins, and albumin, or 
changing the expression of zinc transporter proteins which transports zinc in and 
out of the cell or intracellular compartments. It is also worth noting that the 
majority of zinc is bound with high affinity in the metal-binding domain of 
proteins.  
Many diseases are associated with zinc deficiency caused by the failure of 
regulating proteins important for zinc homeostasis or dietary zinc deficiency. One 
of the most well-known zinc-associated disorders is acrodermatitis enteropathica, a 
condition caused by missense mutation in SLC39A4, the gene that encodes the 
ZIP4 importer protein, which is highly expressed in the apical part of jejunum and 
duodenum of small intestine. The onset of the disease often occurs during early 
childhood, often not long after weaning from breast milk (Cameron and McClain, 
1986). The mutated ZIP4 protein does not possess the capability to bind zinc and 
hampers zinc absorption from the small intestine, leading to severe zinc deficiency 
(Muga and Grider, 1999). In addition to severe diarrhoea, skin lesions and growth 
retardation, there are ocular abnormalities associated with the disease. Decrease in 
thickness and polarity of the corneal epithelium, loss of Bowman’s membrane, 
severe degeneration of the RPE, loss of optic nerve fibres and loss of ganglion cells 
have all been reported (Cameron and McClain, 1986). In 1963, Prasad reported the 
occurrence of growth stunting, and hypogonadism in Iranian patients with zinc 
deficiency (Prasad et al., 1963). Chronic alcohol consumption can lead to reduced 
serum zinc concentration which can cause impaired immunity, diarrhoea and 
depression. Ocular abnormalities associated with chronic alcohol consumption 
include impaired dark adaptation and night vision (McClain et al., 1986). Iron 
chelation therapy using desferoxamine in patients with thalassemia major has been 
associated with growth retardation, reduced hair and leukocyte zinc. Furthermore, 
increased urinary zinc was observed in patients treated with desferoxamine over the 
period of 1 month (De Virgillis, 1998). Many of the diseases are systemic and can 
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be improved by zinc supplementation (Grahn et al., 2001). However, supplements 
need to be prescribed with caution as excessive zinc can result in impaired copper 
absorption, leading to copper deficiency (Yolton, 1981). 
Zinc deficiency results in various conditions in mammals. Animal studies using rats 
have shown that zinc deficiency leads to increased lipid peroxidation in the retinal 
pigment epithelium (RPE), as well as reduced metallothionein in the retina and 
RPE as visualised using electron microscopy (Miceli et al., 1999, Kindermann et 
al., 2005). Furthermore, developmental problems, increased cellular death and 
aberrant gestation have been seen (Jankowski et al., 1995).  Rats subjected to 
marked zinc deficiency during gestation produced pups with severe eye disorders. 
Anopthalmia has also been reported in the pups (Rogers and Hurley, 1987, Grahn et 
al., 2001). Furthermore, in rat kidneys of animals subjected to a zinc deficient diet 
for 60 days, decreased number of glomeruli and increased nitric oxide synthase 
were observed. Increased nitric oxide synthase is a risk factor for vascular and renal 
diseases (Tomat et al., 2005). 
1.5.2. Zinc Overload 
Compared to the significant health problems associated with zinc deficiency, zinc 
overload does not generally cause health issues. In vitro experiments have 
documented the dual role of zinc in rabbit retinas. Isolated rabbit retinas treated 
with 500µM zinc released GABA and NMDA resulting in increased neurotoxicity 
in the eye. This condition could be reversed by adding equimolar concentration of 
the zinc chelator diethyldithiocarbamate (Ugarte and Osborne, 2001). Proteomics 
experiments showed that increasing the zinc concentration to cytotoxic level (10 
ppm) results in reduced expression of eleven genes involved in the electron 
transport chain, and subsequently lower adenosine triphosphate (ATP) levels in 
cells (Kindermann et al., 2005).  
The physiological effects of zinc overload are not very well documented. However, 
it was noted that increased zinc concentration may cause copper deficiency, which 
may result in anemia, neutropenia, arthritis, arterial disease and osteoporosis in 
humans (Danks, 1988). Cells respond to increased intracellular zinc concentration 
by upregulating the expression of zinc exporters and metallothioneins, in addition 
to down-regulating zinc importer expression (Miceli et al., 1999).  
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1.6. Age-Related Macular Degeneration 
1.6.1. Overview of Age-Related Macular Degeneration 
Age-related Macular Degeneration (AMD) is a multifactorial disease which is 
characterised by pathological changes such as pigment (RPE) remodelling, with 
hypertrophy and depigmentation associated with the formation of soft drusen, hard 
drusen and eventually in some cases geographical atrophy of RPE cells. The 
disease is presently the most common cause of blindness in the developed world, 
occurring in >35% in people over 75 years of age (Stone, 2007). Exudative 
choroidal neovascularisation occurs in approximately 10% of patients and 
cumulates in vision loss (Stone, 2007). Focal sub-RPE deposits, or drusen protein-
rich aggregates of > 63µm - <124µm diameter and areeither diffuse,and covering a 
large area (soft drusen) or punctate, brighter and smaller (hard drusen). Figure 1.6 
shows the four stages of AMD as viewed with fundus photography (top panel) or 
immunohistochemical staining (panel below), with early AMD (A) showing several 
small deposits but lacking atrophy of cells and generally causing no extensive 
vision problems. Intermediate AMD (panel B) showed a markedly increased 
number of deposits with some coalescing as well as areas of early geographic 
atrophy. Advanced AMD can result from widespread geographic atrophy, and/or 
choroidal neovascularisation (CNV). Widespread geographic atrophy that affects 
the fovea will result in the loss of cone photoreceptor cells required for producing 
high resolution and colour vision. What triggers the onset of CNV in 10-15% of 
AMD subjects is unknown, however around 80% of vision loss is associated with 
CNV (Jager et al., 2008). 
There are several known predisposing factors for AMD. Genetic factors have 
included polymorphisms at AMD susceptibility loci on chromosome 1 and 10q26. 
High risk polymorphisms in Complement Factor H (CFH) (Klein et al., 2005), 
ARMS2 (Kanda et al., 2007), HTRA1 (Dewan et al., 2006), all located within these 
loci have been shown to predispose an individual to AMD (Stone, 2007, Francis 
and Klein, 2011). Other genetic associations have included polymorphisms in 
Apolipoprotein E (ApoE), ATP-binding cassette A4 (ABCA4), and Chemokine 3 
Receptor 1 (CX3CR1) (Francis and Klein, 2011). Smoking strongly predisposes 
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one to AMD, and therefore has been considered an environmental risk factor 
(Stone, 2007, Francis and Klein, 2011).   
Current treatment options are limited for AMD patients. In early and late stage 
AMD, zinc supplement containing zinc and antioxidants have been prescribed to 
patients (2001). Geographic atrophy at present is untreatable. CNV has been widely 
treated with laser ablation therapy as well as antibodies against vascular endothelial 
growth factor (VEGF) such as Lucentis and Avastin (Rattner and Nathans, 2006).  
Attempts have been made to transplant RPE cells into AMD patients to restore the 
dysfunctional RPE cells (Binder et al., 2007). 
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Figure 1-6- Fundus photograph and pathological features of AMD 
The fundus photographs (top panels) and histopathological micrographs (lower 
panels) shows three stages of AMD, starting from early AMD (A), characterised by 
the presence few small-medium sized deposits. Intermediate AMD (B) with a few 
large deposits and a much increased number of small-medium sized deposits. The 
end stages of AMD showed either geographic atrophy (C), or neovascularisation 
(D). (Image from (Jager et al., 2008) 
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1.6.2. AMD Pathogenesis 
The pathogenesis of age-related macular degeneration (AMD) is likely to be 
multifactorial, involving a complicated range of events. Prior studies have shown that 
the pathogenesis of AMD involves a combination of biological processes happening in 
the RPE, as well as other extrinsic factors. These events cumulatively result in damage 
to the RPE, choriocapillaris, as well as the thickening of Bruch’s membrane. The 
changes in the RPE-choroid interface triggers inflammatory events in the interface, 
resulting in formation of large sub-RPE deposits, geographic atrophy and choroidal 
neovascularisation, the three hallmarks of advanced AMD.  
The eye is highly susceptible to the presence of light-induced oxidative stress. The 
visual phototransduction occurring in the retina means that the region is regularly 
exposed to damaging blue light as well as oxygen, rendering it highly susceptible to 
light induced-oxidative stress (Beatty, et al., 1999). One of the functions of the RPE is 
to combat against oxidative stress by absorbing damaging blue/ultraviolet light through 
the presence of melanosomes in the RPE (Burke, 2011) and photoreceptor pigments 
such as such as lutein and zeaxanthin (Schupp, et al., 2004). The presence of 
lysosomes and phagosome in the RPE helps digests the photoreceptor outer segments 
(POS) to promote regular turnover. Under increased cellular stress, the failure to digest 
and remove the POS promotes the crosslinking of proteins. This crosslinking of 
proteins produces pigmented, insoluble aggregates termed lipofuscin (Jung, Bader, and 
Grune, 2007).  
Lipofuscin is one of the two main cellular debris found in the RPE-choroid interface, 
the other being drusen (Nowak, 2006). One of the major effects of lipofuscin is its 
ability to reduce proteosomal activity of the RPE. One of the main substituent of 
lipofuscin is -retinylidene--retinylethanolamine (A2E). The presence of A2E has 
been shown to interfere with the ability of the RPE cells to phagocytose 
photoreceptors, thereby increasing the presence of debris in the RPE. The disruption of 
RPE metabolism can potentially be implicated in the pathogenesis of AMD  
(Finnemann, 2002). In addition, A2E favours the formation of reactive oxygen species 
which promote more aggregate formation. In vitro, the presence of A2E in ARPE19 
cells exacerbated the cellular damage and apoptosis caused by exposure to blue light 
(Sparrow et al., 2002). While lipofuscin is characteristic of AMD, whether it is a 
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secondary effect or a causative effect of AMD is unknown although there is an age-
related increase in lipofuscin formation. (Swaroop, 2009). Recently, a publication 
indicated that rat subjected to zinc-deficient diet showed a much more prominent 
lipofuscin aggregation than those with zinc-replete diet although the mechanism is yet 
to be uncovered (Biesemeier, et al., 2011) 
Apart from damages caused by oxidative stress, there are other factors which could 
influence and indirectly predispose an individual to AMD. These extrinsic factors 
include age, genetics, and personal habits such as smoking. AMD predominantly 
occurs in people of age > 65 years old, making it the most common cause of legal 
blindness in the aging population. Numerous studies have uncovered the susceptibility 
loci in Chromosome 10q26, where the presence of several genes including ARMS2, 
PLEKH1, and HTRA1 may predispose certain group of population to developing 
AMD (Jakobsdottir, et al., 2005). As of late 2008, studies have also named people with 
mutations in Complement Factor H (CFH) to be predisposed to AMD (Nan, et al 
2008). Regular turnover of the extracellular matrix of Bruch’s membrane by matrix 
metalloproteinases is crucial to maintain an optimal thickness of the matrix. Smoking 
is a strong contributor to the pathogenesis of AMD, with the AREDS study reporting 
smoking as the strongest extrinsic risk factor for AMD (AREDS, 2001).  
 
Another hallmark of AMD is the formation of protein deposits between the RPE and 
Bruch’s membrane termed drusen. Numerous publications have suggested that the 
source of drusen is inflammation occurring in the RPE. (Hageman et al., 2002, 
Anderson et al., 2002, Johnson et al., 2001) It is possible that the initiation of oxidative 
stress exacerbated immune reaction from the RPE/choroid which amplified the 
pathogenesis of AMD. Studies have reported of the upregulation of inflammatory 
cytokines and immune-related proteins in AMD patients such as IL1, IL6, and TNF-α. 
A recent study shows that the upregulation of IFN-γ caused by photooxidative stress of 
the ARPE19 also resulted in the upregulation of CFH. CFH is an inhibitor of the 
complement system which triggers pro-inflammatory complement cascade (Lau, et al., 
2011). Positive immunostaining of coagulating-factor proteins such as thrombin, 
acute-phase proteins, immune-related proteins such as complement proteins, and 
amyloid-β has been seen in drusen (Hageman, et al 2001). In 2005, publications 
showed that a Tyr502His mutation in the CFH gene is related to increased risk of 
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developing AMD (Klein, et al., 2005, Edwards, et al., 2005). Furthermore it is possible 
that in aging population, the reduction of immune function results in lowered ability to 
combat oxidative stress, leaving the tissue more susceptible to AMD. The thickening 
of Bruch’s membrane has been attributed to increase in tissue inhibitor of matrix 
metalloproteinases (TIMP-3). Activity of TIMP-3 is crucial to regulate extracellular 
matrix turnover. TIMP-3 level is increased with aging and in human AMD subjects 
(Kamei, and Hollyfield, 1999). 
 
It is crucial that the RPE functions optimally to absorb damaging blue light as well as 
recycling photoreceptor outer segments. Failure to do so may result in increased 
formation of drusen and lipofuscin.The presence of drusen and lipofuscin resulted in 
morphological and cellular changes within the RPE, Bruch’s membrane and choroid 
interface. These changes include, but are not limited to pigmentation changes in the 
RPE where hypo/hyperpigmentation can occur, and failure to phagocytose 
photoreceptor outer segment which affects RPE metabolism (McLeod et al 2009). The 
choriocapillaris experiences a reduction in lumen diameter as well as a loss of 
fenestration (McLeod et al 2009). Death of RPE cells can trigger a secondary loss of 
choriocapillaris (Mullins et al., 2011, McLeod et al 2009).  
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1.6.3. Use of Zinc in AMD 
Zinc modulates many antioxidants which protect against oxidative stress that might 
be triggered in AMD. Antioxidants present in the Retinal Pigment Epithelium 
(RPE) include catalase, metallothionein (MT) and glutathione peroxidase (GPx). 
Low levels of zinc result in lowered antioxidants that leave the RPE vulnerable to 
oxidative injury which in turn may trigger AMD. Tate and colleagues reported that 
a reduced level of MT in cells results in less zinc being stored, and antioxidant 
levels were also found to be reduced. Similarly, pigmented mice fed with a low zinc 
diet were found to have increased lipid peroxidation as measured by the 
thiobarbituric acid reactive assay (TBARS). The group also found a reduced MT 
level in liver, RPE-choroid and retina (Miceli et al., 1999). Furthermore, lowered 
zinc may affect superoxide dismutase (SOD), a zinc protein that converts O2
•- 
to 
H2O2 to prevent harmful oxidative damage to the cellular environment (Miceli et 
al., 1999). A 24% reduction in zinc concentration was found in the RPE-choroid 
complex of older patients, suggesting that zinc supplementation might have a 
beneficial effect in preventing AMD (Erie et al., 2009).  
Clinical trials have reported mixed results regarding the use of zinc 
supplementation in AMD patients. The AREDS report number eight indicated that 
the consumption of 80 mg zinc oxide for 80 months in a late stage AMD clinical 
trial with 312 people resulted in improvement of vision and prevents night 
blindness. Furthermore, a follow-up study showed that lower oxidised cysteine or 
cystine was found in subjects who took zinc supplementation for AMD. This may 
indicate better protection against oxidative stress (Moriarty-Craige et al., 2007). 
Conversely, a similar study with 3654 patients with early stage AMD consuming 
zinc supplementation over a period of five years did not report a protective effect 
against AMD (Flood et al., 2002). 
Excessive intracellular zinc can result in cytotoxicity, and therefore zinc 
concentration needs to be restrained within tolerable limits (Bozym et al., 2010). 
Wood and Osborne (2003) reported that in human RPE cell culture, zinc 
concentrationsof 25 µM are toxic if not chelated. Toxicity is likely to be caused by 
production of oxidative radicals. A concentration of 18 µM of zinc reduces cell 
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viability in human RPE cell culture to 50% which is reversed once supplemented 
with metabolic substrates and antioxidants (Wood and Osborne, 2003). 
Intriguingly, the concentration of zinc in the RPE-choroid complex is very high, but 
under normal conditions, the cells do not appear to undergo significant oxidative 
stress.   
The varied results found in clinical trials indicate that further studies are required 
before zinc supplementation is introduced routinely as a preventative treatment of 
AMD. A recent study found that sub-RPE deposits contain a very high amount of 
bio-available zinc. Bruch’s membrane was found to contain 254 ppm of zinc, 
meanwhile the macula contains 130 ppm and in the peripheral region of the choroid 
123 ppm (Lengyel et al., 2007). However, presently there is a lack of knowledge 
regarding the source of zinc in these sub-RPE deposits. It was suggested that sub-
RPE deposits may obtain its zinc from the choroid complex, and through Bruch’s 
membrane. It was found that drusen form around choroidal intercapillary pillars in 
older patients (Lengyel et al., 2004). With the knowledge that the overall zinc level 
in the sub-RPE deposits is very high, it is interesting to speculate on the mechanism 
responsible for transport of zinc to the vicinity of sub-RPE deposits. Zinc 
transporter activity or expression might be improperly regulated in AMD patients. 
 
 
 
 
 
 
 
 
53 
 
1.7. Aims of the Thesis 
The highest tissue concentration of zinc in man is found in the RPE/choroid 
complex (Grahn et al., 2001, Karcioglu, 1982). Here zinc is required for regulating 
a myriad of enzymes involved in the retinal cycle, in the phagocytic activity of the 
RPE as well as the oxidative processes that are so important at the RPE-choroid 
complex. We understand a great deal about the role zinc plays in enzymes and 
transcription factors, but how zinc levels are regulated intra- and extracellularly in 
the eye is largely unknown. As zinc deficiency had been associated with serious eye 
diseases like AMD (Grahn et al., 2001) it is perhaps not surprising that zinc 
supplementation is one of the most widely used preventive therapies for AMD, 
despite the mixed results of recent international clinical trials (Mitchell et al., 1995, 
2001, Ho et al., 2011b). In 2004, work in our laboratory reported that sub-retinal 
RPE deposits, the hallmark of AMD, contained a surprising>500 ppm of zinc in the 
extracellular Bruch’s membrane (Lengyel et al., 2007). How accumulation in 
drusen and decrease in Bruch’s membrane and RPE cells contribute to AMD, 
however is largely unexplored. 
The work described thesis aimed to elucidate potential mechanisms of zinc 
transport in the posterior eye and to explore the effects of altering extracellular 
zinc concentration on vascular endothelium and retinal pigment epithelium.  
We embarked on a series of experiments that were designed to address how the 
RPE, the choroid and Bruch’s membrane change their properties in an altered zinc 
environment. We used molecular and cell biology and bioinformatics as well as 
studies on human cadaveric tissues to gather information on how zinc might be 
involved in normal and pathological processes at the RPE/choroid interface. 
1. First we aimed to identify the zinc transporter(s) at the RPE/choroid interface 
in cadaveric tissues and cultured cells. 
2. Then we aimed to characterize how RPE/choroid specific transporter(s) 
contribute to altered zinc balance.  
3. Finally, we aimed at investigating how cells respond to the modulation of 
extracellular zinc environment using cellular models for RPE as well as the 
fenestrated choroidal endothelium. 
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2. Materials and Methods 
2.1. Reagents 
Four percent paraformaldehyde (PFA) was freshly prepared using 32% PFA 
(Electronic Microscopy Sciences, Hatfield, USA) diluted in Phosphate Buffer 
Saline 1x concentration with neutral pH (Gibco Invitrogen, Paisley, UK). Ethanol 
(VWR International, Lutterworth, UK) used are molecular biology grade with 
99.9% purity.  
 
2.2. Buffers, Solutions and Gel Preparations 
4% Paraformaldehyde 
7 parts deionised water 
1 part 32% Paraformaldehyde  
Tris-Buffered Saline 10x 
200mM Trizma (Sigma-Aldrich, Gillingham, UK) 
1500mM NaCl (Sigma-Aldrich, Gillingham, UK) 
Make up 600 ml solution with deionised water and adjust pH to 7.4. Top up volume 
with dH2O to 1000ml.  
Tris-Buffered Saline Tween (TBST) 1x 
900ml Deionised H2O 
100ml TBS 10x  
Tween20 0.1% (v/v)  
SDS-Polyacrylamide Gels (10%)  
For one gel, materials added in consequence:  
Stacking Gel 
2ml deionised water 
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1.65ml Acrylamide-Bis 30%  
1.25ml Tris pH 6.8 
50µl SDS10% (w/v) 
25µl Ammonium Persulphate (APS) 10% (w/v) 
10µl ,,′,′-Tetramethylethylenediamine (TEMED)  
 
Resolving Gel 
2ml deionised water 
1.65ml Acrylamide-Bis 30%  
1.25ml Tris pH 8.8 
50µl SDS10% (w/v) 
25µl Ammonium Persulphate (APS) 10% (w/v) 
10µl ,,′,′-Tetramethylethylenediamine (TEMED) 
 
Ammonium Persulfate (APS) 10%  
10g APS (Sigma-Aldrich, Gillingham, UK) 
100ml deionised H2O 
Aliquot and frozen at -20
o
C 
 
Sodium-Dodecyl Sulfate (SDS) 10%  
10g SDS (Sigma-Aldrich, Gillingham, UK) 
100ml deionised H2O 
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Blotting Buffer 10x 
1500mM Glycine (Sigma-Aldrich, Gillingham, UK) 
20mM Trizma  
Blotting Buffer 1x 
For 500ml 
350ml deionised water 
100ml Methanol (20% v/v) 
50ml Blotting buffer 10x 
5ml 0.02% SDS  
Western Blot Blocking Solution  
5g Non-fat Dry Milk (Bio-Rad, Hemel Hampstead, UK) 
100ml TBST 1x 
Running Buffer 1x 
192mM Glycine (Sigma-Aldrich, Gillingham, UK) 
25mM Trizma 
0.1% (w/v) SDS 
Ponceau S Stain 10X 
1g PonceauS (Sigma-Aldrich, Gillingham, UK) 
50% Acetic Acid (Fisher-Scientific, Horsham, UK) 
In order to use, dilute 1:10. Stain PVDF membrane for 5 minutes with gentle 
agitation before rinsing with H2O for 30 minutes on the shaker at room 
temperature. 
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Lysis Buffer for Western Blot  
50 mM Tris pH 7.4 
150 mM NaCl 
0.5% NP40  
10% Protease Inhibitor Cocktail (Sigma-Aldrich, Gillingham, UK) 
5x Laemmli Buffer (Sample Buffer) 
250mM Tris-Cl pH 6.8  
5%(w/v) Sodium Dodecyl Sulfate (SDS)  
50% (v/v) Glycerol 
500 mM β-Mercaptoethanol  
0.02% (w/v) Bromophenol Blue 
Top up with deionised water to appropriate volume   
Luria-Bertani Broth (LB Broth) 
4g Tryptone (Merck, Feltham, UK) 
2g Yeast extract (Merck, Feltham, UK) 
4g NaCl 
400ml deionised water and autoclave  
Luria-Bertani Agar  
2g Tryptone  
1g Yeast extract 
1.6g NaCl 
3g Agar 
200ml deionised water and autoclave 
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Whenever appropriate, antibiotics were used for agar and broth at concentrations:  
Ampicillin 100µg/ml 
Chloramphenicol 170µg/ml 
Zeocin 30µg/ml 
Glycerol Stock 
20µl Glycerol 
80µl unpelleted bacterial culture  
Immunocytochemistry Blocking Solution for All Cell Lines Apart from 
BEBD5 cells.  
1.16g Bovine Serum Albumin (BSA) (Sigma-Aldrich, Gillingham, UK) 
0.5g Glycine  
200ml PBS 1x  
Immunocytochemistry Permeabilisation Solution for All Cell Lines Apart 
from BEBD5  
0.3% BSA  
0.3% TritonX-100  
In PBS 1x 
Immunocytochemistry Blocking Solution for BEBD5 cells.  
0.2% Fish skin gelatin (Sigma-Aldrich, Gillingham, UK) 
5% Normal goat serum (Sigma-Aldrich, Gillingham, UK) 
In PBS 1x   
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Immunocytochemistry Permeabilisation Solution for BEBD5 cells 
0.1% TritonX-100 in PBS 1x 
2.3. Antibodies 
Please see Appendix 1 for a list of all the antibodies used in this study.  
2.4. Sample Preparation 
2.4.1. Cadaveric tissue dissection 
Human cadaveric eyes not exceeding 30 hours post-mortem were used. In instances 
where sclera was still attached to the back of eye, the whole eye was placed on a 
Petri dish under an inverted microscope. Following removal of the lens, the ora 
serrata was cut 3mm circumferentially and iris removed to facilitate the removal of 
the vitreous humor. Neurosensory retina (NS) attached to the vitreous humour was 
carefully isolated. Retinal pigment epithelium (RPE) cells were collected for RNA 
isolation using 600 µl of lysis buffer applied directly into the eye cup. Remaining 
choroid was rinsed with PBS and collected. For RNA work, RNAlater (Qiagen 
GmbH, Germany) was used to preserve the quality of RNA in choroid samples and 
deactivate RNAses. In order to preserve structure and morphology, tissues were 
treated with 4% PFA and stored in 4
o
C temperature for future use.Remaining 
tissues were returned back to the Department of Pathology at Institute of 
Ophthalmology to be disposed of in accordance with best practise guidelines.  
2.4.2. Tissue Preparation 
Tissues were generally stored in RNAlater, which preserves RNA. A piece of tissue 
< 30 mg in weight was dissected,and placed in a sterile blue homogenizing tube and 
using hand pestle or hand held rotor, ground well to produce homogenous lysate.  
2.4.3. Cadaveric Human RPE Preparation 
The retina, RPE and choroid were removed in subsequent order for RNA isolation. 
The anterior pole was removed from the posterior pole before removing the 
vitreous from the retina. The RPE and choroid was flatmounted. Using pipette, PBS 
was carefully applied onto the RPE layer to dissociate the cells. The RPE was 
placed on microcentrifuge tubes before spun at highest setting (14000rpm) for 10 
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minutes to pellet it. The choroid and retina was cut to < 30mg sections for RNA 
isolation purpose. 600 µl of lysis buffer or alternatively RNAlater was applied to 
per 30mg tissue. The cell lysate was collected and transferred into sterile and 
RNAse free 2ml tube and mixed well either by pipetting or vortexing.  
2.4.4. Cell culture preparation 
Cell cultures were rinsed twice with PBS 1x to remove any traces of cell culture 
medium. 700 µl of lysis buffer containing protein denaturant guanidine thiocyanate 
(RLT) was added to the cell culture dish. A cell scraper (BD Biosciences, USA) 
was used to gather the lysate, which was then mixed by pipetting up and down in 
the cell culture dish. This was then followed by standard RNA isolation procedure 
as described in the manufacturer’s protocol (See section 2.5.1).  
2.5. RBA Studies 
2.5.1. RNA isolation 
Prior to starting the procedure, RNAseZap and DNAZap (Ambion Inc, USA) was 
always used to prevent contamination from genomic DNA and degradation of 
RNA. The addition of β-mercaptoethanol in the lysis buffer (RLT) further 
prevented RNAse activity. All RNA isolation was done using RNeasy Mini Kit 
(Qiagen GmbH, Germany) following the manufacturer’s protocol. The cell or tissue 
lysate collected (700µl) was transferred onto a QIAshredder column (Qiagen 
GmbH, Germany), centrifuged for two minutes at 14000rpm and combined with 1x 
volume of 70% ethanol. The ethanol-lysate mixture was then transferred onto the 
spin column and centrifuged for 15 seconds at 10000rpm, washed once using wash 
buffer RW1, followed by 15 minutes of DNAse digestion step (Qiagen GmbH, 
Germany). The column was then washed again once with buffer RW1 and twice 
with buffer RPE. The RNA was eluted using DNAse/RNAse free water. The 
integrity of the RNA was tested using Bioanalyser (Bio-Rad, Germany) and only 
samples with RNA quality indicator (RQI) value of > 7 were used. Samples derived 
from cell culture regularly reach RQI value of 10, however due to potential post-
mortem RNA degradation, RQI value from cadaveric tissues do not reach RQI of 
10. In order to check for potential cross-contamination between the RPE, retina and 
choriocapillaris, qRT-PCR was performed with rhodopsin, RPE65 and Vascular 
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Endothelial Cadherin (VE-cadherin) for photoreceptor, RPE and endothelial 
specific genes respectively. The lower RQI number and evidence for cross-
contamination (for data and explanation, refer to section 3.6) in cadaveric tissue 
indicated that our results need to be perceived carefully and that a false positive 
result for ZIP12 expression in RPE cannot be completely ruled out.   
2.5.2. Quantification and integrity analysis 
RNA concentration was measured using NanoDrop (ThermoScientific, Horsham, 
UK) and only RNA with 260/280nm ratio above 1.8 was used for all experiments. 
RNA integrity was assessed Bio-Rad Experion (Bio-Rad, Hemel Hampstead, UK).  
2.6. DBA Work 
2.6.1. cDNA synthesis 
Precision Reverse Trancription Kit (PrimerDesign, Southampton UK) was used for 
cDNA synthesis according to the manufacturer’s guide. For every cDNA synthesis 
reaction, 2.5 µg RNA template was used. A mixture of oligo-dT primers and 
random nonamer primers (2 µl), dNTP (1µl), RNA and water were added in a thin-
walled 500 µl microcentrifuge tubes. Samples were heated with lids closed for 5 
minutes at 65
o
C, followed by immediate cooling on ice before 4 µl of MMLV 5x 
buffer, 5.2 µl of RNA-DNAse-free water, and 0.8 µl of MMLV enzyme were 
added. The reaction was placed on 42
o
C hot block for 60 minutes and following 
that stored at -20
o
C until used. See below for detailed protocol.  
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Annealing Step 
RNA template, primer, dNTP and water mix was heated at 65
o
C for five minutes 
before being rapidly cooled on a block of ice.  
No  Amount 
1 RNA template 2-5 µg 
2 Reverse transcription primer (OligoDT and random 
nonamer) 
1 µl 
3 dNTP mix 10mM 1 µl 
4 RNAse/DNAse free water To 10µl 
Extension Step 
The mix containing RNA template, primers, dNTP and water (Annealing Step) was 
combined with MMLV buffer, enzyme and water before heated at 42
o
C for 60 
minutes. All cDNA samples were stored in -20
o
C before used. 
No  Amount 
1 MMLV 5x buffer 4µl 
2 RNAse/DNAse free water 5.2µl 
3 MMLV reverse transcriptase enzyme  0.8µl 
 Total  10µl 
2.6.2. Quantitative RT-PCR 
The primers were designed by PrimerDesign (Southampton, UK). The sequences for 
24 murine and human zinc transporter primers and 3 housekeeping genes along with 
melting temperatures and cycling condition are shown in the Appendix 3 and 4. All 
qPCR reactions were done for 50 cycles with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein (YWHAZ) and ubiquitin C (UBC) as controls.  
For every reaction, 50 ng of cDNA template, 10 µl of PrimerDesign 2x Precision
TM
 
Mastermix, 4 µl of RNAse/DNAse free water and 1 µl of resuspended primer mix 
was included, giving a total reaction volume of 20µl. The mastermix contained 2x 
reaction buffer, 0.025 U/µl TAQ-Polymerase, 5 mM MgCl2, 200 µm of each dNTP 
mix. Alongside this, the mastermix contained the fluorescence dye SYBR-green as 
well as calibrating dye ROX. SYBRgreen is a DNA-binding dye which increases the 
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level of fluorescence when encountering double stranded DNA. ROX was included 
as a baseline for the RT-PCR, normalising for pipetting error. Furthermore, for 
SLC39A12, a TaqMan style primer was designed to confirm observations from the 
SYBRgreen primer. The Applied Biosystems 7900 HT RT-PCR machine was used 
for all experiments. The cycling condition for the RT-PCR was done in four steps, 
comprising enzyme activation at 95
o
C for 10 minutes, 50 cycles of enzyme 
denaturation for 15 seconds at 95
o
C and data collection using the SYBRgreen dye for 
60 seconds at 60
o
C. This was followed by a melt curve analysis to check specificity. 
At least duplicates and a non-template control were performed for every single 
primer.  
The data were analysed using the relative quantification method. The relative 
quantification method measures the fold difference in gene expression through ratio 
of crossing point (Ct) values normalized to ratio Ct values for the housekeeping 
genes. This method was chosen, as it does not require standards with known 
concentration as needed by the absolute quantification method, the accuracy of 
which is often disputed. The algorithm for the relative quantification is shown as 
follows: 
 
Relative Expression = 2
-(∆∆Cp) 
 
∆∆Cp =  ∆CpGene of Interest - ∆CpCalibrator   
∆CpGene of Interest = CpGene of Interest – Average Ct Housekeeping genes  
∆CpCalibrator = Cp calibrator – Average Ct Housekeeping genes 
Equation 1–The relative expression between two genes is calculated using the 
relative expression formula. 
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The relative expression for two genes was calculated by measuring the ∆Ct for the 
calibrator and gene of interest separately. The calibrator can be any other genes in the 
set of genes. In general, we made a comparison with the same gene from different 
sample. We use three housekeeping genes as normalisers, GAPDH, UBC and 
YWHAZ. These three genes were chosen based on geNorm software analysis against 
12 other reference genes performed by PrimerDesign (Southampton, UK) on retinal 
cDNA to represent eye samples. GAPDH, UBC and YWHAZ were the three most 
stable reference genes and were therefore chosen for this study. The raw cyclic data 
for the three genes were averaged using the GeoMean function in Microsoft Excel.  
2.6.3. DNA clean up 
2.6.3.1. EtOH precipitation 
For every 10µl of the sequencing reaction, 40µl of 80% ethanol was added and the 
whole mixturevortexed. The mixture was left on ice for 10 minutes before 
centrifuging for 10 minutes at 4
o
C. After aspirating the 80% ethanol, 180µl of 70% 
ethanol was added before 5 minutes of centrifugation at maximum speed at 4
o
C. 25µl 
Millipore filtered water was used to resuspend the dried DNA pellet.  
2.6.3.2. Millipore Montage system 
This was used as per the company protocol. In brief, the DNA product to be purified 
was applied onto the Millipore blue plate, vacuumed to dryness before two washes of 
25µl each with the washing buffer was carried out.  
2.6.4. Agarose gels 
DNA/ PCR samples were run on 1% (w/v) agarose gels dissolved in 1x TAE buffer 
at 100V with 1% Orange G in glycerol as a loading buffer. Ethidium Bromide was 
incorporated into the gel for visualisation under ultraviolet light. See below for 
agarose gel preparation. 
 
3g Agarose (Sigma-Aldrich) 
300ml deionised H2O  
After boiling in a microwave oven the solution was left to cool slightly and ethidium 
bromide added at 0.5µg/ml 
65 
 
2.6.5. DNA sequencing 
All sequencing was performed using Applied Biosystems 3730 DNA Analyzer. Each 
of the sequenced DNA sample contained 3µl of plasmid DNA, 2.5µl of sequencing 
buffer, 0.5µl of BigDye 3.1, 0.5µl of 100µM primer and deionised water to 20µl total 
volume. The reaction mix was then placed at 96
o
C for 10 seconds, 50
o
C for 5 
minutes and 60
o
C for 4 minutes for 25 cycles before purified either using ethanol 
precipitation or Millipore montage system. For detailed information on sequencing 
condition and materials, see Appendix 4.  
2.7. Protein Studies 
2.7.1. Western Blot 
Most of the experiments were carried out on BioRad AnyKD precast gels or 10% 
SDS-Polyacrylamide gels (for gel preparation, please see section 2.2). Cells and 
tissues were lysed in lysis buffer (See section 2.2) on a rotator at 4
o
C for one hour.  
Lysed tissues or cells were denatured with 5x Laemmli buffer and boiled for 5 
minutes at 90
o
C before being run on polyacrylamide gels. Twenty micrograms of 
sample were used unless stated and triplicates of experiments were performed unless 
stated. The self-casted gels were run at 70V for 30 minutes before the voltage was 
increased to 100V. The precasted gels were run at 120V until the smallest molecular 
weight marker reached the end of the gel. The gels were sandwiched with a PVDF 
membrane (Bio-Rad) between four sheets of Whatman filter paper (two on each 
side). Protein immobilisation was done on Bio-Rad Criterion system at 90-100V for 
90 minutes each time at 4
o
C. Following this, 1x Ponceau S solution was used to 
visualise and check protein transfer and rinsed before placing the membrane on 
blocking solution for at least 30 minutes. Depending on the antibody, antibody 
incubation was carried out at room temperature for two hours, or at 4
o
C overnight 
with rotation. Secondary antibody incubation (anti-HRP) was done at room 
temperature for one hour. All incubation procedures were followed by three washing 
steps of ten minutes each with TBST 1x. The protein was visualised using ECL 
(Calbiochem) and films (Amersham).  
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2.7.2. In Vitro Translation 
Each in vitro translation reaction contained:  
 
20 µl TNT Quick Mastermix  
0.5 µl Methionine 1mM  
1 µl DNA template (1µg) 
3.5µl Nuclease free H2O  
Incubation was carried out at 30
o
C for 90 minutes, and the reaction mixture stored in 
-20
o
C prior to use.  
In order to determine the molecular weight of the protein, TNT Quick Coupled 
Translation system was used. The pcDNA3.1 vector which was amplified, 
contained the T7 polymerase promoter required for the translation system. All 
materials were assembled in a microcentrifuge tube and left to incubate at 30
o
C for 
90 minutes. The resulting product was diluted 1:4 before being run on gel as per 
described in the Western blot protocol in Section 2.7.1.   
2.7.3. Bichinconinic Assay 
The Bichinconinic Assay (BCA) assay was used to determine protein concentration 
in tissue lysates for Western blot. The tissues were lysed as per normal, and BSA 
standards were serial-diluted in the lysis buffer ranging from 0-2000 µg/ml. The 
proprietary BCA working solution was mixed with CuSO4 solution at 1:50 dilution. 
Equal amounts of sample/ standard were mixed with the working solution and 
incubated at 37
o
C for 30 minutes. Two µl of samples and standards were measured 
on the Protein BCA program on the Nanodrop. None of the materials in the lysis 
buffer were found to interfere with the assay. 
2.7.4. Transient Expression of protein in cells 
The plasmid DNA generated was used to transfect various cell lines with different 
success rate. HEK293T and CHO cells were relatively easier to transfect than RPE 
cell lines. A day before transfection, cells were grown on 24 well plates with 
coverslips. BEND5 and ARPE19 cells were seeded at 30000 cells density. HEK293 
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cells were seeded at 60000 cells. All cells transfected were grown to a density of 
80-90% in media supplemented with fetal calf serum but without antibiotics. Eight 
hundred ng of DNA was used with four µl of Lipofectamine2000 diluted in Opti-
Mem reduced serum media. After incubation for four hours, the transfection media 
was topped up with twice as much media and left for 24-48 hours.  
2.8. Cell Culture 
2.8.1. Cell lines 
All of the cell lines were cultured in 37
o
C humidified chamber with 95% air and 
5% CO2. For complete list of cells used in this study, and their growing conditions, 
see Appendix 2. 
 
2.8.2. Propagation and Freezing 
Frozen vials were rapidly warmed and warmed supplemented media added. The 
cells were left overnight to attach before changing to fresh media. Confluent cells 
were detached with 1x Trypsin-EDTA, neutralised with serum-supplemented 
DMEM and centrifuged at 800rpm for three minutes before being resuspended and 
seeded at appropriate density. The density of the cells was determined using a 
haemocytometer after dilution of 1:1 with trypan blue. In order to ensure there were 
enough nutrients for the cells, for every cm
2
 in a confluent flask, 0.3 ml of complete 
medium was added. 
 
On average, 3x10
6 
cells were frozen in a vial. Following standard trypsin-EDTA 
detachment and centrifugation, the cell pellets were resuspended inmedium 
comprising of of 50% DMEM, 40% FCS, 10% DMSO filtered in 0.2 µm Millipore 
syringe. Following this the cells were transferred to a 1.8 ml cryovial (Fisher 
Scientific, Loughborough, UK) cell freezing container (Nalgene) and placed in -
80
o
C for a day before transferring to liquid nitrogen.  
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2.8.3. Cytotoxicity Assay 
The calcein assay was used to determine cell death. A 1mM stock of calcein dye 
(Invitrogen, Paisley UK) was diluted 1:1100 with warm 1x PBS. Propidium iodide 
was added at 1:400. The solution was used to incubate cells for 15-20 minutes at 
37C (standard cell culture condition) before visualised with a fluorescence 
microscope. Positive propidium iodide staining indicated non-viable cells as the 
dye is cell impermeant. The calcein dye shows viable cells.  
2.8.4. Cell Proliferation Assay 
AlamarBlue solution was purchased from ABDSerotec (Kidlington, UK). Cells 
were seeded at 5000 cells per well on a 96-well plate to match the cell density in 
the other experiments with 200µl growth media. After incubation for 1-6 days to 
identify with the other experimental conditions, 10% (volume of media to volume 
of Alamar Blue added) of undiluted AlamarBlue solution was added and left to 
incubate for 2 hours before its absorbance measured at 600nm and 450nm on a 
plate reader. Calculations for the absorbance were made according to the equation 
provided by the manufacturing company and presented as percentage reduction of 
AlamarBlue. As controls, cells without zinc treatment were used and as blanks, 
absorbance of growth media without zinc added was measured. It was pre-
determined that the addition of zinc does not affect AlamarBlue absorbance. 
2.8.5. Wholemount TEM preparation 
Nickel grids 3.05mm (TAAB Microscopy, Aldermaston, UK) were rinsed in 
acetone to remove grease. The grids were then placed on top of 1% formvar film 
floating on a glass container before being covered with sterile coverslips; averaging 
three grids per coverslip. A non-coated glass slide was then used to sweep the film-
grid-coverslip layer from the water. The resulting product was left to dry under a 
culture hood for 24 hours. The film-grid-coverslip layer was then carbon-coated 
before being sterilised for 30 minutes under the ultraviolet lamp. Following this, the 
sterilised coated grids were covered with 1% gelatine for 30 minutes under the cell 
culture hood before aspirated and rinsed with PBS 1x once. Twenty five thousand 
cells were seeded onto the grids overnight before media containing 125 µM 
ZnSO4in growth media was applied onto the cells for a further 20 hours. As a 
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negative control, untreated samples were used, and as a positive control for 
fenestrae formation, cells were treated with 1.25µM Latrunculin A diluted in 
growth media for three hours. Post-treatment, the cells were immersed in 
Karnovsky’s solution and left fixing overnight at 4
o
C. The cells were then washed 
twice for five minutes each with PBS1x solution. Freshly diluted 1% osmium 
tetroxide (OsO4) was used to post-fix the cells for 30 minutes. Care was taken to 
remove and discard the OsO4 waste, and cells were washed in distilled water for 
three times five minutes each. Cells were then placed on serial ethanol dilution for 
five minutes each time, going from 30%, 50%, 70%, 80%, 90%, 95%, 100%, 100% 
and a final 100%. Cells were rinsed and incubated for three minutes in 
hexamethyldisilazone (HMDS) at room-temperature before any solutions were 
aspirated and the coverslips left to dry overnight.  
2.8.6. Transepithelial Resistance Measurement 
Transepithelial resistance measurements of ARPE19 cells were done using ECIS 
Zθ Disposable 8-Electrode Array (Applied Biophysics, USA). Prior to seeding with 
cells, each of the 8 wells in the array was incubated in a 10mM cell-culture grade 
cysteine solution (Sigma Aldrich, UK). Following cysteine treatment, the wells 
were washed once with sterile distilled water and incubated in media for 30 minutes 
at standard incubating condition before 20,000 cells were seeded on each well. The 
arrays were then attached to the ECIS Zᶿ machine and placed in an incubator. The 
use of the ECIS Zθ machine prevented the arrays from being removed as this would 
introduce inconsistencies in the reading, therefore, the arrays were not taken off and 
media was not replaced for the period of 6 days of which measurements were taken.  
2.9. Immunohistochemistry /Immunocytochemistry and Zinc Visualization in 
vitro 
2.9.1. Fixation 
PFA/Triton 
Cells were fixed with freshly diluted 4% PFA in 1x PBS at room temperature for 20 
minutes. PFA solution was discarded, and 300µl of 1x PBS-Triton (See Section 
2.2)  was added per well in a 24 well plate. Following this, blocking buffer was 
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used to wash the cells twice, before incubating in the same buffer for at least 20 
minutes. 
 
Methanol 
Ice cold methanol was added onto cells and immediately placed in a -20
o
C freezer 
for five minutes. After methanol was aspirated, cells were rinsed once with PBS 
before beingreplaced with PBS for at least 5 minutes at room temperature. Blocking 
buffer (as described in section 2.2) was used to block the cells for at least 20 
minutes.  
2.9.2. Immunohistochemistry (Only BEND5) 
The cells were seeded at 3.3x10
4
cell density on glass coverslips in 24 well 
platewith 1% bovine gelatine as coating. Cells were left overnight to allow the cells 
to attach before being treated with either various ZnSO4 concentrations or 1.25 µM 
Latrunculin A (LA) for 20 or 3 hours respectively and left to incubate at 37
o
C. 
Freshly made 4% PFA was used to fix all the cells for 10 minutes followed by two 
PBS 1X washes and stored at 4
o
C. Before staining, the cells were treated with 0.1% 
Triton X-100 in PBS1x to permeabilise cells for 15 minutes. The antibodies were 
diluted in blocking buffer (see section 2.2) and incubated for one hour with both 
primary and secondary layers before washing three times with washing buffer (see 
section 2.2) for two minutes each. The rinsed coverslips were placed cell side down 
on a glass microscopic slide with 10 µl of Vectashield mounting media containing 
DAPI stain (Vector Laboratories). All images were taken usingfluorescence or 
LSM700 confocal microscopy.  
2.9.3. Immunohistochemistry (All other cell lines) 
The cells were seeded at optimum density on glass coverslips in 24-well plate. Cells 
were left overnight to allow the cells to attach. Freshly made 4% PFA or ice cold 
methanol was used to fix the cells for 20 minutes at room temperature or 5 minutes 
at -20
o
C, followed by two PBS 1X washes and stored at 4
o
C. Before staining, the 
cells were treated with 0.3% Triton X-100 in PBS1x to permeabilise them for 5 
minutes. The antibodies were diluted in blocking buffer (see section 2.2) and 
incubated for two hours (primary) and one hour (secondary) before washing three 
times with washing buffer (see section 2.2) for two minutes each. The rinsed 
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coverslips were placed cell side down on a glass microscopic slide with 10 µl of 
Vectashield mounting media containing DAPI staining (Vector Laboratories). All 
images were taken using fluorescence or confocal microscopy.  
2.9.4. Zinc probes 
Prior to treatment, cells were washed twice with pre-warmed PBS1x solution to 
remove traces of phenol red. A 5mM stock of zinc selective dye ZinPyr-1 was 
diluted to 1µM concentration in pre-warmed DMEM high glucose media without 
phenol red. The cells were incubated with the dye for 10 minutes at 37
o
C standard 
incubating conditions. Following three washes in DMEM-high glucose media 
without phenol red, preparations was immediately visualised live using Olympus 
BX51 using 20 x magnifications. All images were using the same exposure. Image 
analysis was done using Image J.  
2.10. Cloning Strategies 
ZIP12 was cloned using Gateway Technology (Invitrogen, Carlsbad USA). 
SLC39A12 was cloned by PCR using retinal cDNA (gift from Dr. Amna Shah). 
The PCR was performed using specially designed AttB primers. Fifty fmol of the 
PCR product was purified using ethanol precipitation and incorporated into the 
entry and expression vectors using BP clonase and LR clonase enzymes 
respectively. The transformed bacteria were plated on LB agar containing the 
appropriate antibiotics selection. A single colony was picked and incubated in LB 
broth also with appropriate antibiotics before purification using miniprep and 
maxiprep kits. The clones were checked for mutations and correct insertions by 
using restriction enzymes and sequencing. Upon sequencing, it was discovered that 
the retinal cDNA had a known silent polymorphism, as this do not change the 
amino acid sequence, the resulting clones continued to be used.  
2.10.1. Cloning Primer Designs 
The PCR primers (for list see Appendix 3) were designed according to criteria from 
Invitrogen. The forward primers contained four guanine residues at the 5’ to promote 
binding, a 25bp attB1 sequence and a TC base pair to maintain the reading frame. 
This was followed by a Kozak sequence (ACCATG), which aids the expression of 
eukaryotic proteins and the first 25bp of SLC39A12 sequence. A similar design 
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procedure was applied to the reverse primers, with also four guanine residues, 25 bp 
of attB2 sequence and an additional base pair to maintain the reading frame. For N-
terminal fusion proteins, the stop codon remained a part of the 25bp SLC39A12 
used, for the C-terminal fusion proteins, it is important to remove the stop codon to 
allow translation of the tag protein.  
2.10.2. Cloning PCR 
Each Cloning PCR reaction contained 
 
2.5µl 2mM dNTPs  
1.0µl 25mM MgSO4 
2.5µl 10 x KOD-PCR buffer  
0.75µl AttB-Forward primer 0.3µM final concentration  
0.75µl AttB-Reverse primer 0.3µM final concentration  
0.5 µl Enzyme – Kod Polymerase (1.0 U/µl) 
1.0 µl CDNA/ Plasmid DNA template  
 
PCR grade nuclease free water was used to make up to 25µl  
 
A Veriti (Applied Biosystem, UK) thermal cycler was used. The PCR conditions 
comprised a two minute denaturation step at 95
o
C and 35 cycles of 15 seconds at 
95
o
C, 30 seconds primer annealing step at 60
o
C and 41 seconds elongation step at 
72
o
C.  
2.10.3. Expression vectors 
For figures of vectors, please refer to Appendix 6.  
pDONR201/Zeo (Invitrogen) was used to create the entry clone for full-length 
ZIP12 protein.   
pcDNA3.2/V5-DEST (Invitrogen) was used to create the full-length ZIP12 with C-
terminal V5 tag fusion protein.  
pcDNA-DEST47 (Invitrogen) was used to create the full-length ZIP12 with C-
terminal GFP tag fusion protein.  
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2.10.4. Transformation of ccdB cells/ E.Coli 
Transformation of competent cells with DNA was performed according to the 
manufacturer’s protocol. One aliquot (200µl) of DH5α (Invitrogen, UK) was 
defrosted on ice and the completed BP/LR Clonase reaction added and incubated 
for 30 minutes. Following a 45 second heat shock step at 42
o
C, super optimal broth 
(SOC) media was added and the sample placed at 37
o
C shaking cabinet for one 
hour. The transformed cells were pelleted before being re-suspended and plated 
onto LB agar plates with antibiotic supplements.  
2.10.5. Purification of Proteins 
A single colony was picked using a plastic picker, and immediately transferred onto 
a 5ml LB broth with appropriate supplementation of antibiotics (See section 2.2 for 
concentrations) before incubated at 37
o
C with 200rpm agitation for at least 16 
hours. Following this, Wizard Plus SV Miniprep (Promega, UK) was used to purify 
the plasmid. Two ml of the overnight culture was centrifuged to produce a pellet, 
which was re-suspended, lysed and neutralised with the buffers provided by the kit. 
After centrifugation, the supernatant was collected and transferred to the miniprep 
column before endotoxin removal solution and multiple washes were performed to 
purify the protein. Proteins were eluted in nuclease free H2O, and protein content 
measured with NanoDrop. Upon sequencing and restriction analysis to confirm the 
right orientation and sequence of clone, a maxiprep was done to produce enough 
plasmid for transfection. Fifty µl of glycerol stock was added to five ml of LB broth 
before placing in the 37
o
C shaker for six hours and transferred onto 100ml LB broth 
and incubated for 16 hours. GenElute HP Endotoxin-Free Plasmid Maxiprep Kit 
(Sigma Aldrich, UK) was used to isolate DNA for maxipreps following the 
protocol provided. The culture was then pelleted and re-suspended before being 
lysed.The supernatant was purified through the syringes provided and washed to 
remove contaminants. Nuclease free water was used to elute the DNA. The 
resulting DNA was precipitated using ethanol precipitation and the concentration 
measured using NanoDrop. All plasmid constructs were aliquoted and stored at       
-80
o
C. 
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2.10.6. Glycerol Stock 
Glycerol was added to bacterial culture at a ratio of 1:4 before transferring into -
80
o
C freezer for storage.  
 
 
2.10.7. Restriction Digests 
All enzymes used were supplied by Promega (UK).  
Each restriction digest contained:  
1µl of plasmid construct (approximately 0.5µg)  
0.5µl of restriction endonucleases  
1.0µl Buffer (depends on endonuclease used)  
Water to 10µl  
 
DNA digests were run for one hour at 37
o
C and resulting digest product was run on 
1% agarose gel and visualised under UV light.  
 
2.11. Statistical Analysis 
Data presented in figure 4.25 is average fluorescence value ± standard deviation 
Statistical analysis for figure 4.25 was performed using Student’s T-test, between 
sham and transfected group and P value (< 0.01) was observed.  
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3. Expression of Mammalian Zinc Transporters in 
the RPE and Choroid 
 
There is little known about the presence and expression of zinc transporters in 
the eye. The work described in this chapter aimed to use quantitative RT-PCR 
to catalogue the presence and determine the relative expression levels of the 10 
SLC30A (ZnT) and 14 SLC39A (ZIP) mammalian zinc transporters in the 
retinal pigment epithelium and choroid. For this, we used RBA isolated from 
ARPE19 (spontaneously immortalised human RPE cell line), SHEF-1 cells (a 
human embryonic stem cell-derived human RPE cell line), primary human 
RPE cells at passages (4 and 12), primary cultures of Muller cells, and human 
retina, RPE and choroid dissected from cadaveric eyes. The primers were 
designed and optimised by PrimerDesign Ltd and all data were normalised 
against three housekeeping genes, GAPDH, YWHAZ and UBC. After 
cataloguing the relative expression levels of the 24 zinc transporters, we found 
widespread expression of the majority of zinc transporters, although 
expression levels did vary between different cell types. Through this 
comparison, we identified one striking anomaly in expression levels that may 
have relevance for zinc homeostasis at the RPE-choroid interface. We found 
that the expression of SLC39A12 gene encoding zinc transporter ZIP12 is 
highly expressed in freshly isolated cadaveric RPE cells but absent in the 
cultured cells tested. Based on this observation, we specifically analysed this 
gene and its protein product in Chapter 4.
2
 
 
 
 
 
                                                 
2
Several parts of this chapter (Section 3.6) have been published in Barzegar-
Befroei, N., Cahyadi, S., Gango, A., Peto, T., and Lengyel, I. 2011. Zinc in Eye 
Diseases. Zinc in Human Health, Editor: Lothar Rink.IOS Press Amsterdam (see 
Appendix) 
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3.1. Intracellular Zinc Transport 
3.1.1. SLC30A Family of Transporters 
The SLC30 gene codes for a family of zinc transporters (ZnTs) which are 
ubiquitously expressed in all organisms (Liuzzi and Cousins, 2004b). The ZnT 
family of transporters specifically promotes the transport of zinc from the cytosol to 
extracellular environment or compartmentalise zinc into organelles within the cell. 
ZnTs possess six transmembrane domains with a variable region between domains 
III and IV, which contains many histidine residues able to bind zinc. Loss of zinc 
transporters due to gene mutations or incorrect translation of mRNA has been 
reported to result in various pathological conditions, which may include embryonic 
lethality, incorrect absorption of zinc, reduced body fat and weight in mice (Huang 
et al., 2007)  and lethal milk syndrome caused by a mutation in the SLC30A4 gene 
encoding the ZnT4 protein (Murgia et al., 2006). The distribution of ZnTs is 
widespread; although some are cell-specific (Redenti and Chappell, 2004b, 
Palmiter and Huang, 2004).  
3.1.2. SLC30A1 / ZnT1 
The SLC30A1 gene codes for the ZnT1 protein, which is an ubiquitous zinc 
exporter protein that functions to reduce intracellular zinc concentration and that 
has been described as “conferring resistance to zinc” (Palmiter and Findley, 1995). 
Northern blot analysis showed that in rat, SLC30A1 mRNA was present in the 
kidney, small intestine, adipose tissue, liver, spleen and thymus tissues (Liuzzi et 
al., 2001b). The protein was found in placenta, kidney, small intestine, and 
moderately expressed in adipose tissue, liver, spleen and thymus. In the mouse 
gastrointestinal tract, ZnT1 was found to be differentially expressed within the 
small intestine, where it was found in the basolateral membrane of the epithelium of 
esophagus, duodenum of the small intestine and cecum of large intestine (Yu et al., 
2007). Within the brain, ZnT1 is expressed in the choroid plexus of mice and rat 
(Wang et al., 2004b, Chowanadisai et al., 2005).  
The evidence that ZnT1 is very widely expressed in almost all tissues on the plasma 
membrane suggests that ZnT1 protein acts as the main form of transporter involved 
in absorption or zinc transfer (Liuzzi et al., 2001b). The importance of ZnT1 was 
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shown by knock-out studies using Drosophila melanogaster where removal of ZnT1 
caused failure of development, and death of larvae due to zinc deficiency (Wang et 
al., 2009b). ZnT1 expression is only activated under excessive zinc condition, 
where N,N,N',N'-tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) treatment in 
HeLa cells was found to increase gene expression of other zinc transporters but not 
ZnT1 (Devergnas et al., 2004). Transcription of SLC30A1 is under the control of 
MTF1 (Kambe et al., 2004, Palmiter and Huang, 2004). The expression of 
SLC30A1 is sensitive to the concentration of extracellular zinc where animal 
studies have shown that cells treated with low concentration of zinc upregulated 
expression of SLC30A1. It is thought that the upregulation of intracellular zinc may 
be caused by zinc absorption or zinc export from intracellular organelles (Bury et 
al., 2008).  
In disease states, expression of SLC30A1 was upregulated for 24 hours after 
ischemic shocks but decreased afterwards (Tsuda et al., 1997). Decreased 
immunolabeling of ZnT1 was observed in preclinical Alzheimer’s disease in human 
brain samples which points to the involvement of zinc and dysregulation of zinc 
homeostasis in the development of AD (Lyubartseva et al., 2010). Huang and 
colleagues reported that there is a concentrated immunolabeling of many ZnT 
transporters including ZnT1 in Aβ plaques in the cortex of brains of Alzheimer’s 
disease subjects. As these were more concentrated in the plaques, it was 
hypothesised that there is increased transport of zinc by the transporters (Zhang et 
al., 2008). 
3.1.3. SLC30A2/ ZnT2 
SLC30A2 gene codes for the ZnT2 zinc transporter protein. The mRNA expression 
of this gene was reported in the small intestine, kidney, placenta, prostate, 
mammary gland and liver using Northern blot analysis (Palmiter and Huang, 2004). 
ZnT2 protein is located on endosomal vesicles and functions to reduce the cytosolic 
zinc concentration (Liuzzi and Cousins, 2004b). In enterocytes, ZnT2 was shown to 
be located in the apical surface of microvilli, with vesicles nearby (Kambe et al., 
2004). ZnT2 is located in the vesicles in M1 human fibroblast cells and functions to 
move zinc to lysosomes, replacing the role of M1 protein in cells (Falcon-Perez and 
Dell'Angelica, 2007). There are two isoforms of ZnT2 protein which codes for 
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proteins of 42 and 35 kDa respectively. The 42 kDa ZnT2 is localized to the 
endosomal compartment and is the major zinc transporter. The 35 kDa ZnT2 is 
located on the plasma membrane, and shows lower expression compared to the 
larger, 42 kDa isoform. Overexpression of these proteins lead to sequestration of 
zinc (Lopez and Kelleher, 2009). 
ZnT2 mRNA expression is sensitive to changes in zinc concentration, and ZnT2 
has been suggested to mainly function in protecting cells from sudden increases in 
intracellular zinc concentration (Liuzzi et al., 2001b). Zinc rich diet in rats led to 
370% increase of ZnT2 mRNA in the small intestine and kidney although its 
expression was negligible under a zinc deficient diet. Exposure of porcine capillary 
endothelial cells to 50 µM/L zinc causes upregulation of ZnT2 which remains for 
96 hours (Bobilya et al., 2008).  
3.1.4. SLC30A3/ ZNT3 
The SLC30A3 gene codes a 40 kDa ZnT3 protein. The mRNA has been detected in 
both the brain and testis of rodents, although so far, the protein has only been 
detected in the brain. ZnT3 mRNA has been found as early as three days before 
birth, and reaches its expression peak three weeks post-natally. ZnT3 localises to 
the synaptic vesicles, which indicated that they may aid in the process of 
neuromodulation, or zinc storage (Liuzzi and Cousins, 2004b). Lysosomal 
localisation of ZnT3 protein has been reported (Wang et al., 2004b). This lysosomal 
immunolabeling was found in fenestrated endothelial cells of the mouse choroid 
plexus. Furthermore, zinc-selenide metallography was able to detect bioavailable 
zinc in the apical membrane of mouse choroid plexus endothelial cells which 
suggests that ZnT3 aids in regulating zinc homeostasis in the choroid plexus of the 
brain (Wang et al., 2004b).  
In the brain, zinc has been widely acknowledged as one of the key factors in the 
elongation of aggregated amyloid-β protein, which leads to the development of 
Alzheimer’s disease. A ZnT3 knock out mouse model was found to be protected 
from the aggregation of amyloid-β protein (Kambe et al., 2004). In INS1-E rat 
pancreatic β-cell cultures, there is a positive correlation between glucose 
concentration in the media and expression of ZnT3 but not many other zinc 
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transporters.  This implies that in a high glucose environment, ZnT3 plays an 
important role in zinc and glucose metabolism, which may be crucial in diabetes 
(Sondergaard et al., 2005).   
3.1.5. SLC30A4/ ZnT4 
The SLC30A4 gene is highly expressed in various epithelial cells especially those 
involved with absorption, such as the small and large intestine. Consistent but low 
expression was found in liver, kidney, spleen, thymus, muscle, adipose tissue and 
mammary glands (Liuzzi et al., 2001b). ZnT4 proteins are localised in the vesicles, 
golgi apparatus and endosome. Immunohistochemistry revealed ZnT4 expression in 
the large intestine in mice (Yu et al., 2007) and in the apical part of fenestrated 
choroid plexus epithelial cells (Wang et al., 2004b). ZnT4 has also been found in 
basal cell vesicles of mouse polarised Caco-2 intestinal cells. Studies in humans 
and rats have shown that SLC30A4 gene expression is not elevated in zinc 
sufficient or enriched conditions (Liuzzi and Cousins, 2004b). Based on this, it is 
suggested that ZnT4 aids absorption of zinc and sequestration into vesicles, until it 
is needed by the cell (Murgia et al., 2006). 
A mutation in SLC30A4 gene has been associated with lethal milk syndrome in 
mice. The recessive single-point mutation in the termination codon results in the 
formation of defective protein (Murgia et al., 1999).  
3.1.6. SLC30A5/ ZnT5 
The SLC30A5 gene encodes zinc transporter ZnT5 protein, which is selectively 
expressed on the apical side of insulin containing pancreatic-β cells as opposed to 
insulin secreting acinar and α-cells (Palmiter and Huang, 2004). Two splice 
variants differ in their C and N terminal regions. Variant A has been expressed in 
the Golgi, meanwhile variant B ZnT5 protein can be seen in the cytosol as well as 
the plasma membrane (Thornton et al., 2011). 
ZnT5 mRNA is found in the duodenum and in the parietal cells of the stomach, 
while the protein can be found in the gastric mucosa as well as the crypts of 
Lieberkuhn (Yu et al., 2007). ZnT5 is involved in the reabsorption of zinc in the 
gastrointestinal tract, as well as delivery of alkaline phosphatase in the secretory 
pathway (Yu et al., 2007). In a human intestinal cell line, CACO-2, ZnT5 isoform 
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B was found to be expressed in the cell’s plasma membrane. The study showed that 
ZnT5 isoform B was able to decrease as well as increase intracellular zinc 
concentration (Thornton et al., 2011).  
3.1.7. SLC30A6/ ZnT6 
SLC30A6 mRNA has been shown to be expressed in the liver, kidney and brain, 
but the protein is only detected in the brain and lung (Palmiter and Huang, 2004). 
The function of ZnT6 protein is to transport zinc from the trans-Golgi network to 
cell periphery (Kambe et al., 2004). In mouse gastrointestinal tract, ZnT6 mRNA 
expression was found in the goblet cells of stomach, and columnar epithelial cells, 
where the protein is concentrated in the perinuclear and peripheral part of the crypts 
of the  columnar epithelial cells (Yu et al., 2007). Immunochemistry showed that 
the ZnT6 protein is expressed in the epithelial cells of choroid plexus (Wang et al., 
2004b). In preclinical Alzheimer’s disease in human brain samples, it was shown 
using immunostaining for tau-protein marker, that ZnT6 was increased significantly 
(Lyubartseva et al., 2010) possibly indicating involvement of ZnT6 protein in AD.  
3.1.8. SLC30A7/ ZnT7 
SLC30A7 mRNA expression is found in various tissues, but the protein is only 
present in the small intestine and lung. In contrast to other ZnT family of 
transporters that are required for absorption process, ZnT7 is located in the 
perinuclear vesicles of the Golgi apparatus. In mouse choroid plexus, 
immunoreactivity of ZnT7 is strongest on the cis-side of the Golgi apparatus 
(Liuzzi and Cousins, 2004b). In the gastrointestinal tract of mice, immunochemistry 
showed that ZnT7 mRNA is expressed in all parts of the small and large intestine, 
Goblet cells in cecum, colon and rectum stain heavily for the ZnT7 protein, 
presumably reflecting a role in zinc reabsorption in the gastrointestinal tract (Liuzzi 
and Cousins, 2004b). ZnT7 is also required in mice for fat metabolism and zinc 
homeostasis. ZnT7 null mice were found to have lowered zinc concentration in the 
serum, liver, duodenum, brain, bone and low body weight and body fat for age 
(Huang et al., 2007).  
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3.1.9. SLC30A8/ZnT8 
ZnT8 mRNA can be detected in brain and liver (Palmiter and Huang, 2004) and 
two SNPs are highly correlated with incidence of type 2 diabetes in Han Chinese. 
Chimienti et al reported the specific expression of ZnT8 in the pancreas as well as 
its localisation in pancreatic beta-cells which produce insulin (Chimienti et al., 
2006, Chimienti et al., 2005). 
3.1.10. SLC30A9/ ZnT9, SLC30A10/ ZnT10 
Not much is known regarding the genes SLC30A9 and SLC30A10, which encode 
for proteins ZnT9 and ZnT10 respectively. In a phylogenetic tree constructed by 
Seve and colleagues (2005), ZnT10 was shown to have the closest phylogeny to 
ZnT1. It is the only zinc transporter so far which is embryonic-specific; at birth 
ZnT10 diminishes, and expression of ZnT1 starts, implying that the two may have 
similar functions and are homologous (Seve et al., 2004). 
3.1.11. SLC39A ZIP FAMILY OF TRANSPORTERS 
The SLC39 genes encode a family of zinc transporters (ZIPs) that are ubiquitously 
expressed in all organisms. Structurally, ZIP proteins are composed of eight 
transmembrane domains with a cytoplasmic loop between domain III and IV 
composed of histidine residues. The ZIP family of zinc transporters promote the 
transport of zinc from the extracellular environment into the cytoplasm or from the 
cellular organelles to the cytoplasm (Liuzzi and Cousins, 2004b). Loss of 
ZIPproteins may lead to the development of various pathological conditions such as 
acrodermatitis enteropathica (AE), an autosomal recessive metabolic disorder 
(Dufner-Beattie et al., 2003). 
3.1.12. SLC39A1/ZIP1 
SLC39A1 encodes for ZIP1 protein, whichis widely expressed (Liuzzi and Cousins, 
2004b). Human ZIP1 protein is localised to the endoplasmic reticulum and plasma 
membrane. In K562 and PC3 cells, ZIP1 mainly localizes on the plasma membrane. 
In COS-7 and HepG2 cell lines, a perinuclear endoplasmic reticulum staining 
pattern was observed (Milon et al., 2001).  
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Animal studies have shown that ZIP1 expression was detected as early as day 14 of 
gestation, and that it is localised to the apical membrane of epithelial cell villi. 
Expression increases until day 20 of gestation and continues postnatally. Changing 
the level of zinc does not alter the level of ZIP1 mRNA in gestation or postnatal 
dam and pup intestine and expression of ZIP1 mRNA was unchanged after dietary 
zinc supplementation in human small intestine enterocytes (Cragg et al., 2005, 
Huang et al., 2006). In a blood-brain barrier model, exposure to 50 µm/L zinc in 
cell culture did not affect ZIP1 expression (Bobilya et al., 2008).  
3.1.13. SLC39A2 / ZIP2 
ZIP2 mRNA encoded by the SLC39A2 gene is expressed in mouse liver, spleen, 
small intestine and bone marrow, as well as human peripheral blood monocytes 
(Liuzzi and Cousins, 2004b). The protein localises to the plasma membrane. Under 
zinc deficient conditions, a marked upregulation of ZIP2 expression and 
downregulation of metallothionein was observed (Eide, 2004). A paediatric study 
showed that ZIP2 mRNA is the only transporter overexpressed in asthmatic infants 
compared to the rest of the transporters which were analysed, including ZnT1, 
ZnT3, ZnT4, and ZIP1 (Xu et al., 2009). In cultures of human THP-1 cells and 
human peripheral blood monocytes, ZIP2 gene expression was increased under zinc 
deficient conditions following treatment with TPEN (Cao et al., 2001).  
3.1.14. SLC39A3/ ZIP3 
The SLC39A3 gene is highly expressed in bone marrow, spleen and intestine 
(Liuzzi and Cousins, 2004b), liver (Liuzzi et al., 2005) and to a lesser extent in the 
fetal and neonatal intestine. A study by Kambe and colleagues (2003) showed that 
the ZIP3 protein is upregulated only under zinc deficient conditions. It was shown 
that ZIP1, ZIP2 and ZIP3 mouse knock-outs had 80% abnormality of the embryos 
under zinc deficient conditions, but did not cause major effects when zinc 
concentration was adequate. These effects highlighted how crucial the functions of 
zinc importers are during pregnancy, at least in animal models (Kambe et al., 
2008). This effect was corroborated by a study by Wang and colleagues (2004), 
who found that mouse ZIP1 and ZIP3 protein is not endocytosed and degraded 
easily from the plasma membrane under zinc deficient conditions. Cells which were 
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treated with TPEN were found to retain a higher amount of zinc (Wang et al., 
2004a).  
3.1.15. SLC39A4/ ZIP4 
The SLC39A4 gene expression is confined to the small intestine, colon, stomach 
and kidney, but not in the liver presumably reflecting a role in the absorption of 
zinc from dietary sources (Dufner-Beattie et al., 2003). ZIP4 protein is located in 
the apical membrane of enterocytes and endodermal cells (Liuzzi et al., 2005). 
Various studies have emphasised the importance of ZIP4 protein in gastrointestinal 
absorption of zinc. The expression of ZIP4 is required during gestation and 
lactation in mice; ZIP4 mRNA was expressed starting from day 18 and reached its 
peak at day 20 (Huang et al., 2006). In Acrodermatitis Enteropathica (AE), 
mutations yielding a premature termination codon that leads to failure of ZIP4 
protein to transport zinc (Liuzzi et al., 2005). 
Studies have demonstrated that zinc affects the stability of SLC39A4 mRNA. Zinc 
sufficiency caused ZIP4 to be engulfed in enterocytes and get degraded. Under zinc 
deficiency conditions, ZIP4 mRNA accumulates in the cytoplasm and ZIP4 protein 
gets transported to the apical membrane. This tightly controlled mechanism implies 
that ZIP4 is important for zinc absorption from diet (Weaver et al., 2007).  
3.1.16. SLC39A5/ ZIP5 
Previous research has indicated that the SLC39A5 gene is mainly expressed in the 
gastrointestinal tract of mice and from immunohistochemistry its protein is 
localised to basolateral membranes. During gestation, ZIP5 expression was first 
detected at day 16, and it remains expressed until birth. During lactation, expression 
of ZIP5 is very strong in intestines from both dams and pups, and remains 
unchanged even in response to a zinc deficient diet (Huang et al., 2006). ZIP5 
functions to prevent excessive amount of intracellular zinc. Zinc deficiency 
increases ZIP5 mRNA expression  and leads to shuttlling of the translated proteins 
to the lateral and basolateral membrane of enterocytes meanwhile zinc sufficient 
conditions prevent translation of ZIP5 and sends membrane to the degradation 
pathway (Weaver et al., 2007). 
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3.1.17. SLC39A6/ ZIP6 
The SLC39A6 gene was found to be expressed in prostate, placenta and mammary 
gland cells. ZIP6, the protein coded by SLC39A6 gene is also called LIV-1 (Taylor 
et al., 2003). Immunohistochemistry has shown the protein’s expression on the 
apical or plasma membrane of neuroblastoma cell line and CHO cells (Taylor et al., 
2003, Chowanadisai et al., 2005). In mice subjected to zinc deficient diet, increased 
expression of ZIP6 was observed, indicative of its crucial function in regulating 
zinc homeostasis in the brain (Chowanadisai et al., 2005). ZIP6 may also have 
potential role in breast cancers (Taylor et al., 2007).  
3.1.18. SLC39A7/ ZIP7 
ZIP7 is currently the only ZIP family transporter found in the ER. The relationship 
betweenZIP7 expression and breast cancer has been explored by Taylor et al where 
ZIP7 expression was higher in tamoxifen resistant breast cancer cells compared to 
wild type cells. Up-regulation of ZIP7 causes increase of zinc influx into the 
cytosol with subsequent increase in phosphorylation of epidermal growth factor 
receptors due to inactivation of phosphatases and activation of downstream 
signaling cascades including MAPK and Erb pathways (Hogstrand et al., 2009, 
Taylor et al., 2008). 
3.1.19. SLC39A8/ ZIP8 
The SLC39A8 gene encodes ZIP8 protein found in lysosomes, endosomes and 
mitochondria (Besecker et al., 2008, Kambe et al., 2004). Studies have shown its 
involvement in the regulation of the immune system. Aydemir and colleagues 
(2008) reported that human T-cells are activated by 15 mg zinc per day 
supplementation for 4 days. SiRNA suppression ofZIP8 expression reduced IFN-y 
secretion by 66%. Furthermore, incubating T cells in increased zinc caused a 
reduction of calcineurin and an increase in CREB phosphorylation, ultimately 
resulting in increased IFN-y secretion (Aydemir et al., 2009). TNF-α exposure to 
lung epithelia can induce SLC39A8 expression. The increase of ZIP8 is thought to 
provide protection for the lung epithelium in inflammatory conditions (Besecker et 
al., 2008). 
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3.1.20. SLC39A9/ ZIP9 
SLC39A9 localises in the trans-golgi network in HeLa cells. In the DT40 chicken 
cell line, knocking out ZIP9 did not cause apoptosis, and nor did it affect cytosolic 
zinc homeostasis as measured through zinquin staining. Secretory pathway function 
is often measured through alkaline phosphatase. ZIP9 overexpression was found to 
decrease ALP activity in wild type and ZIP9 -/- cells. (Matsuura et al., 2009).  
3.1.21. SLC39A10/ ZIP10 
SLC39A10 was found to encode a zinc transporter found in rat renal brush border 
membrane.The gene itself was found to be widely expressed, particularly in small 
intestine, pancreas, testis, brain, liver and kidney of rats. The protein was found to 
immunolocalise at the plasma membrane in LLC-PK1 cells (Kaler and Prasad, 
2007).  
3.1.22. SLC39A12/ ZIP12 
Preliminary studies have implicatedSLC39A12 within schizophrenia possibly 
through  serine to glycine mutations in residue 213 of the transporter protein 
(A213G  S36G)(Bly, 2006).  
3.1.23. SLC39A13/ ZIP13 
Fukada and colleagues reported that a mutation in SLC39A13 is linked to Ehler 
Danlos Syndrome, which results from defective collagen synthesis and improper 
connective tissue development. The protein localises to the perinuclear region 
(Golgi apparatus) of different connective tissue cells. Mouse knockouts of the 
SLC39A13 gene resulted in abnormal connective tissue development, poor bone 
mineral density including dentin, and curvature of the spine resulting in a 
hunchback appearance of SLC39A13 KO mice. A craniofacial abnormality was 
characterised by sunken eyes. Decreased collagen synthesis also results in poor skin 
development (Fukada et al., 2008). 
3.1.24. SLC39A14/ ZIP14 
ZIP14 protein expression has been found on the apical surface of the epithelium of 
transfected MDCK cells.  Girijashanker and colleagues reported that ZIP14 and 
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ZIP8 have high homology which may explain both transporters’ involvement in the 
acute-phase response. In mice, lipopolysaccharide and turpentine, major antigens 
for activation of the immune system, were found to increase the expression of 
ZIP14 in the mouse liver. Furthermore, it was noted that the increase in ZIP14 was 
triggered by inflammatory cytokine IL-6 and TNF-α. IL-6 null mice did not show 
any inflammation, which indicated that ZIP14 expression is required to trigger 
immune response in the liver (Liuzzi et al., 2005). Apart from zinc, the protein is 
also able to transport cadmium and manganese (Fujishiro et al., 2009). 
Relatively little is known about the distribution of zinc transporters in the eye 
despite the fact that the RPE and choroid probably have the highest amount of zinc-
per gram of tissue in the whole body. Also, it is well accepted that zinc plays a role 
in visual processing in the health and disease of the retina (Ugarte and Osborne, 
2001). Currently available literature on expression of zinc transporters is 
summarised in Figure 3.1.  
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Figure 3-1- Distribution of zinc transporters in RPE-choroid complex 
Distribution of zinc transporters in the RPE-choroid complex based on various 
publications. ER- Endoplasmic reticulum, MT - metallothionein (Leung et al., 
2008a, Redenti and Chappell, 2003, Wang et al., 2006b) 
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3.2. Aims 
The aim of this chapter was to provide extensive expression profiling of all 
SLC30A and SLC39A zinc transporters in various cultured RPE, and non RPE cell 
lines, as well as in human cadaveric retina, RPE and choroid using: 
1. Quantitative real time PCR using SYBRGreen detection system for all the 24 
zinc transporters 
2. Quantitative real time PCR with TaqMan probes to clarify and confirm findings 
related to the expression of SLC39A12 
3.3. Expression of SLC30A SLC39A Transporters in RPE Cells 
Methods 
In order to catalogue the expression levels in cells and tissues derived from the 
retina/ RPE/ choroid complex, RNA was isolated from ARPE19, SHEF-1 (Kind 
gift from Dr. Amanda Jayne Carr), primary human RPE cells, freshly isolated 
cadaveric human RPE and choroid. The expression levels of all 24 mammalian zinc 
transporters were measured using gene specific primers labeled with SYBRGreen 
(Table 3.1). Sequences are available in Table 3.2. The primers were designed, 
synthesised and optimised by PrimerDesign (Southampton, UK) (Sequences for 
these primers are available in Appendix 3). RNA quantification was done using 
NanoDrop (ThermoScientific, UK), and RNA integrity was assessed by BioRad 
Experion system. Relative gene expression levels were calculated based on the 
comparative Ct method (Schmittgen and Livak, 2008). This was achieved by 
normalising the cycle (Ct) values (the cross-over threshold value where the signal 
was first detected in a qPCR assay) of the gene of interest to the housekeeping 
genes, thereby giving a ∆ Ct value (shown in Table 3.1). Higher∆Ct values indicate 
lower expression. Genes were grouped according to three arbitrary thresholds: ∆Ct 
values below 5 were considered to be high to medium (in red), ∆Ct between 5-10 
were low (in yellow), and ∆Ct above 10, at which point the genes were probably 
not expressed as judged by the dissociation curves from each PCR product in grey. 
The results are the averages of at least 2 independent experiments carried out in 
duplicate. The low numbers of experiments are not enough to provide an accurate 
data as the variability of the qPCR data can be high. It is recommended that 3 
independent experiments are carried out in the future.  
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As mentioned, the results were verified by closely examining the dissociation 
curves and running the PCR products on 1% agarose gels. Following 
electrophoretic separation, the ethidium bromide labeled PCR products were 
visualised under UV light (Figure 3.2). Non-template controls (amplification in the 
absence of cDNA) were run alongside the samples for the identification of primer 
dimers and non-specific products. While we included in Table 3.1 the ∆Ct values 
for the genes from human cadaveric tissues, we could not apply similar threshold 
categories defined above as the housekeeping genes Ct values for the cadaveric 
tissues were unexpectedly high. This was probably due to variable post-mortem 
degradation of RNA. Nonetheless, comparing ∆Ct values to each other allows the 
identification of potentially highly expressed genes. For ease of interpretation, the 
data is also presented in an additional format, with the same colour scheme as 
previously described (Figure 3.3). 
Results 
Following the q-RT-PCR experiments, most zinc transporters appear to be 
expressed in all cell lines. SLC30A3, SLC30A6, SLC30A7, SLC39A3, and 
SLC39A11 were expressed at a low level, while SLC30A9, SLC39A1, SLC39A7, 
and SLC39A13 were expressed at the medium to high levels in all cell lines. 
SLC30A8, SLC30A10 and SLC39A12 did not seem to be expressed in any of the 
RPE cell lines. There appeared to be some discernable differences in expression 
levels in the different cell lines: highest expression was observed for SLC39A4 in 
ARPE19, for SLC39A6 in SHEF1 and SLC30A1 in primary cultures, SLC30A2 
expression was very low or absent in ARPE19, but present in SHEF1 and primary 
cultures. SLC39A2 was only expressed in SHEF1 cells, but not in ARPE19 and 
primary cultures. SLC39A5 was expressed in ARPE19 and SHEF1 cells but not in 
primary cultures. The absence of genes such as SLC30A8, SLC30A10 and 
SLC39A12 in these cell lines was confirmed by separating the PCR product on 1% 
agarose gels (Figure 3.2).  
In cadaveric samples the presence of zinc transporter expression was visualised on 
1% agarose gels. Those without a clear band or those where bandsco-migrated with 
the non-template controls, andgave similar fluorescence intensity bands to that of 
the non-template control (See Figure 3.2)were deemed to be non-expressed. Based 
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on this, SLC39A2 and SLC39A9 were not expressed in human cadaveric RPE and 
while probably present there was very low expression levels of SLC39A10 and 
SLC39A11. In contrast, we found that the expression of SLC39A12, whose 
expression was absent in all cell lines, appeared to be very high in human cadaveric 
RPE.  
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Table 3-1- Expression of SLC30A1-10, SLC39A1-14 in RPE cells 
Expression of SLC30A1-10, SLC39A1-14 in ARPE19, human embryonic stem cell 
derived RPE cells (SHEF-1), primary cultures of human RPE, as well as cadaveric 
human RPE. Data was expressed in ∆Ct format with mean standard deviation 
values. The results were derived from averaged values from 2-4 independent 
experiments carried out in duplicates. QPCR experiments were conducted on 
Applied Biosystem HT7900 system. The colours red indicated high expression 
(∆Ct < 5), yellow indicated medium expression (∆Ct 5-10), and grey (∆Ct >10) 
indicated low or no expression as assessed by ∆Ct values and melt curve analysis.  
 
  ARPE19 SHEF-1 
Primary 
hRPE 
Cad. HRPE 
  n   n   n   n   
SLC30A1/ ZnT1 4 7.7+1.7 4 7.8+1.8 2 5.0+0.5 4 1.3+1.9 
SLC30A2/ZnT2 4 11.0+1.8 4 8.2+0.6 2 7.8+0.4 4 1.9+5.9 
SLC30A3/ZnT3 3 9.2+0.7 3 8.6+1.0 2 8.2+0.3 4 0.9+3.2 
SLC30A4/ZnT4 3 9.4+1.7 3 10.6+1.7 2 8.8+0.9 4 1.5+3.4 
SLC30A5/ZnT5 2 5.2+0.2 2 4.0+0.0 2 5.0+0.4 4 1.1+3.4 
SLC30A6/ZnT6 2 6.9+0.1 2 5.5+0.0 2 6.8+1.0 4 2.0+6.7 
SLC30A7/ZnT7 2 6.8+0.1 2 5.9+0.5 2 6.4+0.5 4 0.9+6.0 
SLC30A8/ZnT8 4 14.0+1.3 4 12.3+0.4 2 11.8+0.0 4 3.7+4.0 
SLC30A9/ZnT9 2 3.9+0.2 2 3.1+0.2 2 3.6+0.2 4 0.9+5.4 
SLC30A10/ZnT10 5 15.8+1.2 5 10.6+1.6 2 16.1+1.3 4 1.6+2.8 
SLC39A1/ZIP1 2 2.4+1.1 2 2.0+1.3 2 3.4+0.6 4 1.2+3.1 
SLC39A2/ZIP2 5 14.4+1.8 5 8.8+1.8 2 13.4+0.1 4 4.2+4.8 
SLC39A3/ZIP3 3 7.3+2.2 3 6.3+1.9 2 5.8+0.0 4 0.9+5.8 
SLC39A4/ZIP4 2 4.0+0.6 2 5.7+0.0 2 5.1+0.7 4 0.9+2.6 
SLC39A5/ZIP5 3 7.9+1.6 3 5.7+0.6 2 10.2+0.4 4 3.2+3.2 
SLC39A6/ZIP6 2 5.7+1.3 2 3.1+2.4 2 7.7+0.6 4 3.2+6.4 
SLC39A7/ZIP7 2 3.3+1.2 2 2.0+1.3 2 5.1+0.9 4 1.9+5.6 
SLC39A8/ZIP8 2 6.6+1.0 2 5.5+1.0 2 4.8+0.2 4 1.8+4.0 
SLC39A9/ZIP9 2 5.5+1.5 2 4.9+1.6 2 10.2+0.0 4 2.8+3.7 
SLC39A10/ZIP10 2 6.3+1.2 2 3.4+1.3 2 6.5+0.1 4 3.2+3.8 
SLC39A11/ZIP11 2 7.4+1.1 2 5.6+1.1 2 6.4+0.1 4 4.0+0.9 
SLC39A12/ZIP12 5 14.5+2.2 5 11.7+1.6 2 12.3+0.1 4 0.9+0.2 
SLC39A13/ZIP13 2 3.5+1.3 2 4.1+0.9 2 3.9+1.2 4 2.1+3.0 
SLC39A14/ZIP14 2 5.7+0.5 2 3.6+1.0 2 4.2+0.4 4 3.0+3.6 
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Figure 3-2- Confirmation of QRT-PCR using 1% agarose gels 
The PCR products were run on 1% agarose gel and visualised using ethidium -
bromide. The results for ARPE19 are shown in panels A,B,C, primary human RPE 
culture (passage 4) in D,E,F and cadaveric human RPE in G, H, I. The zinc 
transporters and the housekeeping genes for each sample are labeled, with the 
corresponding non-template controls on its right hand side. The 200 and 300 bp size 
markers are labeled on the pictures. For image purpose, the gene names have been 
replaced by protein names, for explanation refer to page 91.  
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Table 3-2 - Human primer sequences for SLC30A family and SLC39A family 
of zinc transporters 
 
  Primer Sequences Homo sapiens  
Gene Accession Number Forward Reverse BP 
SLC30A1 NM_021194 AAGACCCCAGCAGTTAGCA AGGTTGTTTGTTTGGCATGTTT 129 
SLC30A2 NM_001004434 GAGAAGTCGTTGGTGGGTAC GAGGGAGAAGAGGCTGATGA 104 
SLC30A3 NM_003459 CTTTGGCTGGCACCGTTCA CTCGATGTGGTAGTCGCTGTG 124 
SLC30A4 NM_013309 GCACATTTGGAGTCCCTTTTC CATTGTTACCCTACTCTGATTCTTAG 
 
96 
SLC30A5 NM_022902 TTATAGAGCAGTTTGGATGGTTCA 
 
TTCATATTCTGGTGGCAATCTCA 
 
137 
SLC30A6 NM_017964 CATTTGGGTTTGAAAGATTAGAAGTC 
 
GTGTGTATCTCGGGCTGTTC 
 
124 
SLC30A7 NM_133496 TCCTGTGCCTGAACCTCTC 
 
AGTCGGAAATCAAGCCTAAGC 
 
81 
SLC30A8 NM_173851 AGGGAGATTTTAAGGATTTTGAGATG 
 
AGGGAAAGGGTAATGGGAGAG 
 
104 
SLC30A9 NM_006345 TCCATCCAGCCAGAACAAGT 
 
TGTAACAACTCGCCCATCAAA 
 
150 
SLC30A10 NM_018713 ATATCAAGATGCCAGCACAAAAAT 
 
GGGTTCCTTCAAGTCCACATT 
 
97 
SLC39A1 NM_014437 AGGAACAAGAGATGGTCAAGTC 
 
GTATAGTGTCCAACCTCTGATTCT 
 
96 
SLC39A2 NM_014579 TTTGGAGTCGCTGGCATTG 
 
TTTGAGGGTGAGGGTAAATGTC 
 
126 
SLC39A3 NM_144564 TTTGGAGGAGGGGTGTTTCT 
 
GGGTAGTCGGTGCTGATGT 
 
107 
SLC39A4 NM_01167 GCTGCTGCTGTCCCTGTAC 
 
GGTTTCTGGGCTGTAGGTTTG 
 
107 
SLC39A5 NM_173596 GGGGAGAATAGGAGCCAGAA 
 
AAGACGACCCACACACAGAA 
 
105 
SLC39A6 NM_012319 ACTACCATCATATTCTCCATCATCA 
 
CATCACCCATTATCACCATCCA 
 
132 
SLC39A7 NM_006979 GTTCTCCAAGGTCCAGTTTCC 
 
CCCCAATCACTCCCAAATCAG 
 
144 
SLC39A8 NM_022154 CTCTCCTCGGATTGATTTTGACT 
 
AATGCCTCTGGAATAAGTTGGAA 
 
130 
SLC39A9 NM_018375 AGTGGTTGTGGGTGAATAAAGG 
 
GAAATTAACAGCCAAGGGAATGAT 
 
120 
SLC39A10 NM_001127257 TGGTGATGGTGACAATGAAGAA 
 
GCAAATCCAAAGAGCAATCCTAA 
 
84 
SLC39A11 NM_139177 CTGAAATGTCCCTATAAAGAATGAGT 
 
TTGCTACCCCTGTTGGAGAA 
 
86 
SLC39A12 NM_152725 CTTGCCTTCCCCAGACTACT 
 
CCAGAGAGTGTTGAGGAGTTG 
 
103 
SLC39A13 NM_001128225 ATCGTGGTAATGGTGCTGTTC 
 
CCCTCTCTGCCTCTCACATAT 
 
126 
SLC39A14 NM_015359 TTGCCGCTTCCATAAATCAAAG 
 
AAACCCATCTGTAGCATAATCATTAG 
 
127 
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Figure 3-3 – Diagram representation of QRT-PCR data for RPE cells 
Representation of QRT-PCR data for RPE cells in bullet format, separating the high 
(red), medium (yellow) and no expression (grey) for both SLC30 and SLC39 
family of zinc transporter genes. From left to right, data for ARPE19, Shef-1 and 
primary hRPE are presented. 
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3.4. Expression of SLC30A SLC39A Transporters in non RPE Cells 
 
We also assessed the expression of the 24 zinc transporters in other cells and tissues 
including those isolated from rat or human retina (see Table 3.3 and pictorial 
representation Figure 3.4) namely the murine endothelioma cell-line bEND5, 
primary rat retinal ganglion cells (kindly provided by Dr. Richard Foxton), human 
primary cultures of Muller cells (RNA kindly provided by Dr. Astrid Limb) and 
human cadaveric choroid. Similarly, threshold categories defined above as the 
housekeeping genes Ct values for the cadaveric tissues were unexpectedly high as 
described before. In addition human embryonic kidney HEK293 cells were also 
assayed (This cell line will be extensively used in the Chapter 4). In bEND5 cells 
out of the 24 transporters only SLC30A8, SLC30A10 and SLC39A12 were not 
expressed. In primary rat retinal ganglion cells (RGC) out of the 24 transporters 
only SLC30A7, SLC30A8, SLC39A2, and SLC39A12 were not expressed. In 
human primary cultures of Muller cells the genes which were not expressed were 
SLC30A8, SLC30A10, SLC39A5, and SLC39A12. In the HEK293 human 
embryonic kidney cell line it appeared that except SLC39A12 all other zinc 
transporters are detectable, although sometimes at very low levels of expression. 
The presence of SLC30A10 expression was one of the results which could only be 
confirmed after analysis of the dissociation curve. In human cadaveric choroid, 
based on dissociation curve analysis, SLC30A2, SLC30A8, and SLC39A2 genes 
are not expressed.  
 
 
 
 
 
 
 
96 
 
Table 3-3 - Expression of SLC30A1-10, SLC39A1-14 in non- RPE cells 
Expression of SLC30A1-10, SLC39A1-14 in murine BEND5, rat retinal ganglion 
cells, HEK293 cells and human primary cultures of Muller cells. Data were 
expressed in ∆Ct format with mean and standard deviation values. The results were 
derived from averaged values from 2/3 independent experiments carried out in 
duplicates. QPCR experiments were conducted on anApplied Biosystem HT7900 
system. * Left blank due to presence of non-specific product in NTC, see 
confirmation performed using Taqman. The colours red indicated high expression 
(∆Ct < 5), yellow indicated medium expression (∆Ct 5-10), and grey (∆Ct >10) 
indicated low or no expression as assessed by ∆Ct values and melt curve analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  mBEND5 rRGC HEK293 hMuller Cad. hChoroid 
  n   n   n   n   n  
SLC30A1 3 4.6+1.8 2 7.0+0.4 2 6.7+0.5 2 7.2+0.1 4 2.9+2.8 
SLC30A2 3 7.1+2.6 2 7.0+0.8 2 3.9+0.0 2 8.7+2.9 4 5.8+2.5 
SLC30A3 3 8.1+2.8 2 7.0+0.5 2 5.0+0.1 2 6.9+0.3 4 2.1+4.8 
SLC30A4 3 3.5+2.1 2 6.8+0.1 2 7.9+1.1 2 8.2+0.3 4 3.4+2.9 
SLC30A5 3 4.8+0.8 2 6.7+0.1 2 2.9+0.6 2 4.5+0.2 4 3.0+1.4 
SLC30A6 3 5.6+1.4 2 6.8+0.9 2 6.6+0.3 2 6.4+0.7 4 5.5+2.2 
SLC30A7 3 5.2+0.3 2 10.9+2.6 2 9.6+0.3 2 6.4+0.1 4 4.8+2.3 
SLC30A8 3 10.8+1.1 2 11.5+8.8 2 5.6+0.7 2 13.0+1.0 4 5.8+4.8 
SLC30A9 3 3.9+0.9 2 5.9+0.6 2 3.6+0.2 2 4.4+0.7 4 4.5+1.0 
SLC30A10 3 11.6+0.2 2 6.4+0.1 2 10.6+0.2 2 13.6+1.6 4 4.9+4.2 
SLC39A1 3 2.7+0.5 2 6.5+1.5 2 4.0+0.2 2 3.8+0.1 4 1.9+2.1 
SLC39A2 3 7.9+1.9 2 10.1+7.3 2 5.3+0.0 2 12.2+3.8 4 6.8+4.5 
SLC39A3 3 6.3+1.0 2 6.5+0.0 2 3.4+0.1 2 6.1+0.8 4 3.4+2.2 
SLC39A4 3 8.0+1.9 2 6.8+0.4 2 4.1+0.3 2 7.2+0.3 4 3.2+2.0 
SLC39A5 3 8.8+2.6 2 8.3+0.2 2 4.7+1.2 2 10.0+2.8 4 5.9+4.1 
SLC39A6 3 6.6+0.1 2 6.2+0.2 2 5.1+0.2 2 5.6+5.1 4 6.3+3.3 
SLC39A7 3 3.4+0.7 2 7.1+0.4 2 4.6+0.1 2 2.8+0.4 4 3.5+0.9 
SLC39A8 3 6.0+0.7 2 6.0+0.1 2 5.8+0.2 2 6.8+0.8 4 4.9+2.0 
SLC39A9 3 7.5+1.4 2 6.9+0.3 2 9.3+0.0 2 6.8+1.2 4 4.4+2.9 
SLC39A10 3 6.2+2.0 2 9.4+1.8 2 9.3+0.1 2 8.3+4.5 4 5.5+2.6 
SLC39A11 3 4.6+0.4 2 6.1+0.3 2 6.4+0.1 2 6.8+0.2 4 4.6+2.8 
SLC39A12 3 11.5+3.2 2 11.6+3.1 2 *4.7+2.0 2 14.2+1.1 4 2.1+2.9 
SLC39A13 3 4.1+1.4 2 7.1+0.1 2 6.2+0.5 2 4.5+0.9 4 3.3+2.0 
SLC39A14 3 9.3+0.8 2 5.9+0.1 2 4.9+0.0 2 3.2+0.8 4 3.9+2.4 
TaqMan 
SLC39A12   
 
  15.3 
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Figure 3-4- Diagram representation of QRT-PCR data for non-RPE cells 
Representation of QRT-PCR data for non-RPE cells in bullet format, separating the 
high (red), medium (yellow) and no expression (grey) for both SLC30 and SLC39 
family of zinc transporter genes. From left to right, data for mBend5, rRGC, 
HEK293 and hMuller are presented.  
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3.5. Confirmation of high SLC39A12 Expression in Cadaveric Tissue Using a 
TaqMan Style Probe 
Methods 
SYBR-Green dye-based detection is a highly efficient method to quantify the 
expression of the zinc transporters. This means that no specific probes are required, 
which reduces assay setup time and running costs. However, because SYBR Green 
dye binds to any double-stranded DNA, including nonspecific double-stranded 
DNA sequences, it has a potential to generate false positive signals and we showed 
that generation of signals from primer dimers does interfere with the detection of 
lowly expressed gene amplification products. This appeared to be the case for 
SLC39A12 in cultured cells. To overcome this problem, the TaqMan-based 
detection of gene amplification was employed. This method is based on specific 
hybridization between a probe and its target generating a gene amplification 
specific signal. The disadvantage of the TaqMan chemistry is that the synthesis of 
different probes is required for different sequences, making this method less cost 
effective. The probes were labelled with a fluorescent dye (in our case it was 6-
carboxyfluoroscein (FAM) and a quencher that extinguishes fluorescence while 
both attached to the probe. During the polymerisation reaction the probe is cleaved 
and this releases the fluorescent dye from the quencher. As PCR product 
accumulates, fluorescence intensity increases, allowing quantitation of the 
generated PCR products. Table 3.4 shows the fold difference in expression 
compared to ARPE19 cells generated by first calculating the ∆Ct values compared 
to the housekeeping genes (GAPDH, UBC, and YWHAZ) and then calculating the 
∆∆Ct values by comparing the ∆Ct values for the gene of interest to ∆Ct 
SLC39A12 in ARPE19 for normalisation.  
Results 
The values obtained by using SYBRGreen and TaqMan based detection systems 
were similar. The expression of SLC39A12 was 3-4 orders of magnitude higher in 
cadaveric samples and about 2 orders of magnitude higher in primary RPE cultures 
compared to expression in ARPE19. Currently we are confirming the results with 
further experimentations with the TaqMan-based probe for SLC39A12.  
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Table 3-4–Confirmation of SLC39A12 expression using TaqMan-style Probe 
The level of expression of SLC39A12 measured by using SYBR-Green based 
detection or TaqMan -based detection. Cadaveric tissues and primary RPE cultures 
contain higher level of SLC39A12 expression than ARPE19 cells do.  
 
  n  SYBRgreen TaqMan 
ARPE19 3 1.0 1.0 
hRetina 3 2530.4 2014.9 
hRPE 3 1708.7 1922.6 
hChoroid 3 13378.5 12147.5 
Primary  RPE 3 375.0 355.3 
 
3.6. Evidence of Cross-Contamination in Cadaveric Samples 
Method:  
QRT-PCR using RPE65 as RPE specific gene, VE-cadherin as endothelial specific 
gene and rhodopsin as retinal specific gene was used to validate for possible cross-
contamination problem present in cadaveric human samples (Table 3.5). Primers 
for VE-cadherin was kindly provided by Dr. Jenny McKenzie, primers for RPE65 
was kindly provided by Dr. Amanda Jayne Carr and primers for rhodopsin was 
purchased commercially from Applied Biosystem (Carlsbad, USA). The results 
presented here are the results from three or four separate experiments. Furthermore, 
in order to determine whether the expression of SLC39A12 increased with 
pigmentation, comparison was made between pigmented and non-pigmented 
ARPE19 cells. Three cDNA samples were kindly provided by Dr. Ahmed Ahmado 
and Dr. Amanda Jayne Carr. The data was presented as a delta Ct format as 
previously described. With low/ no expression having delta Ct >10 (grey), medium 
expression with delta Ct 5-10 (yellow) and high expression with delta Ct < 5 (red).  
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Results:  
Table 3-5 – Cross contamination in human cadaveric samples  
Cross-contamination present in human cadaveric samples and expression of ZIP12 
in pigmented and non-pigmented ARPE19. Data is presented as the delta Ct value 
for each samples.  
Choroid VE-cadherin 10.60 
Choroid RPE65 1.91 
Choroid Rhodopsin 10.02 
RPE VE-cadherin 16.05 
RPE RPE65 3.66 
RPE Rhodopsin 8.80 
Retina VE-cadherin 13.36 
Retina RPE65 7.61 
Retina Rhodopsin 2.14 
ARPE19 pigmented SLC39A12 17.29 
ARPE19 non-pigmented 
SLC39A12 21.46 
 
In RPE samples, there is very little contamination from the choroid as assessed 
using endothelial specific VE-Cadherin primers, with a delta Ct of 16.05. There is 
moderate contamination (delta Ct 8.80) from the retina as assessed with retinal 
specific rhodopsin. The expression analysis for RPE65 is highest as expected in 
RPE samples with delta Ct of 3.66. In retina samples there is also minimal 
contamination from the choroid, (delta Ct 13.36), moderate contamination from 
RPE65 (delta Ct 7.61). The expression analysis for rhodopsin is highest in retinal 
samples with delta Ct of 2.14. The cross-contamination, particularly those present 
in choroid indicated that the results have to be taken with careful consideration. In 
pigmented ARPE19 cells, the expression of SLC39A12 is marginally increased 
(delta Ct of 17.29) compared to non pigmented (delta Ct of 21.46). However, as the 
changes are minimal and expression level remains very low, the results will have to 
be verified using other means.  
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3.7. Discussion 
The ocular tissues contain exceptionally high concentrations of zinc (See Chapter 1 
– Introduction) suggesting that zinc plays an important role in physiology and, 
potentially, pathology of the eye (Ugarte and Osborne, 2001). The primary 
mechanism(s) mediating zinc homeostasis in these cells is likely to involve at least 
some of the 10 ZnT exporters and the 14 ZIP importers encoded by the SLC30A 
and SLC39A solute-linked carrier families of transmembrane proteins (Liuzzi and 
Cousins, 2004a). While studies in other tissues have underlined the importance of 
these transporters in health and disease (Taylor et al., 2007, Zhang et al., 2008, 
Fukada et al., 2008, Dufner-Beattie et al., 2003), little is known about the 
distribution and function of these transporters in the eye. Here we examine the 
expression profile of all 24 zinc transporters in several cell lines, primary cell 
cultures and cadaveric samples from the retina/RPE/choroid complex to gain a 
better understanding of their distribution.  
3.7.1. Zinc Transporters in Human Cadaveric and Cultured Retinal Pigment 
Epithelium Cells and non-RPE cell lines 
The RPE is one of the most commonly studied cell type in ocular research. 
Previous studies have described the expression levels of zinc transporters in 
ARPE19 cells as well as primary RPE cell cultures from human adults and foetuses 
(Leung et al., 2008a, Rezaei et al., 2008a). ARPE19 is a spontaneously 
immortalised human RPE cell line. While it is widely used for RPE research, 
expression of RPE specific genes and several phenotypic characteristics of ARPE19 
differ from those of RPE in vivo (Cai and Del Priore, 2006, Vugler et al., 2008). In 
their publication in 2008, Leung et al (Leung et al., 2008a) determined the 
expression of 23 zinc transporters (with exception to SLC30A10) in ARPE19 cells, 
as well as primary cultures derived from human foetuses and adults (summarized in 
Table 3.6). Another study (Rezaei et al., 2008a) analysed the expression of the 14 
SLC39A genes (coding for ZIP importers). In our work we analysed the expression 
of all 24 zinc transporters in ARPE19, primary RPE cell cultures and RPE isolated 
from cadaveric eyes (data summarized in Figure 3.2). While the results obtained by 
Leung et al and Rezaei et al on cultured cells are not dissimilar, neither groups 
examined expression in cadaveric tissues. This is perhaps not surprising, 
considering the large variability in RNA samples we found in human cadaveric 
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RPE, which caused quantitative analysis impossible. This variability was probably 
due to post-mortem degradation of RPE and tissue handling. In recent experiments 
we were able to limit RNA degradation by doing a very thorough tissue disruption 
combining both hand held mortar and pestle tube as well as using Qiashredder 
tubes (Qiagen GmBH, Germany). Furthermore, retinal samples require complete 
removal of any vitreous humor attached before lysing.  
However, analysing the dissociation curve from QRT-PCR experiments and 
separating of gene products on 1% agarose gels allowed us to draw some 
conclusion even on the difficult samples. In these SLC39A2, 9, 10 and 11 were 
either absent or had a very low level of expression while others appeared to be 
present with differing expression levels. Interestingly, in ARPE19 (and many other 
cultured cells, see later) the expression of SLC39A12 was absent while there is 
clear expression in cadaveric tissue derived RPE and primary RPE cells at passage 
1 (Leung et al., 2008a) and low expression at passage 4 samples (our experiments). 
This raised the possibility that studying the role of ZIP12 protein might be possible 
by transfection of cultured RPE, which is discussed in details in the next chapter 
(Chapter 4). 
 
 
 
 
 
 
 
 
 
 
 
103 
 
Table 3-6- Summary of zinc transporter expression in various RPE cels 
Summary of zinc transporter expression in various RPE cells based on the work of 
three different laboratories: a (Leung et al., 2008b); b (Rezaei et al., 2008b) and our 
own (Cahyadi, Berzegar-Befroei and Lengyel, unpublished). Black represents high, 
gray low and white no expression of a gene based on qRT-PCR experiments. 
Expression levels are compared to selected housekeeping genes. Abbreviations: 
RPE, retinal pigment epithelium; h, human; hf, human fetal; ha human adult; r, rat; 
m mouse; ND, not determined.  
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While information about the function of zinc transporters in the RPE is very 
limited, we combined our and the previously mentioned expression data with what 
is known about the location and function of zinc transporters in other cells, and 
have generated a speculative working model suggesting where zinc transporters 
might be. This is discussed below and depicted on Figure 3.5.  
The discovery of ZnT1, the first zinc transporter identified (Palmiter and Findley, 
1995) caused a major change in the understanding of zinc transport. It was 
discovered that overexpression of ZnT1 confers resistance to zinc pretreatment 
which was attributed to its plasma membrane localization. This allows the protein 
to constantly pump zinc to the extracellular space. ZnT1 is expected to be found on 
apical cell as well as basal membrane of RPE cells, although it has also been found 
around the perinuclear area of RPE cells (Kirschke and Huang, 2008, Wang et al., 
2009a) (Leung et al., 2008b). The protein is unique compared to other plasma 
membrane transporters, as it is ubiquitously expressed compared to ZnT2 and ZnT5 
which have a more limited expression and this led to the belief that it functions as 
the primary zinc exporter in cells. This was supported by the finding that the ZnT1 
knockout mouse is embryonic lethal due to failure to remove excess zinc from cells 
(Langmade et al., 2000).  Based on its pronounced expression in the RPE, ZnT1 is 
likely to be a plasma membrane exporter in RPE cells. 
ZnT2 has been found in various tissues (Palmiter and Huang, 2004). Its localisation 
has been reported on endosomal vesicles, lysosomes, apical surface of microvilli 
and mitochondria (Kambe et al., 2004, Falcon-Perez and Dell'Angelica, 2007) 
(Kelleher and Lopez, 2008). The protein function is likely to be to reduce zinc 
concentration in the cytosol by transporting zinc into intracellular stores. Zinc 
treatment in various studies demonstrated an increase in ZnT2 at gene expression 
and protein levels (Falcon-Perez and Dell'Angelica, 2007, Bobilya et al., 2008). 
Within the RPE itself, it is possible that ZnT2 localisation in the vesicle/phagosome 
may indicate an involvement in phagocytosis of photoreceptor outer segments and 
degradation of opsins (Gleim et al., 2009). While we did not observe the expression 
of ZnT2 in our ARPE19 samples, gene expression of ZnT2 was reported by Leung 
and colleagues (Leung et al., 2008b, Liuzzi et al., 2001a). 
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ZnT3 protein is located on the apical membrane of the endothelial cells (Wang et 
al., 2004b). ZnT3 is usually associated with synaptic vesicles but has also been 
shown to be present in non-neuronal cells (Palmiter et al., 1996). In the human RPE 
cell lines, mRNA of ZnT3 was found to be expressed in ARPE-19 and human adult 
RPE, but not in human fetal RPE (Leung et al., 2008a), where our study reported no 
expression of ZnT3. If ZnT3 was present in RPE cells then it would be expected to 
be associated with vesicles around the apical plasma membrane. However, ZnT3 
expression will need further verification as we were unable to confirm this 
observation.   
In the eye, ZnT4 expression is found in all types of RPE cell cultures, ARPE-19, 
human fetal RPE, and human adult RPE (Leung et al., 2008a).  It is expected that 
ZnT4 would be localised in the vesicles. In 2003, Henshall et al reported the 
localisation of ZnT4 in the vesicles and on the plasma membrane, indicative of its 
function to mediate efflux from the cells (Henshall 2003).  
ZnT5 expression was absent in the study by Leung et al (Leung et al., 2008b) but 
present in the eye based on in silico data (Seve et al., 2004) and it was observed by 
us in all RPE cells analysed. This transporter is reported to be involved in vesicular 
zinc loading as well as associated with apical membranes, yet the direction of zinc 
transport through this transporter is not clear probably because of alternative 
splicing (Jackson et al., 2007, Valentine et al., 2007, Kambe et al., 2002). The 
expression of ZnT6,7 and 9 was observed both by us and Leung et al (Leung et al., 
2008a). ZnT6 and 7 are involved in translocation of cytoplasmic zinc into the Golgi 
network (Kirschke and Huang, 2003), while ZnT9 is ubiquitously distributed in 
cells it was thought to be involved also in zinc transport into the nucleus (Sim and 
Chow, 1999, Sim et al., 2002). As intracellular immunoreactivity of ZnT7 in RPE is 
very high, transporting zinc into the Golgi might be important for appropriate RPE 
function.  
The expression of ZnT7 in the retina of albino mice is localized to the axons and 
dendrites of ganglion cells,where reactivity was highest in the somata of ganglion 
cell layer, and moderate immunoreactivity was present in nerve fiber layer and 
inner nuclear layer. Weak staining was noted in the inner plexiform layer. 
Intracellularly, ZnT7 localizes to the perinuclear area, or Golgi apparatus (Kirschke 
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and Huang, 2003). In the RPE, expression of ZnT7 was reported by both our study 
and Leung (Leung et al., 2008a).  
None of the RPE cells analysed in this study expressed ZnT8 mRNA. Previous 
studies have indicated the specific tissue localisation of ZnT8, where it is located in 
the pancreatic beta-cells. While we do not see the expression of ZnT8 in any of the 
tissues that we have analysed, Leung et al reported the expression of ZnT8 in 
human cultured fetal RPE, suggesting that this gene may have a developmental 
role. Studies from pancreatic beta-cells have shown vesicular localisation of ZnT8 
(Chimienti et al., 2006), suggesting that if this protein is present in the RPE, it is 
likely to be localised in the same compartment.  
Both Leung et al and our study observed a high expression of ZnT9 in RPE cells. 
While little functional data have been found for this protein, reports have associated 
the protein’s localisation to the nucleus (Sim and Chow 1999,(Sim et al., 2002). 
None of the studies reported the expression of ZnT10 although our data on 1% 
agarose gel seemed to indicate the presence of ZnT10 in human cadaveric samples. 
Seve has indicated that ZnT10 is embryonic specific, although no data are available 
on its function and localisation (Seve et al., 2004).  
Relatively little is known about ZIP transporters. ZIP1-6, 8, 12 and 14 have been 
shown to be located on the plasma membrane and probably mediate zinc transport 
into RPE cells. ZIP7 is localized to the ER and Golgi, ZIP8 is present on vesicles 
and mitochondria and ZIP13 regulates zinc levels in the Golgi (Taylor et al., 2008, 
Aydemir et al., 2009, Fukada et al., 2008). In chapter 4, we will show the 
localization of ZIP12 protein on cultured cells.  
ZIP1 protein is expressed in the ARPE19 cell line, as well as human fetal RPE and 
human adult cell lines (Leung et al., 2008a). Belloni-Olivi and colleagues have 
reported the dual localization of ZIP1 on the plasma membrane as well as 
intracellular vesicles under excessive zinc condition (Belloni-Olivi et al., 2009).  
ZIP2 expression was observed in the ARPE-19 cell line and human fetal RPE, but 
not present in human adult RPE cells (Leung et al., 2008a). Increase in extracellular 
zinc levels in ARPE19 cells can increase the expression of ZIP2 and enzymes 
involved in glutathione synthesis to provide protection against oxidative stress in 
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RPE cells (Ha et al., 2006, Rezaei et al., 2008b). Expression of ZIP2 was also 
induced by various neurotrophic factors (Leung 2008). Studies by Rezaei and 
Leung both reported the expression of ZIP2 mRNA in ARPE19 cells, although we 
did not observe the expression in our studies. We postulate that this could be caused 
by differences in primers used. The expression of ZIP2 appears to be 
developmentally regulated and can be altered by neurotropic factors in RPE cells 
(Leung et al., 2008a) therefore it might be very important for normal and 
pathological processes in the eye. 
ZIP3 expression has been found in both ARPE19 cell line and human cadaveric 
RPE in our studies. In addition to this, Leung et al and Rezaei et al have both 
reported expression of ZIP3 in ARPE19, human fetal and adult RPE cell cultures 
(Leung et al., 2008a). 
ZIP12 is probably the least studied zinc transporter protein. Its gene expression is 
reported to be localized to the retina, kidney and brain according to the EST 
database (http://www.ncbi.nlm.nih.gov/nucest) (See section 4.7). Leung et al. 
(Leung et al., 2008a) reported that the expression of SLC39A12 was found in 
primary cultures of human fetal RPE, as well as human adult RPE but not in ARPE-
19 cells. Rezaei et al (Rezaei et al., 2008a) and our work (Figure 3.2) confirms the 
absence of mRNA for ZIP12 in ARPE-19 cells. However, using TaqMan based 
detection we showed that its expression is 2-4 order higher in primary cultures and 
cadaveric RPE cells than in ARPE19, a finding that is strongly supported by the 
results of Booij et al (Booij et al., 2010b). They have shown that ZIP12 is not only 
expressed in RPE, but categorised it is one of the RPE specific genes. Given the 
important role for zinc in RPE cells, we have attempted to characterize this protein 
(see chapter 4) in order to understand the mechanism of zinc transport.  
 
 
  
Figure 3-5- Zinc transporters in RPE
Based on the literature 
this figure summarizes our understanding of where zinc transporters may be located 
in RPE cells and includes potential zinc buffering or muffling compartments. For 
simplicity, on this figure endosomes, lysosomes, and secretory vesicles are labeled 
as “Vesicles” despite 
melanosomes; MT metallothionein; ER, endoplasmic reticulum.
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3.7.2. Zinc transporters in the choroid and fenestrated endothelial cells 
Because of the difficulty of obtaining high quality RNA from cadaveric tissues, we 
could only generate information in relationship to the choroid through analysing 
zinc transporter expression in bEND5 cells. These cells are used to model fenestrae 
formation in endothelial and in Chapter 6 we will study the effects of zinc in this 
specialized system. While bEND5 cells are derived from rat they provide some 
indication about zinc transporter expression in fenestrated endothelial cells. The 
gene expression profile of bEND5 cells was very similar to that of ARPE19 cells. 
Many transporters appeared to be expressed in these cells although ZnT2, 3, 8, 10 
and ZIP2 and 12 were not. Despite the lack of expression of SLC39A12 in bEND5 
cells, the expression of this protein in cadaveric choroidal tissue is very high 
compared to the other tissues we examined. Given that Boiij et al found that ZIP12 
is highly enriched in RPE cells compared to choroid in laser micro-dissected human 
cadaveric samples, the higher expression of SLC39A12 in choroid samples 
compared to the RPE in our experiments remains to be experimentally validated 
(Booij et al., 2010b).  
3.7.3. Zinc Transporters in the Retina3 
“Relatively little is known about zinc transporters in other parts of the eye. Our 
QRT-PCR data suggest that Muller cells express 8 out of the 10 ZnTs and 11 out of 
the 14 ZIPs, while primary retinal ganglion cells express 9 out of the 10 ZnTs and 
13 out of the 14 ZIPs (see Figure 3.1). Redenti et al (Redenti and Chappell, 2004a) 
found ZnT3 protein in several layers of the retina, namely the inner segments and 
outer limiting membrane of photoreceptors, the inner nuclear layer and outer 
plexiform layer and the strongest labeling was present in both ganglion and Muller 
cells. This associates ZnT3 and therefore zinc with neuronal transmission (Palmiter 
et al., 1996). The only other transporter whose immunolabeling has been reported 
in the literature is ZnT7 (Wang et al., 2006a). Immunolabeling for ZnT7 is present 
in optic nerve fibers, ganglion cells, inner and outer plexiform layers, horizontal 
                                                 
3
 Barzegar-Befroei, N., Cahyadi, S., Gango, A., Peto, T., and Lengyel, I. 2011. Zinc 
in Eye Diseases. Zinc in Human Health. Amsterdam: IOS Press.  
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and amacrine cells and the photoreceptor outer segments (Wang et al., 2006a), 
suggesting that ZnT7 plays a wide ranging role in the retina.” 
3.7.4. Eye Phenotype in Zinc Transporter Knockout Animals4 
“The role of zinc and zinc-dependent mechanisms in development (Prasad, 1998) 
indicated that appropriate zinc homeostasis might be important for normal eye 
development. In support of this, the examination of eye phenotypes of transgenic 
animals showed that an array of developmental abnormalities is associated with the 
lack of zinc transporter genes. For example, in ZIP4 knockout mice, exencephalia, 
severe growth retardation, and hydrocephaly, was accompanied by unilateral or 
bilateral anophthalmia.  The manifestations of these could be exacerbated with zinc 
deficiency and ameliorated by zinc supplementation in heterozygous but not in 
homozygous embryos (Dufner-Beattie et al., 2007). Fukada et al reported that 
ZIP13 is crucial in connective tissue development. ZIP13 knockout caused sunken 
eyes which were also associated with down slanting palpebral fissures (Fukada et 
al., 2008). The abnormalities were attributed to a decrease in dermal collagen fibril 
sizes and thinning of corneal stroma. ZIP13 knockout effects also extended to 
improper osteogenesis and craniofacial tissue development.”  
3.8. Future Plans 
One of the original goals of this thesis was to compare the expression of zinc 
transporters in AMD and control subjects to improve our understanding of how zinc 
homeostasis can be affected in diseased conditions. However, experiments on 
cadaveric tissues presented several problems, which we are just managing to 
resolve. Therefore, in the near future we will analyse zinc transporter expression in 
a selection of cadaveric samples. A comprehensive analysis of immunolocalisation 
of transporters would also be of interest. In a genetics study (in collaboration with 
Professor John Yates), we are examining the results from genome wide association 
studies to identify potential single nucleotide polymorphisms on the 24 zinc 
transporters. Based on preliminary data it appears that there are potential 
association between zinc transporter SNPs and AMD (data not shown) though 
                                                 
4
 Barzegar-Befroei, N., Cahyadi, S., Gango, A., Peto, T., and Lengyel, I. 2011. Zinc 
in Eye Diseases. Zinc in Human Health. Amsterdam: IOS Press. 
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further sampling and verification by PCR will be required before solid conclusions 
could be drawn (data not shown). 
The results presented in this chapter needs to be taken with caution due to cross-
contamination, lower quality RNA due to post-mortem tissue processing, 
particularly in the RPE and choroid samples. Future experiments will have to 
address cross-contamination issues, possibly through creation of very early passage 
primary cultures of human RPE. Furthermore, better dissection procedure need to 
be adopted for cadaveric RNA isolation, particularly in choroidal samples as QRT-
PCR results indicated that there is heavy contamination from the RPE. Possible 
method to alleviate this problem may include laser microdissected samples from 
human cadaveric tissue.  
Conclusion 
Using SYBRGreen and TaqMan based detection assays we were able to start the 
cataloguing of zinc transporter expression in the retina/RPE/choroid complex. 
While this work is far from complete, it helped us and others to identify some 
potentially important zinc transporters for RPE cells. We became particularly 
interested in ZIP12 because of its unusually high expression in freshly isolated RPE 
cells and very low or non-existent expression in cultured cells although major 
caution needs to be exercised during interpretation of the result due to 
contamination from the corresponding tissue as well as low replication number of 
experiments.  
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4. Characterisation of ZIP12: Structure, Function 
and Localisation 
 
As we showed in the previous chapter, several zinc transporters are expressed in 
the RPE-choroid interface. ZIP12 appears to be an exception. Its gene 
expression was either very low or absent in all cultured cells, including human 
primary RPE cultures, but was highly expressed in human cadaveric tissues. 
This finding was supported by recent findings on laser dissected human RPE 
cells, suggesting that SLC39A12 is one of the RPE specific genes (Booij et al., 
2010b). We argue here that ZIP12 is a potentially important candidate gene for 
regulating zinc fluxes at the RPE-choroid interface and its lack of expression 
under culturing conditions might contribute to the phenotypic anomalies 
observed in in vitro experiments using ARPE19 cells. As ZIP12 is probably the 
least studied zinc transporter, we first examined how this transporter might 
function. Available information on ZIP12 was collected through data mining 
and bioinformatic tools to understand the protein structure before the cellular 
localisation of the protein was observed through transiently expressing it in 
various cell lines. Finally the possible relationship(s) between ZIP12 and RPE 
was explored.  
 
There is very little published information on ZIP12 or its gene SLC39A12. Reports 
have linked ZIP12 to schizophrenia (Bly, 2006), Alzheimer’s disease (Grupe et al., 
2006) and cancer (Sotiriou et al., 2006). Despite the paucity of published peer 
reviewed information on ZIP12, we explored what can be found out about ZIP12 and 
its gene SLC39A12 in existing databases. 
 
4.1. SLC39A12 Isoforms 
SLC39A12 (UniProt accession Q504YO), is located on chromosome 10p12.33. 
There are 5 splice variants of SLC39A12 (www.ensembl.org) which is summarised 
in Table 4.1.  
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Table 4-1- Five isoforms of SLC39A12 (ZIP12).Data obtained from 
www.ensembl.org 
Name Amino Acid Length Transcript Length 
SLC39A12-001 690 2725 bps 
SLC39A12-002 654 2639 bps 
SLC39A12-201 691 2808 bps 
SLC39A12-202 611 2483 bps 
SLC39A12-203 557 1900 bps 
 
 
 
Figure 4-1- Five isoforms of ZIP12 
Five isoforms of ZIP12 protein are shown, with the longest SLC39A12-201 isoform 
having 691 amino acid residues, SLC39A12-001 containing 690 amino acid 
residues with a deletion of residue K474. SLC39A12-002 contained a deletion 
between transmembrane III and IV, between residues 474-510 resulting in a protein 
with 654 amino acid residues. SLC39A12-202 has 611 amino acid residues, with 
truncation in the first 80 amino acids. SLC39A12-203 contains truncation in the 
first 134 amino acids. 
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4.2. The ZIP12 protein 
Based on sequence homologies using ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) the ZIP protein family was divided 
into four subfamilies where ZIP12 belongs to the LIV-1 subfamily (Figure 4.2). 
LIV-1 family members are thought to facilitate zinc uptake or influx (Taylor et al., 
2007). There are three defining features of the LIV-1 subfamily:  
-LIV-1 members are expected to have 8 transmembrane domains and are localised 
predominantly on the plasma membrane. 
-All members should contain a histidine-rich motif, which has been suggested to be 
directly involved in zinc transport.  
-All members should contain a highly conserved CPALLY domain at the N-
terminal extracellular domain, whose function is currently unknown (Taylor et al., 
2007).  
Using Compute pI/Mw program from Expasy (http://web.expasy.org/compute_pi/), 
the molecular weight of the 691 amino acid long ZIP12 protein was predicted to be 
76 kDa with an isoelectric point of 5.85. Based on prediction by DAScurve 
(http://mendel.imp.ac.at/sat/DAS/DAS.html), PSIPRED 
(http://bioinf.cs.ucl.ac.uk/psipred/) and TMPRED 
(http://www.ch.embnet.org/software/TMPRED_form.html) confirmed that ZIP12 is 
a protein with 8 transmembrane domains (Figure 4.4). However, Sosui 
(http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html), that uses hydrophobicity 
features of the amino acid sequences to predict helical structures, returned with five 
transmembrane domains and TMHMM (http://www.cbs.dtu.dk/services/TMHMM/ 
) returned seven transmembrane domains on ZIP12. All the transmembrane 
domains are located at the C-terminal half of the protein and the N-terminus is 
predicted to form a large part of the extracellular domain. There is a putative signal 
peptide sequence between residues 1-23 (http://www.cbs.dtu.dk/services/SignalP/) 
which could aid the insertion to the membrane. Overall the ZIP12 protein is 
expected to be a plasma membrane protein. As we will show later a C-terminal 
tagged form of ZIP12 is indeed localized to the plasma membrane (Figure 4.18). 
 
  
Figure 4-2 - Phylogenetic tree of SLC39 families.
SLC39 family of zinc transporters a
belong to ZIP Subfamily II, ZIP
subfamily, ZIP4, 5, 6, 7, 8, 10, 12, 13 and 14 belong to the largest subfamily called 
LIV-1. ZIP7 and 13 is
Image was created using ClustalW and edited in Adobe Photoshop CS4.
 
 
 
Figure 4-3 – Multiple alignments of ZIP12 peptide sequences among six common 
mammals human, mouse, rat, horse, pig and 
 
 
 
 
redivided into 4 subfamilies. ZIP1, 2, and 3 
 4 and 9 belong to Subfamily I, ZIP11 to gufA 
 further grouped into HKE4 within the LIV
cow. 
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-1 subfamily. 
 
 
  
Figure 4-4 – Hydrophobic plot for ZIP12 protein
Hydrophobic plot created using TMpred program showed the presence of 10 peaks 
above the threshold. Combining t
transmembrane domains prediction programs indicated the potential presence of 8 
transmembrane domains 
transmembrane domains are located in the second half of the pr
approximately residues 400
made after comparing various secondary structure prediction programs (see section 
4.2). TMPred returns with 2 additional transmembrane domains before 
transmembrane I, however, this was not shared by the other programs.
 
 
 
 
 
 
 
 
he plot with results obtained from other 
in ZIP12 protein (annotated on the graph). All the 
otein structure from 
-691. The annotation for transmembrane domains was 
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A histidine-rich HXXHXHH sequence can be found between transmembrane 
domains III and IV and a CPALLY-like domain is located adjacent to the TMI on the 
extracellular domain of ZIP12 (Figure 4.5). It is interesting to note that in isoform 
SLC39A12-002 a deletion of 35 amino acids between TMIII and IV eliminated the 
HXXHXHH residues, a histidine-rich sequence which has been suggested to bind 
zinc (Taylor, 2000). NetPhos3.8 program (http://www.cbs.dtu.dk/services/NetPhos/) 
predicted that there are 38 serine, 7 threonine and 6 tyrosine phosphorylation sites 
(data not annotated). One of these is Ser36, the amino acid residue that can be altered 
from serine into glycine, and this polymorphism has been associated with 
schizophrenia (Bly, 2006). This site is a consensus phosphorylation site for glycogen 
synthase kinase-3, suggesting that ZIP12 might be a target for GSK-3 signalling. 
Interestingly, GSK-3 signalling is thought to play a role in the pathogenesis of 
Alzheimer’s disease (Takashima, 2006). This phosphorylation site is just 
downstream of a potential peptidase cleavage site located between residues 23 and 
24 (http://www.cbs.dtu.dk). Annotated in pink are 6 potential glycosylation sites, all 
of which are found on the extracellular domain. In TMV, there is a conserved 
HEXXHEXGD metalloprotease-like domain, which is also present in other LIV-1 
family members.  
Table 4.2 highlights the sequence motifs or relevant sequences found in ZIP12 
human protein sequence. Amino acids 1-20 show the sequence recognised by the 
Abcam (commercial) antibody which is used in this chapter. This sequence 
coincides with the signal peptide which would be cleaved in ZIP12 protein. We 
have used this antibody on cells and sections. Optimisation protocols using various 
fixation methods on ZIP12-transfected cells as well as various antigen-retrieval 
steps such as pressure cooker and microwaving sections did not produce any 
specific staining (data not shown). Upon enquiring with Abcam, it was determined 
that the antibody would not have worked as it coincides with the signal peptide. A 
potential cleavage site is located on residues 23-24 just after the signal peptide. A 
few of glycosylation sites (highlighted in pink) are present, all of which are located 
on the N-terminal of the protein. There is a potential GSK-3 beta phosphorylation 
site on residue 27-31 (red, underlined). In order to understand the function of ZIP12 
further, we designed an antibody which recognises residues 294-305, which will 
subsequently be called ZIP12-5193 and ZIP12-5194 (red, highlighted). Soon after 
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the ZIP12 -5193/5194 sequence is a LIV-1 family-specific CPALLY motif (in 
green). Transmembrane I and II are located between residues 362-393 and 399-420. 
The histidine-rich region between residues 421-447 contains four histidine residues 
which is may have the capability to bind zinc. Transmembrane III is located 
between residues 448-469, and transmembrane IV from residues 540-563. Residues 
474-510 contain a metal-binding motif HXXHXHH. The deletion of this residue in 
the truncated isoform of ZIP12 may have importance in function. Transmemrane V 
is located from residues 540-563. Within transmembrane V from 570-593 there is a 
metalloprotease domain HEIPHEMGD. The rest of the protein contains 
transmembranes VI, VII and VIII.  
All five splice variants of ZIP12 protein share the same sequences, with no 
polymorphisms within conserved peptide sequences, with only deletions and 
truncations present. The longest variant has 691 amino acids (SLC39A12-201). The 
splice variant with the closest homology to SLC39A12-001 is SLC39A12-001 
containing 690 amino acids with a deletion of a lysine residue at position 474 
(www.ensembl.org). SLC39A12-002 contained a deletion between transmembrane 
III and IV, between residues 474-510 resulting in a protein with 654 amino acid 
residues where the histidine rich motif HXXHXHH is located. This result was also 
confirmed using GenBank. Histidine is an amino acid which has the capability to 
bind zinc through its imidazole ring. The loss of histidine-rich sequence in 
SLC39A12-002 creates an opportunity for functional analysis to see whether the 
truncation alters zinc transport capability as the sequence harbors a histidine rich 
motif HXXHXHH. Interestingly, sequence alignment using ClustalW2 shows that 
mouse does not have the human equivalent of sequence 474-510, meanwhile this 
sequence is preserved in other species such as pig, horse and rat.  
SLC39A12-202 has 611 amino acid residues, with truncation in the first 80 amino 
acids. SLC39A12-203 is the shortest isoform of the five, with truncation in the first 
134 amino acids. Alignments of SLC39A12 peptide sequences (Figure 4.3) in 
various species including human (Homo sapiens), mouse (Mus musculus), rat (Rattus 
norvegicus), pig (Sus scrofa), cow (Bos Taurus), and horse (Equus cabalus) showed 
similar protein sizes with often different but conserved amino acid residues 
(www.ensembl.org ). There are three sub-branchings, with pig and bovine ZIP12 
located on separate branches, the third sub-branch comprised of human, horse and 
119 
 
another smaller sub-branch containing rat and mouse ZIP12 sequences (see Figure 
4.3)   
 
1   MCFRTKLSVS WVPLFLLLSR VFSTETDKPS AQDSRSRGSS GQPADLLQVL SAGDHPPHNH 
     Abcam Antibody   Cleavage     S36G GSK-3 
61  SRSLIKTLLE KTGCPRRRNG MQGDCNLCFE PDALLLIAGG NFEDQLREEV VQRVSLLLLY 
 
121 YIIHQEEICS SKLNMSNKEY KFYLHSLLSL RQDEDSSFLS QNETEDILAF TRQYFDTSQS 
 
181 QCMETKTLQK KSGIVSSEGA NESTLPQLAA MIITLSLQGV CLGQGNLPSP DYFTEYIFSS 
 
241 LNRTNTLRLS ELDQLLNTLW TRSTCIKNEK IHQFQRKQNN IITHDQDYSN FSSSMEKESE 
                ZIP12-5193/5194 site 
301 DGPVSWDQTC FSARQLVEIF LQKGLSLISK EDFKQMSPGI IQQLLSCSCH LPKDQQAKLP 
                   CPALLY 
361 PTTLEKYGYS TVAVTLLTLG SMLGTALVLF HSCEENYRLI LQLFVGLAVG TLSGDALLHL 
   TMI               TMII 
421 IPQVLGLHKQ EAPEFGHFHE SKGHIWKLMG LIGGIHGFFL IEKCFILLVS PNDKQGLSLV 
                  TMIII 
481 NGHVGHSHHL ALNSELSDQA GRGKSASTIQ LKSPEDSQAA EMPIGSMTAS NRKCKAISLL 
       Lost in SLC39A12-002 
541 AIMILVGDSL HNFADGLAIG AAFSSSSESG VTTTIAILCH EIPHEMGDFA VLLSSGLSMK 
             TMIV            TMV 
601 TAILMNFISS LTAFMGLYIG LSVSADPCVQ DWIFTVTAGM FLYLSLVEML PEMTHVQTQR 
   TMVI    TMVII 
661 PWMMFLLQNF GLILGWLSLL LLAIYEQNIK I 
   TMVIII 
 
Figure 4-5– Annotated sequence of ZIP12 protein 
The protein sequence for ZIP12 shows 8 potential transmembrane domains 
(underlined sequences labeled TMI-VIII), a classic CPALLY motif (labeled green), 
the HxxHxH zinc site (labeled blue) inside a   a cleavage site between residue 23 
and 24 (labeled with magenta), as well as potential phosphorylation site for 
Glycogen Synthase Kinase 3 (GSK-3) SRGSS (labeled red), between 421-447 
(labeled brown) is the histidine-rich region (data obtained from various sources). 
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Table 4-2 - Details of Sequence Motif Found in ZIP12 Protein Sequence 
Sequence 
Number 
Sequence Potential Motif/ 
Structure 
1-20 MCFRTKLSVSWVPLFLLLSR Abcam Antibody 
1-17 MCFRTKLSVSWVPLFLL Signal Peptide 
23-24 ST Potential cleavage site 
59-62, 134-
137, 162-165, 
201-204, 242-
245, 290-293 
NHSR, NMSN, NETE, NEST, NRTN,  
NFSS 
Glycosylation sites 
27-31 SRGSS GSK3-beta 
phosphorylation site 
294-305 SMEKESEDGPVS    ZIP12-5193/4 
Sequence 
310-349 CLIPIIQC CPALLY domain 
362-393 PTTLEKYGYSTVAVTLLTLG 
SMLGTALVLF HSC 
TMI 
399-420 LI LQLFVGLAVG TLSGDALLHL TM II 
421-447 IPQVLGLHKQ EAPEFGHFHE SK 
GHIWK 
Histidine Rich Region 
448-469 LMG LIGGIHGFFL IEKCFILLVS  TM III 
474-510 
 
KQGLSLVNGHVGHSHHLALN 
SELSDQAGRGKSASTIQ 
Deleted in truncated 
isoform with 654 
amino acids 
493-499 HVGHSHH HXXHXHH 
540-563 LAIMILVGDSL HNFADGLAIG AAF TM IV  
570-593 GVTTTIAILCH EIPHEMGDFA VLLSS TM V  
570-575 HEIPHEMGD Metalloprotease 
domain 
607-625 FISS LTAFMGLYIG LSVSA TM VI 
642-665 DWIFTVTAGM FLYLSLVEML  
PEMTH 
TM VII 
666-689 LLQNF GLILGWLSLL LLAIYEQNIK TM VIII 
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4.3. Specific Expression of SLC39A12 in Tissues 
Based on the EST database, SLC39A12 mRNA is expressed in brain, retina and 
kidney, throughout foetal, juvenile and adult life in human tissues (Figure 4.7) 
(http://ncbi.nlm.nih.gov/UniGene/ESTProfileViewer). Gene microarray data from 
mouse (http://biogps.gnf.org) showed that ZIP12 is expressed in the retinal pigment 
epithelium, the ciliary body, iris, and the eyecup (Figure 4.6). In situ hybridisation of 
mouse brain located ZIP12 to the brain ventricles (see figure 4.7 arrow). It has been 
known that ventricles harbor a high concentration of MTF-1 (Hao et al., 1994), 
which suggests that zinc can be released here and taken up by the brain probably 
through the involvement of zinc transporters.  
 
4.4. Aims 
In chapter 3, we showed the absence of ZIP12 expression in cultured cell lines and 
its high expression in cadaveric tissue. This chapter aims to study how ZIP12 is 
involved in regulating zinc using the following strategy: 
1. Clone ZIP12 and generate tagged versions to express ZIP12 in different cell lines.  
2. Raise and characterise antibodies against ZIP12. 
3. Characterise commercially available ZIP12 antibodies. 
4. Express ZIP12 protein in ARPE19 cells to understand how the expression affects 
the cells’ phenotype.  
5. Analyse available Genome-Wide Association studies or Microarray studies to 
develop further working hypotheses concerning the potential role of ZIP12 in the 
RPE.  
 Figure 4-6– Expression Profile Analysis for SLC39A12
Expression profile analysis done on mouse microarray data and acces
BioGPS (http://biogps.gnf.org
present in various areas of the brain and the spinal cord. Within the eye, expression 
of SLC39A12 is detected 
 
) indicated that the expression of SLC39A12 is 
in the RPE, iris, ciliary body, eyecup and lens.
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Figure 4-7–EST profile and for Slc39a12 and expression of Slc39a12 in brain 
Expression of ZIP12 mRNA is highest in the brain ventricle of mouse (From Allen’s 
brain atlas) http://mouse.brain-map.org/. Expression sequence tag (EST) profile 
analysis showed that the expression of SLC39A12 is limited to the brain, embryonic 
tissue and the eye, as well as being present during organogenesis as well as juvenile 
and adult state. EST profiles approximate gene expression levels from various cDNA 
library sources. The number on the right (125372, 291299, 995094, etc) refers to the 
total number of EST in pool, meanwhile on its left (2, 5, 19, etc) refers to the number 
of Slc39a12 transcript present in the EST pool. The leftmost number (15, 27, 21 etc) 
refers to the number of transcript per million EST, thereby allowing comparison to be 
made between samples.  
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4.5. Cloning and expression of ZIP12 
The cloning of ZIP12 protein was done using Gateway® recombination cloning 
technology(Invitrogen, UK). The method differs from usual cloning using 
restriction enzymes in that preferred DNA fragments can immediately be inserted 
to expression vectors without the need of restriction endonucleases or DNA ligases. 
There are several advantages of using the Gateway Technology in contrast to 
standard way of cloning: 
1. Improved accuracy and easier procedures as the use of restriction enzymes and 
ligases are not required. The design also prevents shifts in reading frames. 
2. Once a donor clone has been generated, the donor clone can be used to produce 
other fusion proteins by immediate insertion to other expression vectors.  
3. The insertion of attB-flanked PCR product to the donor vector or “entry clone” 
only takes 3-4 hours before the entry clone is ready to be plated on Zeocin agar 
plates and is therefore much faster than normal cloning strategies. 
As none of our tested cell lines had ZIP12 expression, commercially purchased 
retinal cDNA (kind gift from Rebecca Kaye) was used as a template for cloning 
(Figure 4.8). The cDNA was used as a template for PCR using a specialised 25 base 
pair primer containing proprietary “attB” sequences and a Kozak sequence for the 
forward primer (for further details see materials and methods section as well as 
appendix). In the case where a C-terminal fusion protein was desired, the primer 
design did not incorporate the stop codon nucleotides to allow translation of the 
fusion proteins. The PCR template was inserted to a donor vector pDONR/Zeo 
through the use of proprietary BP clonase enzyme. The “entry clone” generated 
could then be used for insertion of a variety of expression vectors. Using LR-
clonase, a similar recombination step was performed to insert the flanked ZIP12 to 
the expression vectors (see Appendix 5). ZIP12 proteins were created with the 
longest ZIP12 isoform containing 691 amino acids. The resulting expression vector 
containing ZIP12 was then amplified according to the protocol described in the 
materials and methods section before thoroughly screened for possible mutations 
using T7 promoter, and 5 primers, which screened overlapping sequences of the 
entire SLC39A12 gene  
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Figure 4-8– Gateway Recombination Cloning Technology 
Gateway Technology is a two-step method to create a plasmid DNA containing the 
gene of interest. The process is started by using a DNA template (in our case, 
retinal cDNA) to create a PCR product flanked with proprietary attB cassette 
sequences. The use of BP clonase enzyme allows “swapping” between the attB and 
attP sites in the donor vector, inserting the attB flanked gene of interest into the 
donor vector and creating the attL sites inside the new entry clone (Panel A). This 
step also produced a by-product of attR flanked ccdB sensitivity gene cassette. The 
entry clone is a platform to generate plasmid DNAs that will generate fusion 
proteins. The recombination step of entry clone and destination vector involves the 
enzyme LR clonase, which generates the expression clone containing the gene of 
interest and the by-product of ccdB gene cassette inside what was originally the 
donor vector. 
 
 
 
Figure 4-9– Polymorphism found in retinal cDBA for screening 
The retinal cDNA used for creating the clones was found to have a silent mutation 
T33C which codes for the same amino acid residue aspartic acid. The mutation is a 
known SNP for SLC39A12  (rs691112). 
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Screening the human retinal cDNAresulted in the finding of a synonymous mutation 
(GAT  GAC) in amino acid residue 33 caused by a known SNP(rs691112) for 
SLC39A12 (Figure 4.9). As this did not change the amino acid sequence, the retinal 
cDNA was used in our experiments.  
Two C-terminally tagged ZIP12 fusion proteins were generated (V5 affinity tag and 
GFP). Overexpression was only achieved with the C-terminally V5 tagged ZIP12 
protein. The failure of expression of C-terminally tagged GFP-ZIP12 might possibly 
be caused by the interference of the large (27kD) GFP protein with folding and 
insertions into the membrane, a problem that had been previously reported for other 
GFP-fused membrane proteins (Pedelacq et al., 2006). 
Transient expression of ZIP12-V5 fusion protein was first achieved through 
transfection of HEK293 cells. Transfection efficiency was assessed by using 200, 
400, 800, 1000ng plasmid DNA and 2, 4, and 8µl of LipofectamineLTX (data not 
shown). Following this optimization step, HEK293 cells were routinely transfected 
with 800ng pcDNA3.1-ZIP12-V5 in the presence of 4µl of LipofectamineLTX 
(Invitrogen, UK) per 70,000 cells (Figure 4.10). The cells were incubated with the 
LipofectamineLTX-DNA complex for 30 hours at 37 °C before being fixed with ice 
cold MeOH for 5 minutes at -20 °C. As controls, sham transfections (where only 
LipofectamineLTX reagent was used) were performed following the same protocol 
except DNA was excluded. Transfection efficiency was checked by q-RT-PCR, 
which confirmed ZIP12 fusion protein overexpression with 800ng plasmid and by 
immunolabeling with a V5 and ZIP12 specific antibodies (Figure 4.10) (for antibody 
characterisation see later). 
 
 
  
Figure 4-10– ZIP12 tr
HEK293 cellswere either 
subjected to sham transfection with only the transfection reagent present. The cells 
were fixed with MeOH and stained with ZIP12
(Panels B,F,J)(Invitrogen).  
594 meanwhile V5 antibody was 
cells showed positive staining with V5 and ZIP12
transfected cells show
5194. Quantitation of fluorescence was not performed. Nuclear sta
performed using DAPI. For higher magnification of HEK293 cells transfected with 
ZIP12-V5 protein labeled with V5 and ZIP12
and C. All images were viewed
magnification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ansfection in HEK293 cells 
transfected with C-terminally tagged ZIP12
-5194 (Panels C,G,K)
ZIP12-5194 antibody was conjugated 
conjugated with Alexa-Fluor 488. 
-5194, meanwhile sham 
 no staining with V5 and background staining with ZIP12
-5194, refer to figure 4.17 panels B 
 using LSM700 confocal microscopy with 
127 
-V5 protein or 
 and V5 
with Alexa-Fluor 
Transfected 
-
ining was 
20x 
128 
 
4.6. Generation and Characterisation of Antibodies for ZIP12 
Methods 
Antibodies were generated commercially by Biogenes GmBH (Germany). After 
exploring potential epitopes, considering the position of functional domains, and 
cleavage sites, antibodies were raised in two rabbits against residues 294-305 on 
ZIP12 protein which are located directly before the conserved, extracellular 
CPALLY domain on the N-terminal of the protein. The polyclonal antibodies 
generated in the two rabbits were termed ZIP12-5193 and ZIP12-5194. The 
antibodies were tested on Jurkat cell lysate, purchased from Abcam (Cambridge, 
UK) (Abcam, Cat No AB64463), ZIP12-V5 over-expressed in HEK293 cells and 
ZIP12-V5 over-expressed using a cell-free in vitro translational system. 
Simultaneously, immunocytochemistry was carried out on different cell lines using 
all three antibodies for ZIP12 (ZIP12-5193, ZIP12-5194 and Abcam) in transfected 
and fixed cells. The Jurkat lysate have been suggested to contain ZIP12 using a 
commercially available antibody against ZIP12 (Abcam, Cat No AB64463). 
 
Results 
Five µg protein of the Jurkat lysate was loaded onto precast AnyKD polyacrylamide 
gels from BioRad before being blotted onto PVDF (BioRad) membranes and probed 
with ZIP12-5193 and, ZIP12-5194. The antibodies (undiluted immunosera) were 
diluted between 1:7,000 and 1:30,000 (Figure 4.12). At 1:7,000 dilution we could 
identify two bands on SDS-PAGE with both antibodies one at ~80 kDa and the other 
at ~130 kDa. With dilution the band intensities decreased but to different degrees by 
the two antibodies. ZIP12-5194 labeled the 80 kDa band more strongly while the 
ZIP12-5193 labeled the 130 kDa band more strongly. No other bands were labeled in 
Jurkat cell lysate in this experiment (Figure 4.11). However, none of these antibodies 
labeled the 75kDa protein band identified by the commercial ZIP12 antibody (Figure 
4.12) 
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In order to verify that the two bands observed on Figure 4.11 are both ZIP12, a 
peptide competition experiment was carried out using the synthetic peptide fragment 
we raised the antibodies against. For this, 1µg/1ml of peptide solution was used to 
deplete the 1:7000 dilutions of antibodies and blots containing five µg Jurkat lysate 
were probed with this peptide and antibody complex. Following visualization by 
electrochemiluminescence (ECL) the 80 kDa band was absent, but the 130kDa band 
remained strongly labeled using both of our antibodies. Incubating the PVDF 
membranes with the preimmune serum which demonstrates of any non-specificsignal 
showed no labeling (Figure 4.12). Interestingly, ZIP12-5193 this time labeled three 
bands, a ~ 130 kDa, a ~80 kDa and a ~60 kDa band. Peptide incubation of ZIP12-
5193 did not block the labeling of the 60 kDa band.  
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Figure 4-11–Optimisation of ZIP12-5194 and ZIP12-5193 in Jurkat lysate 
Optimisation of ZIP12-5194 (Panel A) and ZIP12-5193 (Panel B) using diluted 
Jurkat lysate showed the presence of two bands just above 100kD and 75kD. 5µl of 
diluted lysate was used in every single lane. With dilution, the 100kD band was 
able to be seen. This is in contrast with Panel B, where incubation with antibody 
ZIP12-5193 showed that dilution of antibody removed the 75kDa band. Using 
peptide incubation, we had previously determined that the 75kDa band was able to 
be removed after incubation with peptide.  
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Figure 4-12 – Peptide incubation of ZIP12-5193 and ZIP12-5194  
Incubation of ZIP12-5193 and ZIP12-5194 in Jurkat lysate at 1:7000 dilution show 
three bands and two bands at just above 100, 75 and 50 kD respectively. Peptide 
incubation for both ZIP12-5193 and ZIP12-5194 indicated that the band just above 
100 kD was removed. This strongly indicated that the removed band is ZIP12 
protein. Preimmune sera showed no bands. Antibody dilution used for both 
antibodies was 1:7000. ZIP12-Abcam shows a single band at 75kDa. Antibody 
dilution for ZIP12-Abcam was 1:1000.  
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To clarify further whether the different antibodies recognise ZIP12 protein the 
ZIP12-V5 plasmid was expressed using TnT® Quick Coupled 
Transcription/Translation System (Promega, UK).  
Methods 
This system uses a bacterial expression system to synthetically produce eukaryotic 
proteins from plasmid DNA sources without the need for cellular transfection. The 
protein products were run on SDS gels and blotted onto PVDF membrane as before, 
then labeled with a commercially available V5 antibody (Invitrogen, Paisley, UK) 
following the manufacturer’s instructions.  
Results 
At higher concentrations of proteins we noticed two bands; a high molecular weight 
diffuse band at ~175 kDa and one at ~65kDa (Figure 4.13). Dilutions of the protein 
lysate with lysis buffer helped the dissolution of the high molecular weight band 
and above 1:64 dilutiononly the ~65 kDa band was apparent. In the negative 
control, which did not contain the ZIP12-V5 plasmid, no bands were detected 
(Figure 4.14). However, probing the ZIP12-V5 protein with ZIP12 Abcam or ZIP-
5193 and ZIP12-5194 antibodies resulted in no specific immunoreactivity (Figure 
4.14). While we have no clear explanation for this discrepancy, it is probable that 
the lack of cellular mechanisms required for appropriate folding and 
posttranslational modifications (phosphorylation, methylation, glycosylation) could 
have led to the unsuccessful immunolabeling with the ZIP12 antibodies. The 
apparent lower than expected molecular weight for ZIP12 in this cell free system 
appears to support this. 
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Figure 4-13–Cell-free production of ZIP12 protein 
TnT® Quick Coupled Transcription/Translation System (Promega, UK) was used 
to synthetically produce eukaryotic proteins from plasmid DNA sources using a 
proprietary bacterial expression system. Protein products generated using C-
terminally tagged ZIP12-V5 were diluted with lysis buffer and sample buffer to 
final dilution of 1:16 (Lane A), 1:32 (Lane B), 1:64 (Lane C), 1:128 (Lane D), 
1:256 (Lane E) and negative control which does not contain plasmid DNA. Five µl 
of the products was loaded onto SDS-polyacrylamide gels, transferred onto PVDF 
membrane and immunoblotted using HRP antibody before visualising using ECL. 
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Figure 4-14- Staining using V5 and ZIP12 antibodies of TnT Quick coupled 
transcription Translation System 
Staining using V5 and ZIP12 antibodies of TnT Quick coupled transcription 
Translation System produced proteins showing a single band at ~60kDa as seen 
using V5 antibody (Panel V5). The negative control shows no labeling of V5 
antibody (Panel V5 -). Labeling with ZIP12-5194 and ZIP12 Abcam showed no 
labeling both with plasmid DNA included and without (Panels ZIP12 5194, ZIP12 
5194 -, ZIP12 ABCAM, ZIP12 ABCAM-). ZIP12 5193 antibody detected a similar 
band at ~60kDa, however negative control for this antibody showed a positive 
signal of the same size. Dilution used in this experiment is 1:16 and 5µl of diluted 
lysate was used. 
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HEK293 cells over-expressing ZIP12-V5 fusion protein were used to overcome the 
lack of posttranslational modifications and folding of ZIP12 protein. Following 
lysis, 10 µg/lane cell lysates were run on SDS gels, blotted onto PVDF membranes 
and probed with the V5 and the ZIP12 antibodies and in some cases with an 
antibody against actin (Santa Cruz BT, UK). As expected actin migrated to 43kDa, 
corresponding to the size of the protein. V5 staining showed a diffuse band at about 
~175kDa, a similar band to that seen in theTnT® Quick Coupled 
Transcription/Translation System, but no presence of a lower molecular weight 
band. This is unlikely to be caused by failure of all proteins to migrate, as clear 
labeling of appropriately migrated actin was observed. It is possible that the reason 
for this single high molecular weight band is protein aggregation of the 
overexpressed ZIP12-V5 protein with other proteins or itself. Therefore, we tried to 
disassemble this complex by sonication (Figure 4.15) or the use of different 
reducing agent and detergents (Figure 4.16) like beta-mercaptoethanol, Nonidet-
P40 and TritonX-(100). However, none of these alleviated the presence of high-
molecular weight protein aggregates (Figure 4.16B). Most importantly, while V5 
antibody was able to detect the protein aggregates, none of the ZIP12 antibodies 
manage to label the protein complexes (Figure 4.16) though our antibodies detected 
the ~130 kDa and the ~80 kDa bands shown in Jurkat cell lysates even in those 
cells that had not been transfected, indicating that these bands are unlikely to be 
ZIP12. 
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Figure 4-15–Sonication fails to remove protein aggregates 
Twenty µg of transfected HEK293 lysate with C-terminal V5 ZIP12 protein was 
loaded on SDS-page gels before being either sonicated (S) or non-sonicated (NS). 
Membrane strips were blotted with V5 antibody, ZIP125193, ZIP12-5194 and 
ZIP12-Abcam with their respective negative controls (untransfected cells). V5 
labeling produced a high molecular weight smear on both S and NS samples, 
ZIP12-5193 showed the presence of two bands similar to figure 4.11 in both 
conditions, although the same labeling was seen in the negative controls. ZIP12-
5194 labeling showed three bands in NS samples, and only one band in S samples. 
Again, the same labeling was seen in the negative controls. ZIP12 Abcam showed 
no staining. 
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Figure 4-16–Aggregation remains after treatment with reducing agent and 
detergents, 
Transfected HEK293 cells with ZIP12-V5 protein produced large aggregates which 
did not resolve on polyacrylamide gels. Panel A shows dilutions of 5, 2,5 and 1µg 
protein run and labeled with V5 (left) and beta-actin (right). Actin staining 
indicated that no abnormalities in protein running or transfer occurred. Dilution of 
10µg samples 1:1 (total 5µg in each lane) with lysis buffers containing (A) 0.5% 
NP40 + 0.5M β-mercaptoethanol, (B) 0.5% NP40+1.0M β-mercaptoethanol, (C), 
1% NP40, (D) 0.5% NP40 + 0.5% Igepal, (E) 0.5% NP40 + 0.5% TX-100. 
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4.7. Localisation of ZIP12 
Methods 
In parallel with experiments on cell lysates, the localization of ZIP12 was examined 
in ZIP12-V5 transfected cells. We used HEK293, CHO and ARPE-19 cells for 
these experiments. HEK293 and CHO cells were transfected as described 
previously, and immunostaining performed first on methanol fixed cells with V5 
antibody (green) and ZIP12-5194 (red) or V5 antibody (green) and ZIP12-Abcam 
(red) (Figure 4.17). 
Results 
Labeling with the V5 antibody resulted in a plasma membrane, perinuclear and 
punctate cytosolic staining in HEK293 and CHO cells (Figure 4.17, B,F,J). 
Labeling with ZIP12-5194 resulted in similar staining to that of V5 (Figure 4.17, 
C,G). The use of ZIP12-5193 antibody did not result in immune-labeling (data not 
shown). The ZIP12-Abcam antibody failed to label HEK293 cells when fixed with 
MeOH (Figure 4.17, K) or 4% Paraformaldehyde (PFA) (data not shown).  
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Figure 4-17–Immunostaining of HEK293 and CHO cells with ZIP12-5194, 
anti-V5 and ZIP12-Abcam antibody. 
HEK293  (Panel A-D, I-L) and CHO (Panel E-H) cells transfected with C-
terminally tagged ZIP12-V5 protein fixed and permeabilised with MeOH and 
stained with ZIP12-5194 (Panel G) as well as commercial ZIP12-Abcam (Panel K) 
labeled with Alexa 594. HEK293 (Panel A-D) and CHO (Panels E-H) cells showed 
strongly perinuclear staining using V5 antibody which colocalised with ZIP12-5194 
and a membrane staining which has little colocalisation with ZIP12-5194. Staining 
with ZIP12-Abcam did not show labeling (Panel K, HEK293 cells). Nuclear 
staining was performed using DAPI (Panels D,H,L). All fixed cells were stained 
using V5 antibody from Invitrogen and imaged using LSM700 confocal 
microscopy at 63 x magnifications. Scale bar: 10µm. Cell labeling on left hand side 
added.  
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Methods 
As ZIP12 appeared to be present on the plasma membrane on MeOH fixed samples, 
further confirmation for their membrane localization was done on 4% PFA fixed 
HEK293 and CHO cells. Cells were plated onto glass cover slips and transfected as 
described earlier. Four percent freshly prepared PFA was used to fix half of the 
cover slips and cells were rinsed before being treated with 0.1% Triton-X100 in 
PBS solution. The second half of the coverslips was treated with PBS only.  
Results 
Permeabilised HEK293 cells showed the previously described cytosolic labeling 
with both ZIP12-5194 (red) and V5 (green) antibodies (Figure 4.18, B,C). 
However, in non-permeabilised cells the labeling was restricted to the plasma 
membrane (Figure 4.18, F,G). Identical immunolabeling was observed on ZIP12-
V5 transfected CHO cells (Figure 4.19 A-H).  
In addition to localisation of the ZIP12 protein to the plasma membrane, the 
intracellular localisation of ZIP12 was examined. Transfected HEK293 cells were 
fixed with MeOH before being immunostained with V5 antibody, then conjugated 
with Alexa 488 and antibodies specific to endoplasmic reticulum (ER), Golgi or 
Lysosomes (Fig 4.20). Anti-Alpha-6-Isomerase antibody was used as an ER 
marker, anti-9.3Golgi antibody for Golgi marker and anti-CathepsinD as lysosomal 
marker (kindly provided by Professors Karl Matter and Claire Futter). Anti-V5 
antibody labeling of fixed HEK293 cells shows perinuclear and plasma membrane 
staining, as observed earlier which showed colocalisation with the ER marker 
(Figure 4.20, A), but no co-localisation was observed with Golgi, (Figure 4.20, D) 
or the lysosome (Figure 4.20, G), although this could possibly be due to poor 
staining of both organelles which was caused by the small size of the cytosol of 
HEK293 cells.  In order to confirm the ER colocalisation seen on HEK293 cells, 
ZIP12-V5 transfected CHO cells were also labelled with V5 and the ER marker 
alpha-6-isomerase antibody. There was a strong co-localisation in the perinuclear 
area (Fig 4.21, A). The densest staining is regularly observed between the dividing 
cells. The densest staining was observed between the cells, although this is not 
specific to the particular area. It needs to be determined whether the localisation to 
the ER is caused by overexpression artefact or whether endogenous ZIP12 is indeed 
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localised in the ER. However, this requires fully characterised ZIP12-specific 
antibody, which we currently do not have. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4-18–ZIP12 protein is present on the plasma membrane of HEK293
cells. 
HEK293 cellswere transfected with C
fixed with 4% PFA before either 
A-D) or not treated (Panels E
ZIP12-5194. Permeabilised cell
cytosolic staining. Non
membrane staining. Colocalisation was both observed in permeabilised and non
permeabilised samples. 
Invitrogen and imaged using LSM700 confocal microscopy 
10µm. 
 
 
-terminally tagged ZIP12
being permeabilised with TX-100 in PBS
-H). All cells were stained with anti
s (Panel A-D) showed perinuclear staining and 
-permeabilised samples (Panel E-F) showed plasma 
All images were stained using anti-V5 antibody from 
at 63 x. S
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Figure 4-19–ZIP12 protein is present on the plasma membrane of CHO cells.
CHO cellswere transfected with C
with 4% PFA before either being permeabilised with TX
or not treated (Panels E
5194. Permeabilised cell
Non-permeabilised samples (Panel 
Colocalisation was both
All images were stained using V5 antibody from Invit
LSM700 confocal microscopy 
 
 
 
 
 
 
-terminally tagged ZIP12-V5 protein
-100 in PBS (Panels A
-H). All cells were stained with V5 antibody and ZIP12
s (Panel A-D) showed intracellular staining in the cytosol. 
E-H) showed plasma membrane staining. 
 observed in permeabilised and non-permeabilised samples. 
rogen and imaged using 
at 63 x. Scale bar: 10µm. 
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-D) 
-
 Figure 4-20–Organelle localization of ZIP12 protein in HEK293 cells
HEK293 cells were 
fixed with MeOH showed
colocalisation with either 
was performed using antibody against ER
for Golgi was performed
done using antibody against CathepsinD, a lysosome
staining was performed using DAPI. 
antibody from Invitrogen and imaged using LSM700 confocal microscopy 
magnification. Scale bar: 
 
 
transfected with C-terminally tagged ZIP12
 partial colocalisation with ER (panel A), 
Golgi (panel D), or lysosomes (panel G). Staining for ER 
-specific Alpha-P 63 Isomerase. Staining 
 using golgi-specific 9.3 Golgi. Staining for lysosomes was 
-specific organelle. 
Images A,B,D,E,G,H were stained using V5 
10µm.  
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Nuclear 
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 Figure 4-21–ER localization of ZIP12 in CHO cells
CHO cells transfected with ZIP12
V5 (Panels A-D) antibody showed partial colocalisation on the perinuclear area. 
The staining is not specific 
interesting observation that the densest staining was 
stained using anti-V5 antibody from Invitrogen and all picture was imaged using 
LSM700 confocal microscopy 
 
 
 
 
 
 
-V5, fixed with MeOH and stain
to the area between the cells, although it is an 
observed there.
at 63 x magnification. Scale bar: 10µm.
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Our ultimate aim is to understand the role ZIP12 plays in RPE cells. Transfection of 
ARPE19 cells with ZIP12-V5 fusion protein would allow the study of zinc transport 
as well as observing the phenotypical changes associated with the presence of ZIP12 
protein on these RPE model cells. The high mRNA expression has been observed in 
vivo (See Chapter 3) and the absence of ZIP12 gene expression in vitro in ARPE19 
cells provides the ideal system to study this. In order to achieve this, the SCL39A12 
gene must be delivered efficiently and ZIP12 protein must be expressed with a good 
efficacy in ARPE19 cells. However, our attempts at transfecting ARPE19 with 
ZIP12-V5 did not result in a high-enough efficiency for functional assays. The 
transfection efficiency in ARPE-19 cells was < 20 cells per coverslip (100 mm 
diameter) but it allowed us to label the cells with the V5 antibody. As expected, 
ZIP12 protein was localised to the perinuclear and intracellular organelle(s) in 
MeOH fixed cells (Figure 4.22, B). Similar labeling was observed with our ZIP12-
5194 antibody (Figure 4.22, C). Labeling of ARPE-19 cells following 4% PFA 
fixation, but without permeabilisation confirmed that ZIP12 is present on the plasma 
membrane in ARPE-19 cells (Figure 4.23, D,E).  
After co-labeling with organelle specific antibodies, a modest co-localisation of 
ZIP12 with ER (Figure 4.24, A), good co-localisation with the Golgi apparatus 
(Figure 4.24, D) but no co-localisation with lysosomes (Figure 4.24, G) was 
apparent. While transfected HEK293 or CHO cells remainedviable, transfected 
ARPE-19 cells show nuclear blebbings and abnormally shaped nuclei suggesting that 
the present transfection protocol of ARPE19 will need to be refined. 
  
  
 
Figure 4-22–Transfection of ZIP12 in ARPE19 cells
ARPE19 transfected with C
MeOH showed perfect colocalisation between ZIP12
antibody. Nuclear staining performed using DAPI showed cellular debris as well as 
poor morphology of the nucleus indicating cytotoxicity. 
preparations stained using 
LSM700 confocal microscopy 
 
 
 
 
 
-terminally tagged ZIP12-V5 protein
-5194 antibody and V5 
All images were
anti-V5 antibody from Invitrogen and imaged using 
at 63 x magnification. Scale bar: 10µm.
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Figure 4-23–ZIP12 is localized on the plasma membrane of ARPE19 cells
ARPE19 transfected with C
PFA before either not 
PBS. Permeabilised cell (Panel A
with punctate staining. Non
membrane staining. Nuclear staining performed using DAPI showed cellular debris 
as well as poor morphology of the nucleus indicating cytotoxicity. 
stained using V5 antibody from Invi
microscopy at 63 x magnifications. S
 
 
 
 
 
 
-terminally tagged ZIP12-V5 protein and fixed with 4% 
being permeabilised or being permeabilised with TX
-C) showed intracellular staining in the cytosol 
-permeabilised samples (Panel D-F) showed plasma 
trogen and imaged using LSM700 confocal 
cale bar: 10µm. 
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Figure 4-24–Organelle localization of ZIP12 protein in ARPE19 cells 
ARPE19 transfected with C-terminally tagged ZIP12-V5 protein and fixed with 
MeOH showed colocalisation with ER (panel A), very partial colocalisation with 
golgi (panel D), and no colocalisation with lysosomes (panel G). Staining for ER 
was done using antibody against ER-specific Alpha-P 63 Isomerase. Staining for 
golgi was done using golgi-specific 9.3 Golgi. Staining for lysosomes was done 
using antibody against CathepsinD, a lysosome-specific organelle. Nuclear staining 
(in blue) was performed using DAPI. All images were stained using V5 antibody 
from Invitrogen and imaged using LSM700 confocal microscopy at 63 x 
magnification. Scale bar: 10µm. 
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4.8. Function of ZIP12 
To date, no studies have shown the function of ZIP12 in vivo or in vitro although its 
localization to plasma membrane and the functional annotation based on the LIV-1 
family where ZIP12 is assigned suggests that this protein is a potential zinc 
importer.  Based on this, we expected that zinc content in transfected cells might be 
higher than without transfection. Therefore, cells were loaded with 5µM ZinPyr1, a 
zinc selective, high affinity fluorescent sensor, (Walkup et al., 2000) for 10 minutes 
under standard culturing conditions as described in the Materials and Methods 
section. After extensive washing with culture media the cells were imaged live 
using epifluorescence (excitation 488, emission 525 nm, Olympus) at 20x 
magnification. Fluorescence intensities of at least 10 images from triplicate 
experiments were analysed using ImageJ software (http://rsb.info.nih.gov/ij/).  The 
fluorescence intensities of transfected cells were significantly higher than in non-
transfected cells (5.65 ± 1.99 vs 14.30 ± 1.35, p<0.01, Student t-test) (Figure 4.25). 
Pretreatment with 10µM TPEN, a zinc selective cell permeable chelator for 10 
minutes prior the application of ZinPyr1 resulted in a definite decrease of basal 
fluorescence (2.0+0.1) and complete attenuation of the fluorescence in transfected 
cells (1.9+0.1), suggesting that in cells expressing ZIP12, zinc influx is increased.  
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Figure 4-25–Function of ZIP12 
Transfected HEK293 cells were probed with ZinPyr-1 which recognises 
bioavailable zinc. Under basal state, the transfected cells have higher signals of zinc 
within the cells, indicative of zinc influx (Panel C) occurring in the cells compared 
to basal state (Panel A). Treatment of 10µM TPEN for 10 minutes removed 
majority of the zinc signal in both sham and transfected group (Panels B,D). Data 
shown came from average ± standard deviation values of 12 pictures repeated three 
times. Student’s T-test was performed between sham group and ZIP12-V5 
transfected group (p<0.0001).  
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4.9. Discussion 
ZIP12 is probably the least studied zinc transporter to date. It has been linked to 
schizophrenia (Bly, 2006), Alzheimer’s disease (Grupe et al., 2006) and cancer 
(Sotiriou et al., 2006).  
 
Previous studies have shown that the SLC39A12 gene is the most highly expressed 
zinc transporter gene in the retina (Nishimura and Naito, 2008). In addition, ZIP12 
was found to be one of the most highly RPE specific genes amongst the 114 genes 
which have at least 2.5 fold higher expression in the RPE than the choroid or 
photoreceptors, placing the gene on par with more widely recognized RPE-specific 
genes such aslecithin retinol acyltransferase (LRAT) or retinaldehyde-binding 
protein 1 (RLBP1)(Booij et al., 2010b). The observation that a zinc transporter has 
the same high RPE expression level may indicate its potential importance in the RPE 
although we would still have to confirm this result through better RNA isolation 
process for the cadaveric RPE cells.  
The bioinformatics predictions at the beginning of this chapter (Section 4.1) 
suggested that ZIP12 is an 8 transmembrane domain protein whose likely 
localisation is the plasma membrane. Its large N-terminal domain (52% of the 
protein) and its C-terminal short tail were predicted to be in the extracellular space. 
In order to confirm these we generated a C-terminal V5-tagged plasmid for 
expressing ZIP12 in cells that do not normally express it. In addition, we raised 
antibodies against an N-terminal extracellular domain next to transmembrane 
domain I. As expected, the V5 specific antibody labeled the plasma membrane of 
transfected, non-permeabilised cells, suggesting that not only our prediction that 
ZIP12 is, at least partly, a plasma membrane protein was correct but also confirmed 
that the C-terminal tail is pointing to the extracellular space. Labeling of 
permeabilised cells with the V5 antibody showed that ZIP12 protein might also be 
present on the membranes of ER and the Golgi. However, currently we cannot rule 
out that the ER localisation is an artefact caused by protein overexpression. The 
antibody we raised against the N-terminal domain of ZIP12 (5193 and 5194) 
provided mixed results. Experiments on cell lysates could not demonstrate that our 
polyclonal antibodies which were raised in rabbits can detect ZIP12 reliably 
although immunolabeling of transfected cells showed a very good correlation 
between ZIP12-5194 and V5 antibody labeling. For this reason further studies are 
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planned to purify and better characterize our ZIP12 antibodies for immunolabeling. 
Nevertheless, we could confirm that the C-terminus, where the V5 tag is positioned, 
is indeed in the extracellular space and if the protein is confirmed to be an 8 
transmembrane domain structure then the N-terminal large domain is also in the 
extracellular space. The structure of LIV-1 subfamily transporters (See Figure 4.2) 
is highly conserved and usually have three features which define their homology: 
the histidine-rich loop between transmembrane domains III and IV, a histidine rich 
metalloproteinase-like sequence on transmebrane domain V (Loomans et al., 1998) 
and the so-called CPALLY domain just before transmembrane domain I. The 
histidine rich loop between transmembrane III and IV is not strictly limited to the 
LIV-1 subfamily, but is also present in other SLC39 family members (Guerinot, 
2000). Following our results that show ZIP12 on the plasma membrane we believe 
that this loop is located in the cytosol and, together with the metalloprotease-like 
sequence in transmembrane V (Taylor and Nicholson, 2003) facilitates zinc import 
into cells. The exact function of the CPALLY domain is still not known. It might be 
involved in the localisation of ZIP12 to the plasma membrane since ZIP7 and 
ZIP13, both of which lack this motif, are localised to intracellular membranes but 
not the plasma membrane (Taylor et al., 2007, Fukada et al., 2008). It is possible to 
speculate that cleavage of the large N-terminal domain might cause the migration of 
ZIP12 to intracellular membranes although future experiments using truncated 
ZIP12 expression will be required to test this idea. The V5 tagged ZIP12 can 
certainly be detected on intracellular membranes, but whether this is the result of 
regulated protein processing cannot be determined from these experiments. The 
localisation of ZIP12 protein to the ER can certainly be the result of the 
overexpression of the protein in our experiments.  
Following expression of V5 tagged ZIP12 protein in an artificial translational 
system (TnT Quick Coupled Translation System) and in cells we found that ZIP12 
may form aggregates with either itself or some other proteins. This can be the 
caused by overexpression but may also indicate that ZIP12 forms homo or hetero 
dimers with other proteins. Proteomic characterisation of these large aggregates 
(Figure 4.16) is being planned together with co-immunoprecipitation assays using 
anti-V5 agarose affinity gels (Sigma-Aldrich A7345) to identify ZIP12 interacting 
proteins.Interestingly, the protein derived from the Quick Coupled Translation 
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System migrated to ~60 kDa while ZIP12 protein expressed in HEK293 cells has 
an apparent molecular weight of ~80 kDa. This suggests that appropriate folding 
and/or posttranslational modification is important for the ZIP12 protein. As there 
are many potential posttranslational modification sites on ZIP12 (see Section 4.2 
earlier) further experiments will need to clarify which potential sites may play a 
role in the function of ZIP12. One of the candidates for functional modification is at 
S36, a potential glycogen synthase kinase 3 phosphorylation site, that had been 
associated with schizophrenia through a S36G mutation (Bly, 2006), suggesting 
that phosphorylation at this site might be important for ZIP12 function.  
The histidine-rich regions between transmembrane III and IV, which is involved in 
transporting zinc into the cells, appear to be highly conserved in LIV-1 family 
transporters (Taylor and Nicholson, 2003, Taylor et al., 2007). Therefore, the 
plasma membrane location and the orientations of the transmembrane domains 
suggested that ZIP12 will transport zinc into cells.  To test this hypothesis we over 
expressed ZIP12-V5 in HEK293 cells and measured basal zinc accumulation by the 
high affinity zinc selective fluorescence probe, ZinPyr1 (Walkup et al., 2000). The 
specificity of an increase in fluorescence intensity to zinc was assessed by treatment 
with TPEN, a cell permeable zinc selective chelator (Figure 4.25). The source for 
zinc influx into the HEK293 cell is the culturing medium. DMEM complete 
medium contains ~1.5 uM added zinc (manufacturer’s data sheet) that is further 
enhanced by the zinc contained in fetal calf serum (Bozym et al., 2010). While this 
total zinc level translates to nanomolar levels of bioavailable zinc in the medium 
(Bozym et al., 2010) this level is far higher than the picomolar intracellular free 
zinc (Bozym et al., 2006) reported in cells. Nanomolar levels of extracellular zinc 
had been shown to elevate intracellular levels after transfection of cells with zinc 
transporters (Gaither and Eide, 2001, Leung et al., 2008a, Liuzzi et al., 2005), and 
we expected this to be the same for ZIP12 transfected HEK293 cells. While 
HEK293 cells do not express ZIP12 in their native state, they express several other 
zinc transporters on their plasma membrane. Therefore it is not surprising that there 
is a basal level of TPEN chelatable zinc in these cells (Figure 4.25). However, 
when cells were transfected with ZIP12 the intracellular level of ZinPyr1 
fluorescence increased significantly. As this increase could be completely abolished 
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by pretreatment with TPEN, we concluded that this fluorescence signal represented 
zinc influx.  
In summary, we were able to provide evidence that ZIP12 is indeed a zinc importer 
that is, at least partly, located on the plasma membrane as an 8 transmembrane 
domain protein. Its importance for RPE however, could not be investigated due to 
difficulties with transfection of ARE19 cells and problems with commercial 
antibodies and antibodies raised ourselves. Further experiments are being planned 
to clarify the role ZIP12 plays in cells in general and specifically in RPE. 
4.10. Future Directions 
ARPE19 cells were transfected with the ZIP12-V5 plasmid to assess where the 
protein is expressed and how this expression might affect the phenotype of the 
cells. While we were able to transfect some cells with low efficiency, a transfection 
method with better efficacy and less toxicity to ARPE19 cells will have to be 
implemented. Recently a non-viral transfection method using a combination of 
cationic lipid, plasmid DNA and magnetic nanoparticles was reported for ARPE-19 
cells (Fujii et al., 2010) and we are in the process of implementing this in our 
laboratory. Furthermore, a study recently reported the use of the Nucleofection 
(Amaxa AG, Koln Germany) method, which resulted in 78% transfection of 
ARPE19 cells in contrast to 5% observed with LipofectamineLTX, which we used 
in our studies.  Creating a stably transfected cell line would be highly beneficial in 
order to understand the function of ZIP12 protein; however ARPE19 is an unlikely 
candidate for this. The Nucleofection method is non-viral and therefore does not 
create constitutively expressed gene, however, expression was observed at least 7 
days post transfection, which might be sufficient for functional assays like 
measurement of trans epithelial resistance, gene expression and monitoring 
pigmentation. The transfected ARPE19 cells would be useful in measuring the zinc 
influx from different extracellular zinc compartments on polarised cells cultured on 
transwell membranes.  
 
We will also attempt to disaggregate the high molecular weight aggregates 
correlated with overexpression of ZIP12 in cells through optimisation of buffers 
and reagents. Furthermore, proteomics characterisation of the large aggregates 
shown in Figure 4.16 would identify the interacting proteins involved in the 
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formation of aggregates. Optimisation and characterisation of the antibodies which 
were generated and purchased should help us to uncover the localisation and 
possible involvement of ZIP12 with cellular processes and disease states. For this 
we will try to further optimize our immunolabeling and purify our ZIP12 
antibodies. In addition, efforts will be made to isolate RPE RNA free from 
contamination from neighboring tissue compartments. Potential method for this 
include very early passage of human RPE cultures.  
 
There are over 100 potential polymorphisms of the SLC39A12 gene 
(www.ensembl.org). Whether any of these are associated with AMD is now under 
scrutiny in collaboration with Professor John Yates and Dr Valentina Cipriani at the 
UCL Insitute of Ophthalmology using Genome Wide Association Studies data on 
AMD patients. Our preliminary analysis indicated that some polymorphisms are 
associated with AMD but this requires further statistical analysis to confirm the 
results. Further analysis of existing microarray data using data mining tools have 
identified potential protein networks ZIP12 protein is involved in. Together with 
the planned proteomics studies, this will highlight the molecular interactions 
between ZIP12 and other proteins.  
 
It will be important to measure zinc influx by modifying extracellular zinc levels 
and controlled expression of ZIP12. Initial experiments suggested that addition of 
100µM ZnSO4 which elevated the extracellular zinc levels in the media to >100 nM 
is toxic to the transfected cells we tried. At these concentrations, we observed 
reduced cellular density and the appearance of cellular debris in the culturing 
medium in HEK293 cells that were transfected with ZIP12-V5 (data not shown). It 
is expected that most cells are unable to cope with hundreds of nanomolar 
bioavailable zinc (Bozym et al., 2006, Bozym et al., 2010)  so these preliminary 
data are probably not surprising. Interestingly, as we will show in the next two 
chapters, similarly high extracellular levels of zinc are well tolerated by ARPE19 
cells or bEND5 cells used as a model for fenestrae formation.  
Apart from being bound to proteins like metallothioneins, zinc is likely to be stored 
in intracellular stores.  It is believed that metallothionein will bind zinc almost 
immediately after it enters the cell and shuffle zinc into intracellular stores a 
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process termed muffling (Colvin et al., 2010). The muffling process is transient, 
and therefore zinc can be released should there be a need for zinc within the cells. 
Various zinc-binding proteins or cellular organelles such as lysosomes, 
mitochondria, endoplasmic reticulum or Golgi may serve as intracellular stores 
(Colvin et al., 2010). It will be important to examine in detail where and how zinc 
regulation occurs in these cells and how transfection with ZIP12 will affect these 
shuttling mechanisms.  
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5. Potential Role of Extracellular Zinc on RPE Cell 
Differentiation In Vitro: A Preliminary Study 
 
The experimental part of this study was conducted under my supervision by Ms. 
Yemsrach Tadesse as a part of her MSc. I was responsible for experimental design; 
and data analysis was performed jointly. 
In vitro studies of cultured RPE cells have generated much valuable 
information. However, the culture media used to grow cells often contains fetal 
calf serum (FCS), which contains high-affinity metal binding proteins such as 
albumin (Maret and Li, 2009), which in turn may render the cells zinc 
deficient. Since RPE cells are located adjacent to a large and potentially 
mobile pool of zinc, we hypothesise that the addition of zinc to the medium of 
cultured RPE cells will alter RPE behavior including transepithelial resistance 
(TER), ZO-1 protein staining and the expression of RPE-associated genes. 
Majority of the data presented here came are intended to be observational and 
most came from a single experiment and therefore drawing any major 
conclusion from these data would not be warranted before sufficient 
replication of data. 
5.1. Introduction 
The RPE is a monolayer of highly uniform cells located between the photoreceptor 
outer segments of the retina and Bruch’s membrane. General characteristics of the 
RPE cells have previously been described in section 1.3.1. Cultured RPE cells have 
served as a valuable model for RPE cell behaviour and there are various 
immortalised cell lines commonly used in ocular research in addition to primary 
RPE cultures. Some of the more commonly used cell lines include hARPE19 (Dunn 
et al., 1996), hTERT-RPE1 (Bodnar et al., 1998), hD407 (Davis et al., 1995), mBR-
RPE07 (Chen et al., 2008) and rRPE-J (Nabi et al., 1993). These cells are either 
spontaneously arising (hARPE19, hD407, mBR-RPE07), or transformed (hTERT-
RPE1, rRPE-J) cell lines. Since its introduction in 1996 by Dunn et al (Dunn et al., 
1996), ARPE19 has been the most widely used in ophthalmic research as an in vitro 
model of the RPE.  
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Dunn et al, demonstrated that ARPE19 cells form polarised epithelial monolayers 
and express the RPE-specific genes CRALBP, and RPE65. Transepithelial 
resistance of the ARPE19 cells reached about 50-100Ωcm
2
 after 4 weeks in culture 
(Dunn et al., 1996, Dunn et al., 1998). However, despite the extensive use of 
ARPE19 cells, there are discrepancies between these cells and native RPE. RPE65 
protein was not found in cultured ARPE19 cells despite its mRNA being present 
(Vugler et al., 2008), although pigmentation and expression of RPE65 has can be 
induced (Ahmado et al., 2011). While the original study (Dunn et al., 1996) 
reported pigmentation in ARPE19 cells after 4 weeks in culture, various studies 
struggled to demonstrate pigmentation even after prolonged periods of culture 
(Amemiya et al., 2004, Biesemeier et al., 2010, Sonoda et al., 2009). Furthermore, 
studies comparing primary cultures of human RPE and ARPE19 cells have 
demonstrated that TER values are consistently higher in primary cultures of human 
RPE cells >500 Ω cm
2 
vs 50-100 ohms cm
2 
(Sonoda et al., 2009, Geisen et al., 
2006). 
Several groups have sought to enhance the differentiation of ARPE19 cells by 
placing them in an environment that better mimics the in vivo condition. The use of 
porcine lens capsule as a way to create extracellular matrix akin to Bruch’s 
membrane improved the distribution of tight junction proteins ZO-1 and occludin, 
and increased the TER values and the phagocytic capability of ARPE19 cells 
(Turowski et al., 2004). Co-cultures of ARPE19 cells with choroidal endothelial 
cells (Geisen et al., 2006), retinal neurons (German et al., 2008) and glial cells 
(Constable and Lawrenson, 2009) have also been shown to improve ARPE19 cells 
differentiation.  
ARPE19 cells are usually cultured in the presence of 10% fetal calf serum (FCS) as 
first described by Dunn et al (1986). Serum contains many different proteins, 
including albumin, transferring, antibodies and complement factors (Adkins et al., 
2002). Serum albumin is known to bind zinc with a kD of ~45nM (Maret and Li, 
2009) as do several other FCS proteins (Harris and Stenback, 1988). Therefore, we 
speculated that the addition of 10% FCS to the culture media might create a zinc 
deficient environment which may affect the phenotype of the ARPE19 cells.  
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5.2. Aims and Hypothesis 
Hypothesis: 
In this chapter, we hypothesise that elevation of extracellular zinc in the growth 
media will affect the phenotype of ARPE19 cells.  
Methods: 
To test this hypothesis, ARPE19 cells were cultured in the presence of ZnSO4 
enriched growth media and the phenotypic changes induced by the inclusion of zinc 
were assessed by measuring TER, ZO-1 immunoreactivity and RPE specific gene 
expression. 
5.3. Calculating the Zinc Concentration in DMEM/F12 
Methods 
As discussed, zinc binds to proteins in tissue culture media (Maret and Li, 2009, 
Harris and Stenback, 1988). ZnAF2 (Neurobiotex, Galveston, TX, USA), a zinc-
selective fluorescent probe was used to measure the zinc buffering capacity of the 
DMEM/F12 with 10% FCS (complete media) added. A standard curve was 
generated by dissolving increasing concentrations (1-1000 nM) of ZnSO4 in 
deionised water before 5 µM ZnAF2 was added. Fluorescence intensities were 
measured in a specifically designed fluorometer (Neurobiotex, Galveston, TX, 
USA) (Excitation: 460-490nm, emission: 515-525nm). Then, 0, 50, 100, 250 and 
500µM of ZnSO4 were added to the complete media and fluorescence changes used 
to calculate free zinc concentration using the standard curve. Background 
autofluorescence was measured before the addition of ZnAF2, a high affinity 
Zn
2+
probe (Kd 2.7 nM) and subtracted from test readings.  
Results 
The resulting bioavailable zinc concentrations in the growth media were 
approximately ~10 nM, 100nM, 255nM, 755nM and 1550nM respectively (Figure 
5.1). Therefore, in subsequent experiments ARPE19 cells were cultured in the 
presence of 0, 50, 100, 150 and 175µM added ZnSO4. At higher concentrations 
altered morphology and cellular detachment was evident (data not shown), 
indicating toxicity.  
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Figure 5-1– Zinc measurement using ZnAF2 in DMEM/F12 growth medium 
Zinc measurements were performed in 1µM ZnAF2 diluted in solution containing 
ZnSO4 in DMEM/F12 phenol-red free media supplemented with 10%FCS.  
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5.4. Effect of Extracellular Zinc on TER of Cultured ARPE19 Cells 
Methods: 
Measurements of transepithelial resistance (TER) were conducted on ECIS real time 
cell growth monitoring system (Applied Biophysics, Troy, NY, USA) placed into an 
incubator over a six day period. Care was exercised to not remove the electrode array 
chips from the TER measuring device in order to prevent inconsistency and artefacts 
in TER impedance measurement. During this period, growth media was not replaced 
and enough media was placed on the cells to ensure cellular viability was not 
compromised. The data collected were normalised to the TER values measured at 
time 0 (i.e. time when the electrode array was placed in impedance measurement 
device) and data measured the end of the 6 days period. The results (Figure 5.2) are 
the averages of at least 2 independent measurements.  
Results: 
Over the 6 day period, adding increased concentrations of zinc delayed the 
development of TER (Figure 5-2). Without zinc,TER reached a half maximal value 
by 68 hours in culture then a plateau after 96 hours. In the presence of zinc the half 
maximal values were reached after 74 hours in the presence of 50µM, 90 hours in the 
presence of 100µM, 120 hours with 150µM and 130 hours in the presence of 175µM 
ZnSO4. Despite the initial delays, TER reached a similar maximum as the controls 
within 6 days.   
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Figure 5-2- TER measurement in ARPE19 
TER measurement was done on 8-electrode array chips (Wolf Labs, UK) over 6 
days without changing the media. The addition of zinc into the growth media 
seemed to delay the attachment and growth phase, resulting in lowered 
transepithelial resistance, although the TER value reached plateau after 6 days in all 
of the samples. The experiment was repeated 3 times and results averaged.Data are 
normalized against TER for control culture at 6 days.  
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5.5. Effect of Extracellular Zinc on ZO-1 Distribution in ARPE19 Cells 
Methods: 
The TER measurements indicated that the development of tight junctions might be 
affected by extracellular zinc. Therefore, immunocytochemistry using an antibody 
against tight junction protein was performed on cultured ARPE19 cells receiving 
the same treatment as section 5.4. There are several tight junction proteins 
including ZO-1, claudin and occludin (Balda and Matter, 2008). In this study, we 
have chosen to use an antibody against ZO-1, a widely used marker for tight 
junctions (Sonoda et al., 2009).ARPE19 cells were fixed with 4% PFA after 1 and 3 
weeks in culture and labeled with ZO-1 antibody (BD Biosciences, UK) and 
fluorescent-labelled with FITC secondary antibody.  
Results: 
After 1 week of culture, the cells had reached confluency independent of zinc 
concentration, as indicated by cobblestone-like appearance of the cells (Figure 5.3). 
A continuous ZO-1 band of immunoreactivity can be seen in control samples, 
which contain no added zinc. However, in the presence of increasing concentrations 
of zinc the ZO-1 staining became more and more discontinuous after 1 week 
treatment (Figure 5.3). At 3 weeks in culture the ZO-1 stain had a continuous 
appearance in the controls, but in the presence of added zinc at all concentrations 
the ZO-1 labeling was discontinuous (Figure 5.3). 
 Figure 5-3–Immunostaining for ZO1 on ARPE19 cells
Immunostaining for 
week after culturing (Panel A) which p
in DMEM/F12. The addition of zinc at 50µM (Panel C) did not show any 
difference compared to non
(Panel D), discontinuous ZO
concentration of zinc for 1 week (Panel E, G) and 3 weeks (Panel F, H).
Immunostaining was conducted using ZO
dilution and fluorescent stained with FITC (BD Biosciences) at 1:300. Images were 
taken using epifluorescence microscope BX51 (Olympus) at 63x magnification. 
 
ZO1 on ARPE19 shows clear formation of tight
ersists after 3 weeks of culturing (Panel B) 
-zinc treated cells in Week 1. Although after 3 weeks 
-1 staining was observed in cells g
-1 antibody (BD Biosciences) at 1:400 
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5.6. Cell Proliferation Assay using alamarBlue 
Methods: 
As the TER measurements and ZO-1 staining was done in sub-confluent cells to 
observe effect of zinc immediately after seeding, a cell proliferation assay was 
performed to confirm that immunostaining results are not caused by effect of zinc 
on cellular proliferation. AlamarBlue solution was purchased from ABDSerotec 
(Kidlington, UK). ARPE19 cells were seeded at 5000 cells per well on a 96-well 
plate with 200µl growth media to match the experimental conditions in the previous 
sections. After incubation for 1-6 days, 10% of alamarBlue solution was added and 
left to incubate for 2 hours before its absorbance measured at 600nm and 450nm. 
Calculations for the absorbance were made according to the equation provided by 
the manufacturing company and presented as percentage reduction of alamarBlue. 
As controls, cells without zinc treatment was used and as blanks, growth media 
without zinc added was used. It was pre-determined that the addition of zinc does 
not affect AlamarBlue absorbance.  
Results:  
After 1-3 days (Figure 5.4), percentage reduction of alamarBlue is reduced as the 
concentration of zinc added increased. Cell viability was very low after addition of 
150µM zinc on day 1, although the level slowly increased as the growth time 
increase. However, towards the end of 6 days, the reduction levels of alamarBlue 
reached approximately the same level with exception of ARPE19 cells grown in the 
presence of 150µM ZnSO4 which shows reduction in cell viability after 6 days. 
Treatment with 200 and 250µM of ZnSO4 resulted total loss of cellular viability 
(data not shown). The result suggests that zinc delays cellular proliferation, which 
may possibly affect the ZO-1 staining pattern seen.  
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Figure 5-4 – Percentage reduction of alamarBlue in ARPE19 cells 
Percentage reduction of alamarBlue in ARPE19 cells cultured in DMEM/F12 
supplemented with increasing concentration of ZnSO4 (0-150µM). In the first 3 
days there is a lower reduction of alamarBlue with increasing zinc concentration, 
after 3 days, the changes become less pronounced, eventually level of cellular 
viability reaches the same level after 6 days with the exception of cells with 150µM 
added zinc which had less alamarBlue reduced.  
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5.7. Zinc Induced Changes in ARPE19 Gene Expression 
Methods: 
The effect of extracellular zinc addition to DMEM/F12 complete media on gene 
expression of RPE marker genes was assessed. Quantitative RT-PCR was carried 
out to monitor changes in RPE65, RLBP1, SILV, BEST1 and TJP1 expression. 
RPE65 is a protein involved in the visual cycle where it aids the conversion of all-
trans-retinol to 11-cis-retinol (Strauss, 2005). RLBP1 is a gene encoding for a 
retinaldehyde binding protein 1, which binds 11-cis-retinal in the visual cycle. 
SILV encodes the protein PMEL17, which is expressed in the RPE and is present in 
melanosome precursors. BEST1 encodes for bestrophin1 protein, which forms 
basolateral, calcium activated chloride ion channels (Kunzelmann et al., 2007). The 
TJP1 gene is not RPE-specific but codes for a tight junction protein and is a marker 
for differentiated RPE cells. 
ARPE19 cells were plated at a density of 12000 cells/cm
2
. RNA samples were 
isolated weekly for 6 weeks using the RNEasy Kit (Qiagen, Crawley, UK), assayed 
for RNA quality and stored at -80C until being analysed by Q-RT-PCR. The culture 
medium was prepared as explained above by adding 50µM, 100µM and150µM 
ZnSO4. Similar to the methods used in Chapter 3, gene expression changes were 
evaluated by the comparative delta CT method (Schmittgen and Livak, 2008). 
Expression was compared to 3 housekeeping genes: GAPDH, YWHAZ and UBC 
and fold expression was calculated by expression= 2^-∆∆Ct. It is important to 
highlight here that this experiment provided only a single point for every 
measurement; therefore statistical evaluation be carried out.  
Results: 
It appears that addition of zinc has a marked, concentration dependent effect on 
RPE65 gene expression at week 1 and 2 (Figures 5.5 and 5.6).  RPE65 gene 
expression (red) was stimulated by up to one order of magnitude by 150 uM zinc. 
At week 2, BEST1 expression was up-regulated by almost one order of magnitude 
and at week 6, TJP1 expression was up-regulated by 1.5 orders of magnitude, 
although this was not apparent at week 3, 4, and 5 (Figure 5.5, 5.6). While there 
appears to be a down-regulation of some of the other genes at week one and two 
(Figure 5.6), the decreases were small and possibly not of significance.   
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Figure 5-5- QPCR data showing relative expression of RPE65, TJP1, SILV, 
BEST and CRLBP1 in ARPE19 cells 
QPCR data showing relative expression of RPE65, TJP1, SILV, BEST and 
CRLBP1 in ARPE19 cells cultured over the period of 6 weeks after addition of 100 
and 150µM ZnSO4 in the growth media. The results were normalised against 
values obtained for untreated ARPE19 cells (relative expression = 1). After 1 week 
of culture, only expression of RPE65 was 7.5x higher compared to untreated cells, a 
trend which continues in week 2. However, results were markedly more variable at 
weeks 3-6. The experiment was repeated once. Red: RPE65, Blue: BEST1, TJP1: 
Green, RLBP1: Black, SILV: Black. 
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Figure 5-6 – Logarithmic relative expression of RPE65, TJP1, SILV, BEST 
and CRLBP1 in ARPE19 cells 
Logarithmic relative expression of RPE65, TJP1, SILV, BEST and CRLBP1 in 
ARPE19 cells cultured over the period of 6 weeks after addition of 100 and 150µM 
ZnSO4 in the growth media. The results were normalised against values obtained 
for untreated ARPE19 cells (relative expression = 1). After 1 week of culture, only 
expression of RPE65 was 7.5x higher compared to untreated cells, a trend which 
continues in week 2. However, results were markedly more variable at weeks 3-6. 
The experiment was repeated once. Red: RPE65, Blue: BEST1, TJP1: Green, 
RLBP1: Black, SILV: Black. 
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5.8. Discussion and Future Perspectives 
We hypothesized that culturing ARPE19 cells in a culture medium that contains 
10% FCS potentially places the cells into an environment that is deficient in 
biologically available zinc. As zinc has been shown to be important for the 
appropriate function of cultured RPE cells (Tate et al., 1995), we set out to explore 
whether or not elevated extracellular zinc altered the morphology or cause gene 
expression changes to these cells. In order to show this, we assessed the effect of 
zinc on   TER, distribution of ZO-1 immunoreactivity and the expression of RPE65, 
RLBP1, TJP1, BEST1 and SILV genes in pilot experiments. 
The RPE depends on a fine regulation of material diffusion through expression of 
cellular junctions. The expression of tight junctions results in the formation of high 
transepithelial resistance. These are characterized by formation of specific tight 
junction proteins ZO-1, occludin and claudins (Geisen, et al., 2006). The 
localization of tight junctions on the apical-basolateral membrane of RPE cells 
ensures control of material diffusion. ZO-1 protein is crucial for the formation of 
tight junction, where it binds to other proteins such as those belonging to the 
occludin family and forms a support structure for tight junction (Sonoda, et al., 
2009). The function of ZO-1 protein is not only limited to its structural capacity, 
ZO-1 has been shown to maintain cellular signaling by controlling ZO-1 associated 
nucleic acid binding protein (ZONAB), a transcription factor which controls 
proliferation of epithelial cells through interaction with cell division kinase 4 
(CDK4) (Balda, Garrett, and Matter, 2003). Based on the importance of ZO-1 in 
epithelial functions, we have used ZO-1 as a marker for tight junction formation for 
our studies.  
Our results show that after 1 week of culture, all ARPE19 cells cultured in the 
presence of zinc had reached confluency. However, with increasing zinc 
concentration, the staining of ZO-1 was more discontinuous. The same results were 
repeated after 3 weeks of culture but the staining of ZO-1 was becoming 
increasingly discontinuous. This indicated that addition of zinc at 50-150µM 
concentration is associated with lowered permeability of RPE. The failure for tight 
junctions to mature in those cultured in the presence of zinc may pose several 
problems for the RPE to function appropriately.  
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The failure of tight junctions to form properly can result in the loss of polarity to 
RPE cells. The loss of polarity in the RPE can affect the paracellular signaling 
between the RPE/choroid interface. As discussed in section 1.4.2, RPE barrier 
function requires optimal balance between secretion of pro-angiogenic factor 
VEGF as well as anti-angiogenic factor PEDF. Non-polarized cells show markedly 
lower expression and secretion of VEGF and PEDF (Sonoda, et al., 2010). The 
secretion of VEGF is required to mediate the fenestration in the adjacent 
choriocapillaris (St. Geniez, et al., 2009). The lowered of VEGF secretion will 
reduce material diffusion presumably mediated by the fenestrated choriocapillaris. 
Furthermore, there is a synergy between the formation of tight junction protein and 
localization of Na, K-ATPase channel, which is responsible to generate ATP for 
RPE metabolism. In human RPE primary cultures, the reduced function of Na, K-
ATPase channel caused by potassium deficiency resulted in lowered transepithelial 
resistance (Rajasekaran, et al., 2003).  
The increase in cellular permeability has been related to increase in the metastatic 
potential in cancer (Martin and Jiang 2008). The increase in permeability has been 
attributed to reduced expression levels of tight junction proteins (Liu, et al., 2008) 
In RPE cells, it is possible that the loss of polarity and increased permeability may 
lead to migration of RPE cells. It is known that disruption of tight junction can 
result in RPE cells adopting the characteristic epithelial-mesenchymal transition 
commonly encountered in cancer. Intra retinal RPE migration cases have been 
reported in AMD patients (Ho, et al., 2010).  
It is still uncertain why zinc seems to reduce the staining of ZO-1 protein after 3 
weeks in culture. The preliminary data presented in this chapter does not seem to 
support the use of zinc in culturing ARPE19 cells as zinc addition correlates with 
poor tight junction maturation and thus affecting RPE permeability. Furthermore, 
our data with alamarBlue assay indicated that RPE proliferation seems to be 
delayed by the presence of zinc in the first 6 days of culture. If the results presented 
here are indicative of what happened in vivo, keeping in mind the highly 
preliminary nature of the data, it may possibly mean that further research need to be 
carried out in order to determine how oral zinc supplementation (Newsome, 1988) 
affects the RPE/choroid interface in early AMD subjects where disruptions to the 
RPE are still minimal. Zinc supplementations are thought to improve immune 
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function that is deficient in aging subjects, yet minimal studies have been done on 
the effect of zinc on cellular junctions of RPE cells. The study presented here 
would greatly benefit from having further optimization of the amount of zinc added 
to ARPE19 cells. It is possible that the ~200-500nM free zinc available in cultured 
ARPE19 with 125µM ZnSO4 added is already providing too much stress for the 
cultured cells. Furthermore, this study was done on non-differentiated ARPE19 
cells and thus it would be feasible to repeat the study using differentiated ARPE19 
cells, optimized zinc concentration, and correlating the study with measurements of 
transepithelial resistance of ARPE19 cells.  
Hu and Bok have reported that reducing concentration of FCS used in culturing 
media to 1% is essential for human fetal RPE cell culture differentiation. The 
culturing condition was maintained for one month in which the cells finally reached 
maturation (Hu and Bok, 2001). As previously discussed, the presence of strong 
zinc binding proteins in serum can potentially create a zinc deficient environment 
for cellular growth. The DMEM/F12 media contained 1.5µM of ZnSO4, meanwhile 
the protocol used by Hu and Bok contained 5µM of ZnSO4. This suggests that the 
reduction of FCS may increase free zinc concentration due to lowered buffering 
capacity which pushes cells towards in vivo phenotype. However, as serum 
contains a lot of of other components, this is fairly speculative. Therefore, in order 
to confirm the effect of zinc on RPE cells, it is recommended that a culture media 
supplemented with appropriate substitutions for FCS are used to confirm the effect 
of zinc addition to growth media.  
In parallel with TER measurement and the ZO-1 immunostaining, the expression of 
some RPE specific gene was monitored. The qPCR measurements showed that at 
least in the case of the RPE65 gene, zinc has a concentration-dependent enhancing 
effect on expression. RPE65 protein is a highly important enzyme, which converts 
all-trans-retinyl ester into 11-cis retinol (Moiseyev et al., 2006) without which the 
visual cycle cannot be completed. Mutations in RPE65 have been associated with 
blindness (Thompson et al., 2000) and RPE65 deficiency has been associated with 
severe loss of photoreceptors (Rohrer et al., 2003). Based on this, zinc is potentially 
important in maintaining visual function through modulation of RPE65.  
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5.9. Future Plans 
A recent publication by Ahmado et al (Ahmado et al., 2011a) has exhaustively 
sought the most optimal conditions under which to culture RPE cells. They reported 
that DMEM high glucose with the addition of pyruvate generated better 
differentiated ARPE19 cells when compared to DMEM/F12 or DMEM high 
glucose without pyruvate. Furthermore, phagocytic function, pigmentation and 
expression of RLBP1, RPE65 and PMEL17 proteins were most prominent in 
ARPE19 cells grown in DMEM high glucose. It would be interesting to examine 
the TER measurements, ZO-1 staining and RPE-associated gene expression caused 
by adding zinc to DMEM high glucose with pyruvate. It is warranted that 
experiments be carried out on confluent cells in order to eliminate the false positive 
result caused by the effect of zinc on cell proliferation. It would also be of interest 
to explore the effects of growing cells in Matrigel (BD Biosciences, Oxford) and 
reducing the concentration of FCS to 1% as described by Ahmado and colleagues 
(Ahmado et al., 2011b). The decrease of FCS content would be expected to increase 
the concentration of freely available zinc.  
In the future, it will be important to check whether coating of culturing surfaces and 
the use of serum deprivation are necessary to differentiate ARPE19 cells into a 
more in vivo-like phenotype. It will also be important to assess whether there is a 
need for the presence of extracellular zinc when plating the cells or whether 
addition of zinc would achieve a better phenotype when added after the cells 
reached confluence. A further question is whether addition of zinc to polarised cells 
(cells cultured to confluence on Transwell membranes) will affect cell 
differentiation depending on whether zinc is added apically or basally. Once 
appropriate conditions are found experiments using externally elevated zinc need to 
return to the basic characterisation of the cells in which TER, gene expression 
changes and pigmentation changes are monitored for an extended period of time to 
see the long term effect of zinc supplementation on RPE cells. Despite the many 
questions raised by this pilot experiment we propose that an appropriate zinc 
environment might be important for the development of appropriate RPE 
phenotype.  
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6. Effect of Zinc on Fenestrae Formation: an in 
Vitro Study using bEBD5 Cells 
 
The fenestrated choriocapillaris plays a crucial role in the clearance of 
unwanted material from the retina and the RPE. In pathologic conditions such 
as AMD fenestration of the capillaries is compromised but the mechanism 
behind this is not fully understood. In this chapter we explore the effect of zinc 
(ZnSO4) on the formation of fenestrae in bEBD5 cells, a murine cellular 
endothelial model system for fenestrae formation. Fenestrae formation was 
assessed through immunofluorescence staining for PV-1 protein, a 
glycoprotein found in the diaphragm of fenestrae (Stan et al., 1999). Actin 
immunoreactivity was used to monitor changes in the cytoskeleton. We found 
that treatment of bEBD5 cells with~400nM bio-available zinc for 20 hours 
induced PV-1 rearrangement into the so called “sieve plates”, an indicator of 
fenestrae formation. Fenestrae formation itself was confirmed by whole mount 
electron microscopy. The sizes of zinc-induced fenestrae were found to be 
~60nm which corresponded to their size in vivo and when chemically induced 
(Latrunculin A) in vitro. To assess the specificity of zinc treatment bEBD5 cells 
were exposed to equimolar levels of various divalent metals. Treatment with 
calcium, nickel and iron was able to induce fenestration but the extent of this 
fenestration was marginal when compared to that following treatment with 
zinc. Magnesium sulphate did not induce fenestrae formation and copper and 
cadmium were highly toxic to bEBD5 cells. Bioavailable zinc is present at high 
concentration in Bruch’s membrane adjacent to the choriocapillaris, therefore 
it could affect the endothelial cells and modulate the formation of fenestrae in 
vivo. The discovery that zinc can induce fenestrae suggests that maintaining an 
optimum level of bio-available zinc within Bruch’s membrane might be crucial 
for the optimal function of the choriocapillaris and that entrapment of zinc in 
sub-RPE deposits in AMD might be involved in the defenestration seen in this 
disease.  
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6.1. General Introduction 
6.1.1. The Endothelium 
Endothelium is classified according to whether or not fenestrations are present. In 
the fenestrated capillaries, discontinuous and fenestrated endothelia are found. 
(Aird, 2007). Two types of fenestrae may be present; one with and one without thin 
3-5 nm diaphragms (See Figure 6.1) (Braet and Wisse, 2002). Continuous 
capillaries are found in the myocardial vasculature (Predescu et al., 1994), central 
nervous system as a part of the blood-brain-barrier (Hofman et al., 2001), lung and 
skeletal muscle (Schnitzer, 1992). Discontinuous fenestrations are found in the liver 
sinusoids (Braet and Wisse, 2002), spleen and bone marrow (Satchell and Braet, 
2009). Continuous fenestrated capillaries are present in the kidney glomeruli, 
digestive system (Satchell and Braet, 2009) and the choriocapillaris (Mancini et al., 
1986). There is a marked difference in fenestrae diameter and density, especially in 
man (diameters ranging from 50-300 nm in diameter and density from 15-25 
fenestrations per µm
2 
(Braet and Wisse, 2002). This is in contrast to other animals 
such as rat, mouse and chicken, all of which have fenestrations with a tight range of 
diameters from around 80-100 nm (Braet and Wisse, 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1- Types of endothelia 
Types of endothelia: continous (a, b, c, d), fenestrated (e), and discontinuous (f). 
Picture accessed from http://www.cvphysiology.com/Microcirculation/M016.htm  
date:20 06 11 
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6.1.2. PV-1 Protein 
PV-1, a protein coded by Plasmalemmal Vesicle Associated Protein (PLVAP) gene 
is a specific protein present in the stomatal diaphrams of fenestrated endothelia 
(Stan, 2004, Stan, 2007). In its monomeric form, the molecular weight of PV-1 
protein is 50-60kD, although the protein usually forms dimers (Stan, 2004, Stan, 
2007).  Northern blot analysis of human tissues suggested that the expression of 
PV1 is ubiquitous, with expression highest in the thyroid gland and small intestines 
(Stan et al., 2001). EST data from NCBI has indicated that tissue expression for 
PLVAP gene was found in all states of development and its expression is highest in 
the mammary gland, nerve, spleen and thyroid. Furthermore, the expression is also 
associated with various tumors. The protein PV-1 is present as a dimer in the 
fenestrae diaphragms (Stan, 2004). Formation of fenestrae is highly dependent on 
PV1 expression. Treatment of endothelial cells in culture with Phorbol Myristate 
Acetate (PMA) was found to upregulate both the protein levels as well as its 
expression. Activation of ERK1/2 kinase pathway is crucial for the formation of 
fenestrae as inhibiting ERK1/2 prevented PV-1 upregulation (Stan, 2004). It is also 
known that PLVAP expression is dependent on kinases p38, PI3K but not MEK1 
(Strickland et al., 2005). Expression of PV-1 has been associated with pathological 
states. Immunohistochemical staining of ischaemic human brain showed that PV-1 
expression peaked 7 days post ischemia (Shue et al., 2008). In another study, the 
expression of PLVAP was found in various malignant neoplastic tissues, including 
kidney, colon, pancreatic carcinoma and non-small cell lung carcinoma (Strickland 
et al., 2005). PV-1 is a highly valuable marker for fenestrae formation as its 
homogenous distribution within cells changes into the so-called “sieve plates” once 
fenestration starts. 
6.1.3. Importance of Endothelium in RPE-choroid Interface 
The choriocapillaris is outside of the tight blood-retinal barriers at the vessels of the 
neural retina and the retinal pigment epithelium (Cunha-Vaz, 1979). The 
choriocapillaris has fenestrations mainly on the side facing Bruch’s Membrane and 
the RPE. The main function of the choriocapillaris is presumed to be to mediate 
transport of solutes and nutrients to the outer retinal layers through the RPE 
(Bernstein and Hollenberg, 1965) and clear the debris generated through the 
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processing of photoreceptor outer segments (Bok, 1993). The transport between the 
RPE and choroid is highly dependent on signalling by the RPE. Esser et al showed 
that epithelial cells associated with fenestrated endothelium continuously express 
VEGF as a way to control angiogenesis and fenestration (Esser et al., 1998). 
Interestingly, a mutant mouse which expresses solely VEGF188 but not the 
VEGF164 and VEGF120 present in the RPE was devoid of choroidal fenestration 
and had a thickened endothelium at 12 months of age (Saint-Geniez et al., 2009a), 
highlighting the specificity of VEGF isoforms in fenestration. Apart from pro-
angiogenic factors, the RPE also mediates the prevention of neovascularisation, 
possibly by releasing and maintaining level of pigment-epithelium derived factor 
(PEDF) (Ida et al., 2003, Mori et al., 2001, Park et al., 2011).  
Maintaining proper interaction between the choroidal endothelium and the RPE is 
likely to be crucial to the maintaintenance of normal function(s) at this interface. 
Several studies have indicated that ageing compromises the integrity of the RPE-
choriocapillaris interface. Animal studies haveshown that vasculature density and 
fenestrations decrease with age (Burns and Hartz, 1992).  
Structural changes in AMD affect the morphology of the RPE and the. McLeod et 
al (McLeod, et al 2009 IOVS) concluded that significant loss of the RPE and 
vasculature occurred in human AMD eyes with geographic atrophy compared to 
aged non-AMD eyes. They also showed that no fenestrations could be observed in 
the region of RPE loss (McLeod et al., 2009). The presence of sub-retinal RPE 
deposits is thought to contribute to these changes as they interrupt the 
communication between RPE and the choroidal capillaries. Various environmental 
and non-environmental factors like diet and lifestyle factors (Wright et al., 1983), 
alcohol (Wang et al., 2005), smoking and nicotine (Espinosa-Heidmann et al., 
2006, Yang et al., 2010) can interfere with fenestrae formation. Here we present 
evidence that zinc is important for fenestrae formation as well. 
6.2. Aims and Hypothesis 
Fenestration of the choroidal capillaries is maintained through the release of VEGF, 
and probably other biomolecules, by the RPE(Roberts and Palade, 1995). The 
thickening of Bruch’s membrane and the development of sub-RPE deposits is 
thought to interfere with the diffusion of these intermediaries (Booij et al., 2010a) 
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causing the defenestration and eventually the atrophy of the choriocapillaris. 
Impaired nutrient exchange and product removal then leads to the degeneration of 
the RPE. As zinc, both bound and bio-available, is present in Bruch’s membrane in 
high concentrations (Lengyel et al., 2007), we hypothesised that zinc is one of the 
biomolecules involved in fenestrae formation. Totest this hypothesis we: 
1. Used a cellular model system for fenestrae formation. 
2. Exposed cells to extracellular zinc, and monitored fenestrae formation using 
immunocytochemistry and TEM. 
3. Determined the specificity of zinc-induced fenestration by treating bEND5 cells 
with equimolar concentrations of other divalent metals. 
4. Identified the signalling pathway(s) involved in zinc induced fenestrae formation 
using bioinformatic tools 
Latrunculin A treatment of bEBD5 cells as a Model for Fenestration 
Methods: 
In this study, we followed the protocol of Ioannidou et al (2006) who used cultured 
bEnd5 cells and Lantrunculun A (LA) treatment  to induce fenestrae formation 
(Ioannidou et al., 2006). Latrunculin A is a toxin isolated from Latrunculia 
magnifica,or red sea sponge (Coue et al., 1987). Latrunculin A (1.25uM)has been 
shown to bind to actin leading to the disruption of the cytoskeleton (Ioannidou et 
al., 2006).  As a consequence LA induces a widespread relocation of PV-1 proteins 
and, fenestrae formation (Ioannidou et al., 2006).  
Results: 
Figure 6.2 summarizes the results of 1.25 µM LA on bEND5 cells. PV-1 
immunoreactivity (panel B) highlights typical “sieve plates”, an indication that PV-
1 protein was redistributed. A counterstain with Rhodamine Phalloidin shows that 
the cytoskeleton was disrupted.  Actin staining shows bands of immunoreactivity in 
the control samples, which were replaced by punctate, dotty linear staining. Using 
whole-mount transmission electron microscopy (TEM), we were able to reproduce 
Ioannidou’s results and show that not only PV-1 redistributed into “sieve plates” 
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but that it also led to formation of fenestrae.  Figure 6.2 shows uniform fenestration 
resulting from Latrunculin A treatment. The average diameter of the fenestrae was 
74±19nm, similar to the 60-80nm reported by Ioannidou et al (see Figure 6.8). At 
higher magnification, the cores of each fenestration become apparent (Figure 6.2 
Panel F). The structure holds the size of the fenestration and is present in every 
single fenestra. In this chapter, we will highlight the effect of zinc and various other 
metals in inducing fenestrae formation, and Latrunculin A treatment will be used as 
a control for each of the reactions.  
 Figure 6-2- LA induces fenestrae formation
Treatment of bEND5 cells with 1.2
(Panel B) and actin (Panel C). 
63x magnification, scale bar 10µM. 
uniform layers full of fenestration (Panel D, 800x magnification
magnification, scale bar: 0.5µM
diaphragms (Panel F, 12000x magnification
 
5µM of Latrunculin A resulted in rearrangement of PV
Panel A, B,C were taken using LSM700 confocal microscope with 
TEM analysis showed typical actin rearrangement forming thin 
, scale bar: 1µM
). High magnification shows the presence of typical fenestrae 
, scale bar: 200 nm) 
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6.3. Treatment with ZnSO4 can Induce PV-1 Protein Rearrangement 
Methods: 
The bEND5 cells were cultured in DMEM with added glutamine and pyruvate 
supplemented with 10% FCS, 1% penicillin streptomycin, 1x NEAA, and 50µl of 
50mM β-mercaptoethanol. Zinc, in the form of ZnSO4, was added to this media. As 
some of the constituents of this media can bind added zinc we calculated the 
buffering capacity (with the help of Prof. Richard Thompson, University of 
Maryland, USA) and measured bioavailable extracellular zinc concentration using 
ZnAF2 (see Chapter 5) and found that bioavailable zinc levels detected were below 
1µM, with up to 250 µM added ZnSO4 (Figure 6.3). At 100, 150, 175, 200 and 
250µM added ZnSO4, the concentration of free zinc detected was 447±68, 600±73, 
629±33, 698±50, and 926±214 nM respectively. Based on the calculation, the total 
amount of zinc present in growth media of bEND5 cells at 125µM is 516 nM. 
 
Figure 6-3- Measurement of free intracellular zinc using ZnAF2. 
The presence of zinc buffering constituents in the growth media of cells buffered 
zinc. Addition of 100, 150, 175, 200 and 250µM ZnSO4 resulted in 447±68, 600±73, 
629±33, 698±50, and 926±214 nM respectively. R
2
= 0.97. 
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Results: 
In untreated (control) samples (Figure 6.4, panel C), the cytoskeleton appears normal 
and PV-1 is distributed homogenously, apart from dense perinuclear staining. When 
cells were exposed to 125µM ZnSO4, (a concentration chosen based on the 
experiments in Chapter 5 on RPE cells), corresponding to ~370-500 nM bioavailable 
zinc, for 20 hours, rearrangement of PV-1 became apparent (Figure 6.4, panel E,F). 
However, no rearrangement of actin was apparent. Compared to LA treatment, which 
produced widespread “sieve plates” formation and a substantial rearrangement of 
actin, zinc treatment induced the formation of smaller clusters of sieve plates without 
apparent actin rearrangement (Figure 6.4, panel E,F).  
Next we explored how different concentrations of zinc affect “sieve plate” formation. 
Cells were treated with 50, 100, 125, 150, 175 and 200µM of added ZnSO4 for 20 
hours at 37
o
C with 5% CO2. PV-1 rearrangements were only seen starting at 100µM 
(50µM data not shown), in the form of very fine PV-1 rearrangements inside the cells 
close to the plasma membrane of the cells (Figure 6.5 Panels E-H). At 125µM, more 
defined clusters of sieve plates were produced (Figure 6.4 Panels E-F). At 150µM 
and 175µM, sieve plates did not increase compared to 125µM (Figure 6.5 Panels I-
P). At 200µM added zinc evidence of cells losing membrane integrity was apparent 
(Figure 6.5 Q-T). In pilot studies 250µM ZnSO4 treatment resulted in clear 
indications of toxicity with cells shrinking, as well as nuclear condensation and 
blebbing (Data not shown). This confirms the notion that there is a narrow range of 
“bioavailable” zinc that can be tolerated by cells.   
In order to minimise the possibility of zinc toxicity, it was decided that the lowest 
concentration that could induce PV-1 rearrangement, namely 125µM, would be used 
for subsequent experiments.  
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Figure 6-4 – 125 µM added ZnSO4 cause PV-1 protein rearrangement 
Treatment of bEND5 cells with 125µM of added ZnSO4 for 20 hours caused PV-1 
protein rearrangement and formation of sieve plates (Panels E-L) compared to 
untreated cell (Panel A-D). Actin staining using Rhodamine Phalloidin indicated 
the lack of cytoskeletal changes (Panels C, G, K). Panels E-H showed a more 
extensive PV-1 rearrangement compared to Panels I-L. Pictures were taken using 
LSM700 confocal microscope at 60x magnification. All scale bars  = 10µm.  
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Figure 6-5 – Treatment of bEBD5 cells with 100-200µM of added ZnSO4 
Treatment of bEND5 cells with 100-200µM of added ZnSO4 caused varying levels 
of PV-1 protein rearrangement and formation of sieve plates (Panels E-T) 
compared to untreated cell (Panel A-D). Actin staining using Rhodamine Phalloidin 
(Panels C, G, K, O, S) indicated the lack of cytoskeletal changes. Pictures were 
taken using LSM700 confocal microscope at 60x magnification. All scale bars  = 
10µm. 
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Next the time-course of fenestrae formation was investigated. The cells were 
exposed to 125 uM added zinc for 3, 6, 9, and 20 hours. While fenestration could be 
seen as early as 3 hours, 9 hours of zinc treatment was required for consistent 
fenestrae formation. Untreated samples again showed diffuse and homogenous 
staining of PV-1 protein across the cytoplasm with normal staining of actin and 
DAPI. At three hours of treatment, minor changes in PV-1 staining could be 
observed. After six hours, there was rearrangement of PV-1 where diffuse PV-1 
staining could be seen around the cells (Figure 6.6 Panels I-L). At 9 hours and 20 
hours, several clusters of sieve plates could be seen (Figure 6.6 Panels M-T).  
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Figure 6-6 – Time course treatment with 125µM of added ZnSO4 
Treatment of bEND5 cells with 125µM of added ZnSO4 for 3-20 hours showed 
rearrangement of PV-1 protein from 3 hours (Panel E-H), however, sieve plates 
formation were only apparent in cells treated with zinc for 9 and 20 hours (Panels 
M-P and Q-T). Actin staining (Panels C, G, K, O, S) was conducted using 
Rhodamine Phalloidin Dye. PV-1 staining was done using anti-PV1 antibody and 
Alexa 488 secondary antibody. Pictures were taken using LSM700 confocal 
microscope at 60x magnification. All scale bars  = 10µm. 
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6.4. Electron Microscopy Confirmation of Zinc Induced Fenestration 
 
PV-1 immunoreactivity is a reliable indicator of PV-1 protein translocation but by 
light microscopy we cannot confirm that this has led to fenestrae formation. 
Therefore fenestrae formation was monitored by whole mount transmission electron 
microscopy.  
Methods: 
bEND5 cells were grown overnight on formvar coated nickel TEM grids in the 
presence of standard culture media supplemented with 10% FCS and 1% penicillin-
streptomycin. The cells were then treated either with LA for three hours or 125µM 
ZnSO4 for 20 hours or were left untreated as controls. The timing of the LA 
treatment was synchronized with the 20 hours zinc treatment, meaning that LA 
treatment commenced 3 hour before the zinc treatment finished. Therefore, all 
reactions were stopped at the same time by fixing the cells. Following fixation, the 
cells were treated with osmium tetroxide and were viewed using a JEOL10TEM 
microscope.  
Results: 
Cells treated with LA showed the expected rearrangement of actin and formation of 
fenestrae. The endothelial cells have multiple sieve plates arranged around 
cytoskeletal actin bundles which radiated from the nucleus (Figure 6.7 Panel A). At 
5000x and 12000x magnification (Figure 6.7 Panel B and C), the fenestration formed 
by LA treatment showed uniform pattern. These fenestrae formed by ZnSO4 and LA 
all possessed central diaphragms (Figure 6.7, Panel C and I). Limited spontaneous 
fenestrae formation was apparent in untreated control cells but they were very small 
(Figure 6.7, Panel E). Cells treated with 125µM ZnSO4 for 20 hours were 
consistently fenestrated (Figure 6.7, Panel G-I) and sieve plates were present (Figure 
6.7, Panel G).   These sieve plates covered smaller areas than in LA-treated cells. 
This confirms our findings with PV-1 antibody labeling.  
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Figure 6-7 – TEM pictures showing fenestrae formation 
Transmission electron microscopy showed fenestrae formation after treatment with 
1.25µM Latrunculin A (LA) (Panels A,-C) and 125µM added ZnSO4 (Panels G-I). 
Fenestration was not observed in untreated cells (Panels D-F). Panels A-G showed 
formation of fenestrae at 800x magnification, where extensive changes in cellular 
cytoskeleton was observed in cells treated with LA (Panel A), zinc treatment forms 
smaller areas of fenestration without extensive cytoskeletal arrangements (Panel G). 
At higher magnifications, LA treatment forms highly uniform fenestration pores 
(Panel B 5000x, scale bar 1µm. Panel C 12000x, scale bar 0.5µm) and zinc 
treatment forms smaller areas of fenestration, also with uniform size (Panel H 
5000x, Panel I 12000x, scale bar 200nm). Images taken with JEOL10TEM. 
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Furthermore, we would like to compare the size of fenestrae formed ZnSO4 
treatment compared to those formed by LA.   
Methods: 
Six pictures and four pictures of 12000x magnification were randomly taken from 
LA and zinc sulphate treated bEND5 cells from three different experiments 
respectively. Areas with fenestrae were imported into ImageJ software. After 
removal of speckles and outliers, the area and diameter of individual fenestrae were 
determined. Objects less than 40nm in diameter were rejected as it had been 
determined from manual observations that the smallest of the fenestrae assessed 
was 46nm in diameter. 
Results: 
The size of 393 fenestrae from ZnSO4 treated samples, and 775 fenestrae from LA 
treated samples were estimated. Fenestrae of LA-treated cells were 74+19 nm in 
diameter and those from ZnSO4 treated cells were 67+14 nm.  
The size distributions for zinc and LA-treated cells are as follows. In zinc treated 
samples, 20.9% of the fenestrations formed were of 45-64nm in size, compared to 
9.7% in LA treated group. 22.4% were of 55-65nm size in ZnSO4 treated samples 
compared to 23.0% in LA treated group. Most fenestrations formed were 65-74nm 
diameter, with 31% of ZnSO4 treated group and 24.8% of LA treated group falling 
into this category. 13.0% of ZnSO4 treated group formed fenestrations 75-84nm in 
size compared to 24% in LA treated group. The data indicate that the sizes of 
fenestrae formed are variable in both treated groups. Zinc induced fenestration 
formed more fenestrae in the 45-54nm group compared to LA which have more 
fenestrae in the 75-84nm range (Table 6.1, Figure 6.8).  
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Table 6-1 - Total fenestrae formed in ZnSO4 and LA treated groups. Four and 
6 pictures were analysed for ZnSO4 and LA- treated groups respectively. 
% of Total Fenestrae Formed 
125 uM ZnSO4 1.25 uM LA 
45-54 20.9 9.7 
55-64 22.4 23.0 
65-74 31.0 24.8 
75-84 13.0 24.0 
85-94 8.7 8.1 
95-104 2.0 4.4 
105-114 0.5 1.9 
115-124 0.5 1.7 
125-134 0.3 0.9 
135-144 0.0 0.4 
145-154 0.0 0.1 
155-164 0.0 0.3 
165-174 0.0 0.4 
>175 0.8 0.4 
Fenestrae 
analysed 393 775 
Pictures analysed 4 6 
 
Figure 6-8 – Sizes of fenestrae were measured in ZnSO4 and LA treated bEBD5 
cells. Treatment with ZnSO4 and LA resulted in formation of fenestrae of 
various sizes. Data are expressed as percentage of total fenestrations formed 
against the diameter in nm and summarised in Table 6.1 
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6.5. Cell Viability Assays 
ZnSO4 treatment to up to 150µM was not found to be overtly toxic. Based on 
MINEQL (Environmental Research Software, Hallowell, USA) calculation, the 
bio-available  zinc concentration present in DMEM high glucose used for bEND5 
cells is <1.0µM zinc (Professor Richard Thompson, personal communication). We 
have shown here that using ZnAF2 measurement, addition of 125µM added ZnSO4 
the bioavailable zinc concentration is ~370-500 nM. However above, 200 µM of 
added ZnSO4 abnormal nucleus shape signalled cell toxicity.  
Methods: 
To gain a better understanding of cellular viability, calcein AM and propidium 
iodide staining were used to measure the extent of cell death in our assays. 
Propidium iodide is a DNA intercalating agent, which stains the nucleus of necrotic 
or apoptotic cells. In contrast to the cell-impermeant nature of propidium iodide, 
Calcein AM is a highly cell-permeant fluorescent dye, which fluoresces strongly 
selectively in live cells.  
Results: 
Figure 6.8 shows that bEND5 cells untreated, treated with 1.25 µM LA or125µM 
ZnSO4 for three hours or treated with 125µM ZnSO4 for 20 hours showed no sign 
of cell death. In all four groups, the green Calcein AM staining could be seen 
clearly highlighting the shape of the cells.The two main phenotypes of the cells, a 
smaller more elongated shape and larger more rounded cells were present in all four 
tested groups. In LA treated groups, the rearrangement of cytoskeletal network 
could be seen through the calcein dye.  
Qualitative assessment of the cells does not indicate a difference in the cell 
numbers as assessed through calcein staining, while the lack of propidium iodide 
staining showed no evidences of cell death. No floating cells were observed in any 
of the experiments. 
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Figure 6-9–Calcein assay and propidium iodide staining in bEBD5 cells 
The use of propidium iodide and calcein AM allows the differentiation between 
dead and live cells. Panel A shows bEND5 cells treated with 1.25µM LA, Panel B 
shows untreated cells. Panel C and D shows cells treated with 125µM ZnSO4 for 3 
and 20 hours respectively. The calcein staining (green) shows that cell viability was 
preserved after zinc treatment (Panel C and D), and there is a lack of propidium 
iodide staining in all treated and untreated groups. Representative images taken 
from 3 independent experiments. Scale bar 100µm.  
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6.6. Treatment of bEBD5 Cells with Other Divalent Metals 
 
In order to explore the specificity of zinc, the effects of various divalent metals on 
fenestrae formation was examined. The selection of metals was based on results 
obtained on synchrotron X-ray fluorescent studies on Bruch’s membrane and sub-
RPE deposits which showed that apart from zinc, there is an accumulation of 
copper, iron, nickel, calcium, magnesium and cadmium (Lengyel unpublished data) 
(Wills et al., 2009).   
Methods: 
Equimolar (125 uM) concentration of CaSO4, FeSO4, CuSO4, NiSO4, MgSO4 and 
CdSO4 were used to treat bEND5 cells for 20 hours. Treatment of cells with 125µM 
CuSO4 and 30uM CdSO4 severely compromised cell viability. Cadmium sulphate 
treatment caused all the cells to die (data not shown), while CuSO4 treated samples 
had visible nuclear blebbing, shrinking cells and compromised actin structure 
(Figure 6.11 M-P). Therefore these metals were not examined further in any detail. 
To assess the effectiveness of divalent metals in inducing fenestrae formation we 
followed the characterisation steps described for zinc. Namely we visualized 
changes in PV-1 and actin distribution followed by whole mount TEM to determine 
whether fenestrae were formed. Results were compared to untreated, 125 µM 
ZnSO4 treated and 1.25 uM LA treated cells. 
Results: 
Treatment of bEND5 cells with CaSO4 (Figure 6.10 Panel I-L) showed PV-1 
rearrangement but only at the edges of the cells.TEM results confirmed the 
presence of fenestration here (Figure 6.12 Panel E-F), but these fenestrae were 
much sparser, though similarly sized,to those formed in the presence of zinc 
(~65nm diameter). Following treatment with FeSO4, PV-1 formed large clumps 
rather than sieve plates (Figure 6.11 Panel E-H) although fenestrae formation is 
clearly visible on TEM (Figure 6.12 Panel G-H). These fenestrae, however, were 
sparsely distributed, just like in the case of CaSO4, and there were several areas 
with only misshapen but very large fenestrae.  Nickel sulphate treatment produced 
sieve plate formation only rarely (approximately 10 cells per cover slips) (Figure  
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6.10 Panels M-P). However, in these cells sieve plates looked similar to those seen 
with zinc. Despite the similarity in sieve plate formation in NiSO4 treated cells we 
could not see fenestrae by TEM (Figure 6.12 Panels I-J).  Magnesium sulphate 
(Figure 6.11 I-L) did not lead to sieve plate or fenestrae formation. Visible change 
in actin staining could be observed in some of the metal treated cells, most visibly 
in CuSO4, CaSO4 and MgSO4 treated samples. In CuSO4 treated samples, changes 
in actin staning could be seen in the cytoskeletal changes related to the cell death. 
In CaSO4 and MgSO4 treated cells, there is visible activation of stress fibers as seen 
through rhodamine phalloidin staining of the actin cytoskeleton. 
We also showed that confluent cell layers behave similarly to disperse invididual 
cells. Treatment of bEND5 cells with equimolar concentrations of with ZnSO4, 
CaSO4 and NiSO4 (125µM) shows the same observation as before (Data not 
shown). Treatments with these metals but not LA produced cells with normal actin 
structures and normal nuclear staining. Treatment with 125µM FeSO4 and 125µM 
MgSO4 did not provoke fenestration (Data not shown).  
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Figure 6-10 – Effect of divalent metals on fenestrae formation 
Treatment of bEND5 cells with equimolar concentrations of 125µM added 
ZnSO4(Panels E-H), CaSO4(Panels I-L), and NiSO4 (Panels M-P) for 20 hours 
showed rearrangement of PV-1 protein which is not seen in the untreated cells 
(Panels A-D). Actin staining conducted using Rhodamine Phalloidin does not show 
cytoskeletal rearrangements (Panels C,G,O) with the exception of calcium (Panel 
K), which shows activation of stress fibers. with exception of CaSO. Pictures were 
taken using LSM700 confocal microscope at 60x magnification. All scale bars = 
10µM.  
 Figure 6-11- Effect of divalent metals on fenestrae formation
Treatment of bEND5 cells with equimolar concentrations
FeSO4(Panels E-H), MgSO
showed no rearrangement of PV
D). PV-1 staining was done using anti
antibody. Actin staining 
with the exception of magnesium (Panel K), which shows activation of stress fibers. 
conducted using Rhodamine Phalloidin does not show significant cytoskeletal 
rearrangements apart from Cu
using LSM700 confocal microscope at 60x magnification. All scale bars  = 10µM
Figure 6-12–Effect of divalent metals on fenestrae formation (TEM)
Transmission electron microscopy
equimolar (125µM), ZnSO
and NiSO4 (Panels I-J). Fenestration was not observed in untreated cells (Panels A
B). ZnSO4 treatment produces f
CaSO4 treatment is limited to the periphery. FeSO
fenestration within the cells. NiSO
A,C,E,G,I at 5000x magnification and pane
Scale bars = 5000x, 0.5µm, 12000x 200nm
 
 of 125µM added 
4(Panels I-L), and CuSO4 (Panels M
-1 protein compared to untreated cells (PanelsA
-PV1 antibody and Alexa 488 secondary 
does not show cytoskeletal rearrangements (Panels C,G,O) 
SO4-treated group (Panel O). Pictures were taken 
 showed fenestrae formation after treatment with 
4 (Panels C-D), CaSO4(Panels E-F), FeSO
enestrate with varied sizes. Fenestrae formed after 
4treatment produced patch of 
4treatment failed to produce fenestration. Panels 
ls B,D,F,H,J at 12000x magnification. 
. 
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6.7. Possible Signalling Pathway(s) Involved in Zinc – Induced Fenestration 
Activation of extracellular-signal-regulated kinases (ERK1/2) kinase pathway is 
crucial for formation of fenestrae as inhibiting ERK1/2 prevented PV-1 up-
regulation (Stan, et al 2004). It is also known that expression of PLVAP, the gene 
for PV-1, is dependent on kinases such as p38 and phosphatidylinositol 3-kinases 
(PI3K) (Strickland et al Pathology 2005). In fact, these proteins are part of the 
signalling cascade for VEGF, that stimulates fenestrae formation, as well as 
nicotine that inhibits it. In addition these molecules are affected by zinc itself. In 
this section we aim to understand whether phosphorylation of ERK is involved in 
zinc induced fenestration. 
Methods: 
To identify the molecules involved in zinc-induced fenestrae formation we explored 
information available in Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Inc., 
California, USA). Using the “grow” and then the “connect” functions in pathway 
builder in IPA the molecules shared by VEGF, nicotine and zinc signalling 
pathways were explored (Figure 6.13). Amongst the several overlapping molecules 
there were ERK1/2, IP3 and NFkB that were shared by all three molecules. Akt is 
shared between VEGFand nicotine while Src is shared between VEGFA and zinc. 
Interestingly, p38 is only connected to zinc. Naturally, IPA may not contain all 
possible relevant data, but nevertheless indicated that molecules that have been 
suggested to be involved in PV-1 regulation and fenestrae formation are shared by 
these signalling molecules.  
The way some of these molecules are involved in signalling is through 
phosphorylation. Therefore, we treated bEND5 cells with 125 uM zinc for 20 hours 
then lysed the cells and proteins were separated on SDS-PAGE, blotted to 
Nitrocellulose and probed for phospho-specific antibodies and antibodies that 
detect both the phospho- and non-phospho- forms of ERK1/2, PI3K,, P38, and 
AKT. 
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Results: 
Our results indicated that phosphorylation of ERK1/2 or pERK1/2 at all time points 
(Figure 6.14) does not seem to be involved in zinc-induced fenestration suggesting 
that other kinases would be responsible.  However, beta-actin expression seems to 
gradually increase up to one hour and returns back to normal at 20 hours. The 
pictures are representative diagrams from three independent experiments.  
 
Figure 6-13–Relationship between VEGF, nicotine and zinc 
Ingenuity Pathway (IPA) software showed relationship of VEGF, nicotine and zinc, 
the three molecules which have been shown to be involved in AMD. Using the 
“grow” and “connect” functions, various signalling pathways were explored. 
VEGFA affected KDR, 1,4,5-IP4, PI3K, ANGPT2, AKT, SRC, ERK1/2, 
bevacizumab and ranibizumab. Zinc affects PI3K, IL6, SRC, ERK1/2, P38, NFқB, 
and caspase. Nicotine affects SRC, PI3K, Akt, Pkc, ERK1/2 and NFқB. Shared and 
overlapping pathways have been summarised in table 6.2. 
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Table 6-2 - Overlapping pathways between VEGFA, zinc and nicotine. 
Bo VEGFA Zinc Bicotine 
1 PI3K PI3K PI3K 
2 ERK1/2 ERK1/2 ERK1/2 
3  NFkB NFkB 
4 AKT  AKT 
5 SRC SRC  
6  PKC* PKC 
7  P38  
 
Figure 6-14–Phosphorylation of ERK1/2 is not involved in fenestrae formation 
Probing of 10µg untreated (first lane) and 125µM ZnSO4 treated for 1, 5, 10, 30, 60 
minutes and 20 hours revealed that there is no increase in ERK1/2 phosphorylation, 
nor of its phosphorylated form pERK1/2. Beta-actin expression seems to increase 
after 1 minute and sustained up to 1 hour before decreasing again at 20 hour time 
point. Picture is representative from three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
202 
 
6.8. Discussion 
The hypothesis to be tested in this chapter was that zinc was involved in fenestrae 
formation in endothelial cells. Data presented support this in that zinc can induce 
fenestration. Furthermore, elements of the signal transduction cascade that is 
involved in the zinc induced signalling leading to fenestration have been identified. 
To our knowledge this is the first demonstration of zinc-dependent fenestrae 
formation.  
Zinc and VEGF 
The choroidal vasculature differs from the retinal vasculature in that it is fenestrated 
(Bernstein and Hollenberg, 1965). In 1986, Mancini et al published that the 
fenestrations found in the choriocapillaris were not randomly distributed, but they 
were found predominantly in the endothelium closest to the RPE (Mancini et al., 
1986)(Mancini et al 1986). The endothelium thickens further away from the RPE 
and it was speculated that there might be a signal from the RPE that “polarizes” the 
endothelium and induces the fenestration formation (Mancini et al., 1986). 
Fenestrae initially increase with age but in advanced age the number of fenestrae 
decreases (Burns and Hartz, 1992). This is further affected by age related 
pathologies like AMD (McLeod et al., 2009). At present the major signal that 
controls fenestration is believed to be Vascular Endothelium Growth Factor 
(VEGF). Esser et al described VEGF basally secreted by RPE as a regulator of 
angiogenesis and vascular permeability (Esser et al., 1998). When adrenal cortex 
capillary endothelial cells were co-cultured with epithelial cells transfected with 
VEGF 164 and VEGF120 many fenestrae were induced on the endothelium (Esser 
et al., 1998). Furthermore, treatment of adrenal cortex endothelial cells with 
VEGF165 or fibroblast growth factor (FGF) showed that fenestrations could be 
induced by VEGF but not FGF (Saint-Geniez et al., 2009b). There are three VEGF 
isoforms but only VEGF120 and VEGF164 can induce fenestration VEGF188 
cannot (Saint-Geniez et al., 2009b),(Saint-Geniez 2009 PNAS). Loss of fenestration 
in the VEGF188 expressing animal model led to formation of sub-RPE deposits 
providing evidence that supports the notion of a link between fenestrationin AMD 
(Saint-Geniez et al., 2009b). There is an inverse correlation between zinc levels and 
VEGF production. Treatment of PC-3 and DU-145 prostate cancer cell lines with 
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TPEN, a zinc selective chelator, at 2-8µM for 2 hours suppressed VEGF levels 
(Golovine et al., 2008). Zinc chelation in HT-29, another prostate cancer cell line, 
also reduced the level of VEGF (Gurusamy et al., 2011). Overexpression of hZIP1 
protein, a plasma membrane zinc transporter that imports zinc into cells, also 
inhibited VEGF production (Golovine et al., 2008). The mechanism behind the 
effect of zinc on lowering VEGF levels is thought to be through the inhibition of 
transcription of hypoxia inducible factor (HIF-1) a pro-angiogenic factor often 
associated with the aggressiveness of tumours (Nardinocchi et al., 2010).  
Zinc and PV-1 
In our experiments a surrogate marker for fenestrae formation was the 
redistribution of Plasmalemmal Vesicle Associated Protein-1 (PV-1) into the so 
called sieve plates. PLVAP (the gene encoding PV-1) encodes a TypeII 
transmembrane glycoprotein that is associated with the caveolae of fenestrated 
microvascular endothelial cells. It is normally expressed in the lung, liver, kidney, 
immature brain and in the eye (Stan, 2007). This protein is only associated with 
fenestraethat have diaphragms, these being formed by PV-1 dimers (Stan, 2007).  
RNA silencing of PLVAP expression led to large variability in fenestrae diameter 
providing support that this protein does controls the size of fenestrae (Ioannidou et 
al., 2006). The fact that the diameter of zinc-induced fenestrae was similar to those 
requiring PV-1 in vivo or following LA treatment suggested zinc-induced 
fenestration does involve PV-1.  It is not known whether zinc or any metals could 
directly affect PV-1 or PLVAP. Our search did not locate any metal response 
element transcription factor up to 1000bp upstream of the 5’ un-translated region of 
PLVAP gene therefore it is not very likely that altered zinc balance would lead to 
regulation of gene expression and recent zinc supplementation experiments in our 
laboratories did not demonstrate changes in PLVAP expression of this gene 
(Barzegar-Befroei and Lengyel, personal communication). It seems probable, 
therefore, that sieve plate formation and formation of fenestrae does not involve 
direct PV-1/zinc interaction.  
It is believed that the formation of fenestrae requires the reorganization of the 
cytoskeleton. It had been reported that zinc, and several other divalent metals, can 
affect polymerisation of actin, although only at very high (>300 uM) concentrations 
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(Strzelecka-Golaszewska et al., 1978). At the levels of bio-available zinc in our 
experiments (~200 nM) we did not see discernable evidence for actin remodelling, 
although we cannot rule out local changes in the cytoskeleton around the zinc-
induced sieve plates. Therefore we assume that fenestrae formation in our 
experiments is unlikely to be due to a direct zinc/cytoskeleton interaction. 
Zinc can be toxic to cells (Bozym et al., 2010). However, treatment of bEND5 cells 
with up to 150 µM externally added ZnSO4 did not appear to be toxic to these cells, 
as shown by a calcein/propidium iodide assay. Similar concentrations of 
extracellular zinc have been widely used in other studies with success. Richard  et 
al added 150µM of zinc chloride to cultured human skin fibroblasts and noted that 
these concentrations,in the presence of FCS, lowered the concentration of 
thiobarbituric acid reactants as a marker of lipid peroxidation  (Richard et al., 
1993). In Chinese Hamster Ovary (CHO) cells, addition of up to 100µM zinc 
chloride to media supplemented with FCS increased metallothionein levels within 
the cells without inducing toxicity (Wallace et al., 1995). It is particularly important 
to emphasize that the high concentration of externally added zinc does not translate 
to equal amount of bio-available zinc. We and others (Bozym et al., 2006, Bozym 
et al., 2010) found that growth media with FCS very strongly buffered zinc levels, 
keeping bio-available zinc < 1 uM. It is interesting to note that in the absence of 
added zinc, but in the presence of FCS, cells are potentially in a zinc deficient 
environment (Bozym et al., 2010, Bozym et al., 2006). This might need to be taken 
into account when results on cultured cells are interpreted. Overall, it appears 
unlikely that the zinc-induced fenestration of bEND5 cells would, per se be 
associated with toxicity. 
We have also examined the specificity of zinc-induced fenestrae formation by 
treating bEND5 cells with CaSO4, FeSO4, NiSO4, MgSO4, CdSO4 and CuSO4. 
While CdSO4 and CuSO4 were toxic to cells, other divalent metals except Mg SO4 
were able to induce either PV-1 rearrangement, fenestrae formation or both. 
However, these effects were marginal compared to the reliable sieve plate and 
fenestrae formation seen in the presence of zinc. Interestingly NiSO4 was able to 
induce sieve plate formation in a few cells, but this was not accompanied by 
fenestrae formation. This suggests that PV-1 reorganization is not sufficient to 
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induce fenestration. Based on the results with divalent metals it is concluded that 
fenestrae formation was not specific to zinc but is most prominent in zinc-treated 
cells.  
The formation of stress fibers observed in CaSO4, and MgSO4 treated cells may be 
mediated through activation of Rho GTPases. The activation of Rho GTPases is 
particularly important in cellular movement, particularly in cellular migration 
through extension of lamellipodium, and cell contraction (Manneville and Hall, 
2002). The cellular movement and contraction is achieved through changes in stress 
fibers, a structure formed of myosin II, and actin filaments (Nobes and Hall, 1995). 
Studies have reported the role of calcium and magnesium in regulating Rho 
GTPases in various cells. Katoh and colleagues reported that isolated stress fibres 
in vitro can be activated using calcium and ATP through phosphorylation of myosin 
light chain (Katoh et al., 1998). Calcium has also been shown in regulating Rho 
GTPases in adrenal chromaffin cells (Gasman et al., 1999), and plant pollen tubes 
(Yan, Xu, and Yang, 2009). It is known that Rho-GTPases induce endothelial cell 
permeability (Wójciak-Stothard et al., 2001) and magnesium is essential for activity 
of Rho-GTPase activating proteins (Zhang et al., 2000). As we did not observe 
fenestration in either magnesium or calcium, it is possible that these two metals 
have effect on proliferation of or activate other mechanism in bEND5 cells. Such 
effect has been seen in human umbilical vein endothelial cells (HUVECs) treated 
with physiologically viable millimolar concentrations of magnesium. Increased 
proliferation was observed, as well as increased nitric oxide level, suggesting that 
magnesium treatment may have vasodilatative effect on endothelial cells (Maier, et 
al., 2004). It would be interesting to do functional assay on Rho-GTPase activation 
on magnesium or calcium treated bEND5 cells to observe how these metals affect 
the cell line.  
Twenty hours treatment of bEND5 cells with >30µM CdSO4 results in nuclear 
blebbing, major cell contraction and cytoskeletal rearrangement. This is probably 
not surprising, considering various other studies have reported on the toxicity of 
cadmium on endothelial cells. Loss of stress fibers and cytoskeletal rearrangement 
have been reported in MDCK cells treated with very high (500µM) concentration 
of cadmium (Hernandez et al., 1989). Using egg yolk angiogenesis assay, it was 
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shown that treatments with as low as 1µM cadmium chloride reduces angiogenesis 
and wound healing, an effect possibly mediated by lowered production of nitric 
oxide (Kolluru, et al., 2006). It needs to be stressed that unlike the zinc 
concentration, we did not optimize the concentration of cadmium. It is likely that 
>30µM of cadmium exceeds the buffering capacity of bEND5 cells which activated 
the pro-apoptotic mechanisms  
The fenestration induced by zinc appears to be a relatively slow process as we did 
not observe sieve plate formation by light microscopy until 9 hours after the start of 
the treatment. However, formation of some fenestrae can be seen as early as 3 hours 
of zinc treatment by TEM. The process appears to be concentration dependent 
requiring the increase in bio-available zinc to ~200 nM for a reliable and repeatable 
effect. This corresponds to 125 µM added zinc. The environment the choroidal 
capillaries are nested in is high in zinc including bio-available zinc (Lengyel et al., 
2007). Indeed, bio-available zinc can be readily detected adjacent to the fenestrated 
choroidal capillaries in ex vivo human eyes (Figure 6.15, courtesy of Gango and 
Lengyel, Unpublished) by autometallography, providing evidence that zinc is 
present around the choriocapillaris and potentially able to initiate a cascade of 
events leading to fenestration. Based on literature data on fenestrae formation and 
signalling by VEGF (inducing fenestration), nicotine (inhibiting fenestration) and 
zinc we developed a model using IPA to explore whether phosphorylation is 
involved in zinc-induced fenestrae formation. We identify here that ERK1/2 is not 
involved in regulating zinc-induced fenestration in bEND5 cells, suggesting that 
fenestration is mediated by other kinases or cellular processes.  
Taken together, it is feasible to speculate that both zinc and VEGF are involved in 
regulating fenestration of the choroidal endothelium and individually or 
synergistically regulate fenestration at places like the RPE/choroid interface where 
there is high enough concentration of zinc to exert an effect. The potential for a 
dual regulation of fenestrae formation had not been previously described. This 
would allow both zinc and VEGF to participate in the health, and in fact pathology, 
of the outer retina-blood barrier.  
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Figure 6-15–Bioavailable zinc in Bruch’s membrane 
Autometallography on ex vivo human eyes shows the presence of bioavailable zinc 
in the RPE-Bruch’s membrane area (electron dense speckles) (Figure A, B) 
adjacent to the choriocapillaris (CC). Oblique sections show the presence of 
fenestrated endothelium (Figure A) between the BM and CC, where the diaphragm 
of the each fenestra is apparent at higher magnification (Figure B). RPE: Retinal 
Pigment Epithelium, BM: Bruch’s Membrane, CC: Choriocapillaris. Scale bars: 
Figure A, 200nm, Figure B, 100nm. 
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6.9. Further research 
Further experiments will be required to decide whether the model for dual action 
through both zinc and VEGF does really fit the in vivo situation. We will need to 
explore how fenestrae formation is affected when VEGF and zinc are present in the 
growth medium, an experiment that is already in the planning. It will also be 
interesting to see whether in vivo zinc deficiency in animals would alter fenestration 
of the choroidal capillaries and we are collaborating with Professor John Beattie at 
the Rowette Institute in Scotland to induce controlled zinc deficiency in mice. Zinc 
deficiency had been associated with loss of endothelial cell permeability (Di Cello 
et al., 2005). Whether in the choriocapillaristhis translates to loss of fenestrae will 
be exciting to explore. The generation of zinc deficiency in mice study is about to 
be finished and we will have the chance to analyse eyes for molecular and 
morphological changes. We will also need to explore further the molecular 
networks involved zinc-induced fenestration. Experiments are ongoing to identify 
the changes in protein phosphorylation in cell homogenates as well as in cells.  
6.10. Conclusion 
In conclusion we propose here that the under normal conditions, optimal zinc and 
VEGF levels are required to maintain a healthy outer retina-blood barrier including 
appropriate fenestration of the choriocapillaris. Pathological changes like 
thickening of Bruch’s membrane or development of sub-RPE deposits will prevent 
VEGF and/or zinc to reach the choroidal microvessels as well as lead to entrapment 
of zinc in proteinaceous aggregates the impairment of clearance through the loss of 
fenestration will be seriously compromised. As sub-RPE deposit formation has 
been strongly associated with the choroidal capillaries (Lengyel et al., 2004, 
Mullins et al., 2011) the issue of altered zinc availability will probably need to be 
addressed. In fact, zinc supplementation has a positive effect on progression to end 
stage disease in AMD as described in the AREDS study no 8 (2001) and zinc 
supplementation had been shown to directly affect the RPE/choroid interface one of 
the steps in this positive effect might be through the reopening of fenestrae to 
provide better clearance of waste products.  
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7. General Discussion 
Zinc is an indispensable and ubiquitous trace element present in many tissues in a 
wide range of organisms. The overall amount of zinc found in the human body is 
estimated to be 1.4-2.3 grams (Strauss, 2005). The highest tissue concentration of 
zinc in man is found in the RPE-choroid complex where the zinc content is 472 
µg/g dry weight (Karcioglu, 1982). The high zinc concentration of zinc in the RPE-
choroid complex is likely to be required for its function in regulating enzymes 
involved in the retinal cycle, phagocytic activity of the RPE and combating free 
radicals present in the RPE-choroid complex.  
In 2004, Lengyel et al reported that sub-retinal RPE deposits contained a very 
high>500 ppm of zinc (Lengyel et al., 2007). This observation raises questions 
about where zinc in the RPE-choroid interface is coming from, and how it reaches 
the sub-RPE space. Furthermore, it remains unknown whether the bioavailable zinc 
found in Bruch’s membrane (see Figure 6.15) is needed for RPE function, or 
whether it is involved in pathological processes. It is known that zinc deficiency is 
associated with age-related macular degeneration (AMD) (Newsome et al., 1988) 
and clinical trials have reported that zinc supplementation can delay AMD-
associated vision loss (Ho et al., 2011a). This has highlighted the need to better 
understand how zinc is metabolised and transported at the RPE/choroid interface. 
At the outset of this study, we aimed at obtaining support for this idea by examining 
three major areas. 
We set out to study the largely unexplored zinc transporters at the RPE-choroid by 
determining the expression for all the 24 known zinc transporters genes at this site. 
In parallel with our work two other groups published partial characterisation of zinc 
transporter expression (Leung et al., 2008a, Rezaei et al., 2008a), highlighting 
potential antioxidative functions of zinc transporter proteins (Rezaei et al., 2008a). 
Throughout this basic characterisation we identified ZIP12 protein as a potentially 
important zinc transporter at the RPE-choroid interface based on its gene 
expression in cadaveric RPE. We acknowledge the major caveat contributed by the 
cross-contamination present within the cadaveric samples, and thereby suggest 
improvements in isolating RNA from cadaveric tissues to be carried out to improve 
the data presented in this thesis and to confirm that ZIP12 is indeed expressed in the 
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RPE. Other studies have suggested that ZIP12 protein appears to be specific to 
RPE, as shown by the Bergen group (Booij et al., 2010b). Based on this and the 
lack of published data on ZIP12, after a careful consideration we carried out a 
series of experiments to learn more of the function of this protein. ZIP12 turned out 
to be a zinc importer located at least partly on the plasma membrane. Therefore, it 
is likely that if ZIP12 is confirmed to be present in the RPE, it is likely to be 
involved in loading, or reloading zinc into RPE cells. While the association of 
ZIP12 polymorphisms or mutations with AMD was not examined in this thesis, we 
have started to analyze results of genome-wide association studies to look at 
whether polymorphism of SLC39A12, the gene for ZIP12, could be associated with 
AMD (in collaboration with Professor John Yates). In order to understand the 
protein’s potential function, we started the characterisation of commercially 
available antibody as well as generating an antibody against ZIP12 to monitor the 
localisation and potential reorganisation of ZIP12 in tissue sections. The plasma 
membrane localisation predicted from sequence data was confirmed (Chapter 4) but 
further characterisation of the antibodies and its distribution in disease is awaited. 
This part of the project still has to overcome several obstacles as none of the 
antibodies could unambiguously detect ZIP12.  
The high concentration of zinc present in the extracellular matrix between the RPE 
and the fenestrated choroidal capillaries called Bruch’s membrane (Lengyel et al., 
2007) gave rise to the speculation that zinc could be directly involved in 
modulating the RPE and/or the choriocapillaris. To explore one possible action, we 
exposed both epithelial and fenestrated endothelial cell lines to elevated 
extracellular zinc and found that both responded to increased zinc. ARPE19 cells 
changed their transepithelial resistance and RPE specific gene expression profile in 
response to zinc treatment. However, it is likely that the changes in transepithelial 
resistance are mediated by the effect of zinc on cell proliferation as assessed 
through alamarBlue assay. In parallel, using immunocytochemistry and electron 
microscopy we found that the presence of extracellular zinc by itself can induce 
fenestrae formation. These show that if bioavailable (free or easily releasable) zinc 
levels reach ~200-500 nM in Bruch’s membrane it could directly affect both of 
these cell types. It has already been mentioned earlier that this concentration could 
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potentially be present in Bruch’s membrane (Lengyel et al., 2007), and an even 
higher concentration might be available locally (Nan et al., 2011, Nan et al., 2008). 
Based on the information above and data we obtained from literature we developed 
a model for zinc regulation and deregulation at the RPE-choroid interface (Figure 
7.1). This model is based on the assumption that under normal conditions zinc 
(Figure 7.1 –A), derived from the RPE or the blood, can be maintained at a 
concentration that is sufficient for the regulation of enzymes like matrix 
metalloproteinases that play an important role in the maintenance of elasticity and 
permeability of Bruch’s membrane (Hussain et al., 2011). The presence of zinc 
transporters on the plasma membrane will help to maintain zinc influx into the cells 
in order to create a “healthy” zinc balance. We speculate that this zinc balance will 
be important for maintaining the phenotype of the surrounding cells will help to 
maintain pigmentation and optimal functioning of RPE and will facilitate the 
maintenance of the fenestration of the choroidal endothelium.  
In diseases like AMD this balance could be altered in several ways: As AMD is 
associated with systemic zinc deficiency, replenishment of zinc in Bruch’s 
membrane from the circulation will be compromised. Possibly, a negative gradient 
could develop triggering the removal of zinc from Bruch’s membrane. Zinc levels 
in the RPE have also been shown to decrease in AMD (Tate et al., 1995, Tate et al., 
1999, Newsome et al., 1988) possibly due to decrease in pigment in parallel with 
accumulation of lipofuscin (Biesemeier et al., 2010, Schraermeyer et al., 1999) 
therefore replenishment from this source could also be compromised. A third factor 
that could contribute to the loss of biologically active zinc in Bruch’s membrane is 
its entrapment in sub-RPE deposits (Lengyel et al., 2007).  
Once the bio-available zinc levels dip below functionally required levels the 
reorganization of Bruch’s membrane by metalloproteinases will be altered, 
potentially contributing to the thickening of Bruch’s membrane. Furthermore, the 
loss of bio available zinc may trigger VEGF production in the RPE by signalling to 
the RPE that fenestration requires more VEGF. Zinc deficiency in Bruch’s 
membrane could directlylead to elevated VEGF levels through the lack of 
regulation of VEGF expression by zinc (Golovine et al., 2008, Nardinocchi et al., 
2010) in RPE. These eventually could lead to the development of choroidal 
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neovascularisation (CNV) or so-called wet AMD. Alternatively, through its 
potential direct effects on the RPE, zinc deregulation could lead to cell atrophy and 
the development of dry AMD.  
Zinc supplementation could therefore have several direct or indirect effects on the 
RPE-choroid interface. By elevating zinc levels in the circulation (2001) zinc could 
potentially reverse the zinc deficiency in Bruch’s membrane. While we do not 
know whether this happens, systemic injection of radioactive zinc has been shown 
to reach the RPE (Newsome et al., 1992). The most likely route for the selective 
enrichment of zinc in RPE is through the bloodstream/ choroidal capillaries and 
therefore Bruch’s membrane. Elevated zinc might help to bring VEGF levels under 
control and help the reforming of fenestration to allow better clearance of waste 
material and the availability of zinc to regulate proteases could help the clearance 
process. Therefore, it is probably not surprising that zinc was able to slow the 
progression to blindness in wet AMD (2001)(AREDS report number 8). 
In conclusion, we have shown the expression of zinc transporters in the RPE-
choroid interface, as well as potential effects of altering extracellular zinc 
concentration on cellular models of vascular endothelium and retinal pigment 
epithelium. Based on our results, we have tried to model how zinc can affect the 
RPE-choroid interface. While the studies require further experimentation, it is 
hoped that the model and the results presented within this PhD will perhaps help 
refine our current understanding and treatment strategies for AMD.  
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Figure 7-1–Schematic model of normal and diseased RPE 
Schematic model of the normal RPE (A) and the diseased (AMD) RPE (B). In the 
normal RPE (A), melanin, metallothionein (MT) and phagocytic activities of the 
RPE are optimal. No thickening of Bruch’s membrane is observed, and fenestrated 
capillaries allow material transport to occur. In diseased RPE (B), studies have 
shown that there is reduced melanin (Me) and metallothionein (MT), accumulation 
of lipofuscin (Lf) material, and thickening of Bruch’s membrane. In AMD, sub-
RPE deposits develop between Bruch’s membrane and the RPE. The loss of 
fenestration which has been observed in AMD cases can further obstruct material 
transport from occurring, leading to a vicious cycle which cumulatively results in 
RPE atrophy. Figure legends: MT- metallothionein, Me – melanin, Lf – Lipofuscin, 
ER – endoplasmic reticulum.  
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8. Appendices 
8.1. Appendix 1 – Antibodies 
Bo Bame of 
Antibody 
Reacting 
Species 
Staining  Dilution Source 
1 Alpha-P 63 
Isomerase 
Rabbit 
Polyclonal 
ER  1:500 ICC Kind gift from  
Prof. Karl Matter 
2 9.3 Golgi Rabbit 
Polyclonal 
Golgi 1:500 ICC Kind gift from  
Prof. Karl Matter 
3 ERGIC53 
(Intermediate 
Compartment 
of Golgi) 
Mouse 
Monoclonal 
Golgi 1:200 ICC Kind gift from 
Prof. Karl Matter 
4 GI50059 Mouse 
Monoclonal 
Lysosomes 1:50 ICC Kind gift from  
Prof. Karl Matter 
5 CathepsinD Rabbit 
Polyclonal 
Lysosomes 1:200 ICC Kind gift from  
Dr. Claire Futter 
6 TGN46 Sheep 
Polyclonal 
Lysosomes 1:300 ICC Kind gift from  
Dr. Claire Futter 
7 V5 Mouse 
Monoclonal 
V5 peptide 1:200 ICC 
1:10000  
WB 
Invitrogen 
8 ZIP12 
ab64463 
Rabbit 
Polyclonal 
ZIP12 
protein 
1:200 ICC 
1:1000 WB 
Abcam 
9 ZIP12 first 
bleed 5193 
Rabbit 
polyclonal 
ZIP12 
protein 
1:200 ICC 
1:7500 WB 
BioGene Germany 
10 ZIP12 first 
bleed 5194 
Rabbit 
polyclonal 
ZIP12 
protein 
 
1:200 ICC 
1:7500 WB 
BioGene Germany 
11 ZIP12 final 
bleed 5193 
Rabbit 
polyclonal 
ZIP12  
protein 
1:200 ICC 
1:7500 WB 
BioGene Germany 
12 ZIP12 final 
bleed 5194 
Rabbit 
polyclonal 
ZIP12 
protein 
1:200 ICC 
1:7500 WB 
BioGene Germany 
13 Actin C2 Mouse 
Monoclonal 
Actin 1:500 WB Santa Cruz 
Biotechnology 
14 PV-1 Rat 
monoclonal 
PV-1 
protein 
1:400 Kind gift from 
Prof. David Shima 
15 GFP B2 Mouse 
Monoclonal 
GFP 
protein 
1:500 WB Santa Cruz 
Biotechnology 
16 Horseradish 
Peroxidase  
Goat-anti-
Mouse 
HRP 
protein 
1:7500 WB Jackson 
ImmunoResearch 
17 Horseradish 
Peroxidase  
Goat-anti-
Rabbit 
HRP 
protein 
1:7500 WB Jackson 
ImmunoResearch 
 
18 RhodamineP
halloidin 
- Actin 1:300 ICC Invitrogen  
19 Phospho-
p44/42 
MAPK  
Rabbit 
monoclonal 
Phospho 
ERK1/2 
1:1000 WB Cell Signalling 
20 p44/42 
MAPK  
Rabbit 
monoclonal 
ERK1/2 1:1000 WB Cell Signalling 
21 Phospho-Akt 
(SER473) 
#9271 
Rabbit 
monoclonal 
Phospho 
AKT 
1:1000 WB Cell Signalling 
22 Akt Antibody 
#9272 
Rabbit 
monoclonal 
AKT 1:1000 WB Cell Signalling 
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23 Phospho-
PI3K p85 
(Tyr458) 
/p55 
(Tyr199) 
Rabbit 
monoclonal 
Phospho 
PI3K 
1:1000 WB Cell Signalling 
 
 
 
 
24 p38 MAPK 
Antibody 
#9212 
Rabbit 
monoclonal 
P38 1:1000 WB Cell Signalling 
25 Phospho-p38 
MAPK 
(Thr180/Tyr1
82) Antibody 
#9211 
 
Rabbit 
monoclonal 
Phospho 
Pp38 
1:1000 WB Cell signalling 
26 Src 184Q20 Mouse 
Monoclonal 
Src 1:400 WB Invitrogen 
27 SRC [Py418] Rabbit 
Polyclonal 
PhosphoSr
c 
1:1000 WB Invitrogen 
27 ZO-1 Mouse 
Monoclonal 
Primary 
Antibody 
1:400 BD Biosciences 
28 FITC Goat anti 
Mouse 
Secondary 
Antibody 
1:300 ICC BD Biosciences 
29 Alexa 488  Goat anti  
Rat 
Secondary 
Antibody 
1:1000 ICC Invitrogen 
30 Alexa 568 Goat anti 
Rabbit 
Secondary 
Antibody 
1:1000 ICC Invitrogen 
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8.2. Appendix 2: Cell Lines 
 
No Name of  
Cell Line 
Type Media  Supplements Seeding 
Density 
1 ARPE-
19 
Human RPE DMEM/F12 10% FCS 
1% Penicillin/Streptomycin 
1:3 
2 RPE-1 Human RPE  DMEM/F12 10% FCS 
1% Penicillin/Streptomycin 
1:3 
3 BEND5 Murine 
endothelioma 
DMEM 4.5g/L 
glucose with 
Glutamine and 
Pyruvate 
5 ml NEAA 100x  
10% FCS (v/v) 
1% Penicillin/Streptomycin 
(v/v)  
50 µl of 50mM b-
mercaptoethanol 
1:3 
4 HEK293 Human 
embryonic 
kidney 
DMEM 4.5g/L 
glucose with 
Glutamine and 
Pyruvate 
10% FCS 
1% Penicillin/Streptomycin 
1:15 
5 Primary 
RPE 
culture 
Human RPE DMEM/F12 10% FCS 
1% Penicillin/Streptomycin 
1:3 
6 MDCK Madin-Darby 
canine kidney 
with 
epithelial-like 
appearance 
DMEM 4.5g/L 
glucose with 
Glutamine and 
Pyruvate 
10% FCS 
1% Penicillin/Streptomycin 
1:10 
7 CHO Chinese 
hamster ovary 
DMEM/F12 10% FCS10% FCS 
1% Penicillin/Streptomycin 
1:5 
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8.3. Appendix 3 – Primer List 
8.3.1. Cloning Primers 
ZIP12-attB 
CTerminal 
FWD GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCAT
GTGCTTCCGGACAAAGCTCTCAG  
REV GGGGACCACTTTGTACAAGAAAGCTGGGTGTATTTTA
ATATTTTGCTCATATATA 
ZIP12-attB 
NTerminal 
FWD GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCAT
GTGCTTCCGGACAAAGCTCTCAG 
REV GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATATT
TTAATATTTTGCTCATAT 
 
8.3.2. Sequencing Primers 
No Name Sequence 
1 T7 Promoter  TAATACGACTCACTATAGGG 
2 V5  ACCGAGGAGAGGGTTAAGGGAT 
3 M13 
Forward 
GTAAAACGACGGCCAG 
4 M13 Reverse CAGGAAACAGCTATGAC 
5 ZIP12-
FWD1 
ATGTGCTTCCGGACAAAGCTC 
6 ZIP12-
FWD2 
CTATTACATTATTCATCAGGA 
7 ZIP12-
FWD3 
CAGTTCCTTGAATCGTACGAA 
8 ZIP12-
FWD4 
CATAGCTGTGAGGAGAACTAC 
9 ZIP12-
FWD5 
CATAGGAGCAGCCTTCTCATC 
10 ZIP12-REV1 CCTCCAGCTATTAGTAATAGT 
 
11 
ZIP12-REV2 TTATATTTTAATATTTTGCTCATAT 
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8.4. QRT-PCR Primer Sequences (Primer Design, Southampton, UK)  
8.4.1. Mouse Primers 
 
  Primer Sequences Mus Musculus  
Gene Accession Number Forward Reverse BP 
SLC30A1 NM_009579 TCTGGGCAGGTTTATGTCATG 
 
CCACTTTTATACATAGAACCCACTTA 107 
SLC30A2 NM_001039677 TTAGCCTCTTCGCCCTCTG GATGGAAAGCACGGACAACA 
 
107 
SLC30A3 NM_011773 GTCACTGGCATCCTCCTGTA 
 
CATTAGCAGATTGGCACAGACA 
 
117 
SLC30A4 NM_011774 TAAAGTGGGTGTACCTGTAATCTC 
 
CTTCCTCTATGGGTTCTGACAAG 
 
131 
SLC30A5 NM_022885 ACACCCAATAACAGACCAACTC 
 
CACTACCACTCCTCCAGACA 
 
88 
SLC30A6 NM_144798 AAGTGCTCCTCCAGACAACA 
 
GCCAAATCCAAGGGTCCAAA 
 
125 
SLC30A7 NM_023214 CCTGTGCCTGAACCTCTCT 
 
GTGGAAGGAGTCGGAGATCA 
 
88 
SLC30A8 NM_172816 CCCTGCTGTCTGTCCTTTG 
 
CCTGCTTGGATCTGGTAATCA 
 
97 
SLC30A9 NM_178651 GGGTTCCTTTGGCGTTGAG 
 
TGTGCTTTCGTCCTGTGTTC 
 
132 
SLC30A10 NM_001033286 TGAGACAGAAGAGTTGCTTGAG 
 
TGCCCATCAGCCTCCAAAT 
 
119 
SLC39A1 NM_13901 AAGTAGTGAGGACCAAAGAGTTC 
 
CGTCTGTAGTAACTTCGCTATCT 
 
134 
SLC39A2 NM_001039676 CCTGGGCTTTTTCTTTGTCTTC 
 
CGCTGGATGCTTGTGGAAT 
 
133 
SLC39A3 NM_134135 ACAATGGCATTCTCTCCTTTCC 
 
CTGGCACTTGGGATGACTCT 
 
119 
SLC39A4 NM_028064 GCTTCTTTTCCTGCTCCACAA 
 
GACAAGGACTGGGATGGGATA 
 
118 
SLC39A5 NM_028051 GGTGGCAGTATCGCATGGA 
 
CTGGAGAAGCCGTCTGAGAA 
 
98 
SLC39A6 NM_139143 GGAGACGCACCAAAGATGTAA 
 
GGCTCACTCACAGACTCATTG 
 
115 
SLC39A7 NM_001077709 CTCCGTTCTTCGTGCTGTTC 
 
GGAAGCAAAACTGAGCAGGAT 
 
89 
SLC39A8 NM_026228 CCAGTGTTTGTCAGCAGAAGA 
 
TCGCAGGGATGGAAGTTCA 
 
126 
SLC39A9 XM_891220 TTCTCTGCTGGGACATTTCTTTA 
 
GCGTCACACACTTGCTCTT 
 
130 
SLC39A10 NM_172653 CTGGTTCCTGAAGATAAGACAAATAT 
 
AAGCAGACTAATGACGGTGATAG 
 
81 
SLC39A11 NM_027216 GGATGGATATTGTAGTCTGTGAATG 
 
AATGTGTGATTGAAGCCTTTGAT 
 
106 
SLC39A12 NM_001012305 TGCCCTGCTCCATCTCATAC 
 
GCCTCCAAGTAGTCCCAACA 
 
115 
SLC39A13 NM_026721 TGAAGCCATAATCCCCAACTATT 
 
CCACATCTCTAACATCCACAGT 
 
111 
SLC39A14 NM_144808 AGGCTCCTGCTCTACTTCATAG 
 
CGTAATTGTCCTGAGGGTTGAA 
 
106 
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8.5. Appendix 4: PCR and DBA Sequencing Conditions 
8.5.1. Cloning PCR Cycling Conditions 
95’C 95’C 60’C 72’C 75’C 
2’ 15” 30” 41” 2’05” 
Denaturation  Annealing Elongation Hold 
 35 Cycles  
 Name of Primers Product Size Optimisation 
time 
MgCl/MgSO4 DMSO 
1 ZIP12-attBForward-CTerm 
ZIP12-attBReverse-CTerm 
2000 kb X =60’C 
A=41” 
B=2’05” 
2 mM No 
2 ZIP12-attBForward-NTerm 
ZIP12-attBReverse-NTerm 
2000 kb X =60’C 
A=41” 
B=2’05” 
2 mM No 
 
 
8.5.2. DNA Sequencing Conditions 
95’C 96’C 50’C 60’C 10’C 
5’ 10” 5’ 4’ ∞ 
 25 Cycles  
 
Bo Materials Amount 
1 BigDye 3.1  0.5 µl 
2 Sequencing buffer 2.5 µl 
3 Sequencing Primer (100 µM) 0.5 µl 
4 Plasmid DNA 3.0 µl 
5 Deionised nuclease free H2O 16.5 µl 
  20 µl 
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8.6. Appendix 5: Plasmids Used 
GATEWAY DONOR 
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DESTINATION CLONES 
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